



The Robert Larner, M.D.
College of Medicine

THE UNIVERSITY OF VERMONT

MACAULAY A. C. ONUIGBO
CURRICULUM VITAE

Positions: Professor of Medicine
Department of Medicine, Division of Nephrology
The Robert Larner, M.D. College of Medicine
University of Vermont
Burlington, VT 05401
USA

Interim Chief of Nephrology (October 2021 – September 2024)
The Robert Larner, M.D. College of Medicine
University of Vermont
Burlington, VT

Medical Director
University of Vermont Medical Center Joy Drive Hemodialysis Unit
South Burlington, VT

Medical Director
Home Dialysis Unit
University of Vermont Medical Center
Burlington, VT

Address: Room 2308, Rehab 2, UHC Campus
1 South Prospect Street
Burlington, VT 05401
Department of Medicine
The Robert Larner, M.D. College of Medicine
University of Vermont
Burlington, VT 05401
Voice: (802) 847-2280
email: macaulay.onuigbo@uvm.edu
website: <http://www.med.uvm.edu/medicine/nephrology/home>

Consultant Nephrologist, University of Vermont Medical Center,
Burlington, VT: February 12, 2018 – Present.
<https://www.uvmhealth.org/medcenter/provider/macaulay-onuigbo-md>

EDUCATION

Year	Institution	Degree	Area of Degree, Accolades
2012	University of Wisconsin Consortium MBA Business School, Wisconsin	MBA	Business Administration
2002	University of Maryland School of Medicine, Baltimore, MD	Fellowship	Clinical Nephrology
2000	Greater Baltimore Medical Center, Baltimore, MD	Residency	Internal Medicine
1996	University of Texas Health Science Center, Houston, TX		Research Nephrology Fellowship
1989	University of Nigeria Teaching Hospital, Enugu		Clinical Nephrology Fellowship
1988	College of Medicine, University of Nigeria	MSc	Medical Biochemistry
1981	College of Medicine, Enugu Campus, University of Nigeria	MD	Medicine & Surgery

LICENSES, CERTIFICATION

Years	License/Certification
2018-Present	Vermont
2016-2018	Georgia
2012-2015	Texas
2002-Present	American Board of Internal Medicine – Nephrology
2002-2019	Wisconsin
2000-Present	American Board of Internal Medicine – Internal Medicine
1999-2003	Maryland
2019-2022	Pennsylvania
2023 - Present	New York

FACULTY POSITIONS HELD

Years	Institution	Academic Title	Department
July 1, 2019-Present	The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT	Professor	Medicine
2018-July 1, 2019	The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT	Associate Professor	Medicine
2010-2018	Mayo Clinic, Rochester, MN	Associate Professor	Medicine
2005-2010	Mayo Clinic, Rochester, MN	Assistant Professor	Medicine
2000-2002	University of Maryland School of Medicine, Baltimore, MD	Assistant Instructor	Medicine
1990-1994	College of Medicine, University of Nigeria, Enugu Campus	Senior Lecturer	Medicine

1989-1994	University of Nigeria Teaching Hospital, Enugu, Nigeria	Consultant Nephrologist	Medicine
-----------	---	-------------------------	----------

OTHER POSITIONS AND MAJOR ADMINISTRATIVE POSITIONS HELD

Years	Location/Program Name	Role
2021-Present	LCOM, University of Burlington, VT	Interim Chief of Nephrology
2016-Present	College of Business, University of Wisconsin MBA Consortium	Professor/Instructor
2014-Present	College of Health Sciences, Nnewi Campus, Nnamdi Azikiwe University, Nnewi, Nigeria	Visiting Associate Professor
2008-2011	Mayo Health System Practice-Based Research Network, Mayo Clinic, Rochester, MN	Regional Director
2006-2018	Department of Nephrology, Mayo Clinic Health System, Eau Claire, WI	Vice-Chairman
2002-2018	Home Dialysis Program, Department of Nephrology, Mayo Clinic Health System, Eau Claire, WI	Medical Director

HONORS AND AWARDS

Year	Name of Award
1978	National (Academic) Merit award – Ministry of Education, Nigeria
1981	Best Student Prize Award, Final MBBS (MD) examination
1999	Second Prize Winner, Poster presentation (Macroaspartate Transaminasesemia) at the 8th Annual Maryland Associates Meeting, American College of Physicians
2007	Fellowship of the American Society of Nephrology (FASN)
2009	Mayo Health System MacMillan Management Scholarship Award
2010	Mayo Health System (MHS) Education System Oriented Application Research (SOAR) Grant Award
2012	MBA Summa Cum Laude – University of Wisconsin Consortium
2012	University of Wisconsin MBA Consortium Most Outstanding Graduate
2014	Mayo Clinic 2014 Division of Hypertension and Nephrology Integration Research Award
2014	“Best Abstract” Award, 16th International Conference on Dialysis/Renal Research Institute, NY
2016	Mayo Medallion (The Physician Mayo Medallion is an adaptation of the Military’s Commander Coin)
2016	Election to membership, O’Brien Kidney Research Center, Mayo Clinic, Rochester, MN, USA. September 2016 – January 2018
2019	The Robert Larner, M.D. College of Medicine, University of Vermont The Teaching Academy Medical Education Fellowship Program Certificate. September 2018 – May 2019.
2020	Election to Expert Teacher, The Robert Larner, M.D. College of Medicine Teaching Academy, University of Vermont, Burlington, VT. Effective 12-11-2019 - Present.

2024 ScholarGPS (Powering Scholarly Analytics) in July 2024 named Dr. Macaulay Onuigbo as one of the top 0.5% of all scholars worldwide.

KEYWORDS/AREAS OF INTEREST

Chronic kidney disease (CKD) progression - The natural history of CKD
Acute kidney injury from drug toxicities
Intraoperative hypotension and postoperative acute kidney injury
Acute kidney injury (AKI) and its impact on long-term renal outcomes
Non-dialytic therapy (NDT) in ESRD care
Healthcare delivery and organization in the 21st century
The application of Health Information Management in Reengineering Healthcare
Healthcare Cost Management and Healthcare Financing
Stress and Burnout in the Healthcare Workplace
Cognitive Drift from the EMR as a factor in physician stress and CPOE errors
Hemodialysis Filter Rotator (HDFR) for Anticoagulation-free Hemodialysis

SUMMARY OF PROFESSIONAL ACTIVITIES - OVERALL

RESEARCH

I have contributed to the modern Medical English Literature and published and reported on several new clinical syndromes including the following: the first cases of lone CMV-induced glomerular vasculopathy in renal allografts (2002), the syndrome of late onset renal failure from angiotensin blockade (LORFFAB, 2005), the concept of Renoprevention (2009), the syndrome of rapid onset end stage renal disease (SORO-ESRD, 2010), Cognitive Drift with the EMR (2012) and Quadruple Whammy (2013). Other recent contributions to the Medical English Literature include the concept of Ethicomedicinomics, where the forces of ethics, medicine and economics collide (2012), a novel fingerprint biochemical assay method of diagnosing pleural effusion complicating peritoneal dialysis in patients using Icodextrin solution (2019) and a new mechanistic method of achieving anticoagulation-free hemodialysis using a novel Hemodialysis Filter Rotator (2020). Furthermore, in October 2020, we successfully submitted a US patent application on the Hemodialysis Filter Rotator in collaboration with the University of Vermont (UVM) Innovations Unit. I have published 4 Nephrology books, 20 book chapters, authored over 190 peer-reviewed publications including over 120 PubMed-cited journal publications and over 230 published conference abstracts. My research interests include acute kidney injury with emphasis on nephrotoxicity of therapeutic agents and the role of intra-operative hypotension in post-operative AKI, CKD progression and CKD population health management. I am a frequent reviewer for journals in Nephrology, Hypertension and General Internal Medicine. For community service, I was part of a team that developed a Telemedicine portal – BlackHealthOnline, BHO - to deliver robust, portable, reliable, convenient, affordable, and patient-centered care to patients in the developing world. Unfortunately, in 2018, due to unforeseen circumstances and exigencies, the project failed to take off. I was elected to the rank of Expert Teacher of the LCOM Teaching Academy in January 2020.

My long-term research interests include chronic kidney disease (CKD) progression, the impact of acute kidney injury (AKI) on CKD progression, Renoprotection strategies, Renoprevention paradigms, and perioperative risk stratification of CKD patients. The overarching goals include the minimization of iatrogenic nephrotoxicity and the identification of potentially preventable risk factors to prevent or alleviate the incidence of postoperative AKI, a significant contributor to hospital-acquired AKI. Furthermore, we have interest in leveraging Healthcare Informatics/Information Technology to optimize CKD care in the general population via the application of the analysis of serum creatinine trajectories.

Previously, we had investigated the critical, albeit neglected, role of intraoperative hypotension (IOH) in the pathogenesis of post-operative AKI. Most of the known risk factors for postoperative AKI such as older age >65 years, diabetes mellitus, heart failure, COPD, anemia, obesity, reduced GFR and higher stage CKD, post-operative low cardiac output, sepsis and volume depletion are usually not amenable to therapeutic manipulation, or very minimally so. Nevertheless, we have demonstrated that IOH is a preventable and crucial causative factor

in postoperative AKI. We are in the process of developing randomized clinical trials that would evaluate the optimal intraoperative SBP or MABP levels that would translate to the best renal outcomes. Furthermore, we had worked with collaborators in the Singapore College of Anesthesiologists in 2016 to design a micro-Doppler system to measure renal artery hemodynamics as correlates of intra-arterial systemic blood pressure.

Since joining the Nephrology faculty here at UVM in February 2018, I have constituted a multidisciplinary team, the Postoperative Acute Kidney Injury Research Group (PARG) to investigate IOH and postoperative AKI together with the correlation of renal injury following both cardiac and non-cardiac surgeries with continuously monitored real time urinary oxygen tension. The PARG includes faculty and staff from Nephrology, Cardiothoracic Surgery, Orthopedics, Perfusion Services, Critical Care Medicine and Anesthesiology.

In a research collaboration effort with UVM Department of Computer Science, we have prototyped The CKD Express © App Version I, an IT-enabled remote monitoring and management platform for CKD health. The overall concept is the ability to leverage Healthcare Informatics/Information Technology to optimize CKD care. Between 2019 and 2020, I have collaborated with the Department of Computer Science, University of Vermont, to develop The CKD Express © App Version I, an IT-based App that enables remote and total care of CKD populations anywhere in the world. The App, under the direct management of Nurse Practitioners/Research Coordinators, and with supervisory oversight from me, will track, monitor and analyze eGFR trajectories of enrolled patients and then trigger and stipulate new directions and instructions to the patients via a secure network, in real-time. The App is unique, innovative, disruptive, state-of-the-art, and revolutionary. It provides convenient, effective, efficient, and patient-centered CKD care with significant cost savings through reduced waste. It enhances patient and provider satisfaction. It reduces patient wait times for nephrology referrals by freeing the backlog of the need to follow these patients who will then have their CKD care managed remotely via this App. The need for this App was magnified by the COVID-19 pandemic and will enable CKD patients to be managed without the need for unnecessary repeated frequent visits to the Nephrology Clinic. Unfortunately, we were never able to get this projection to fruition.

The Hemodialysis Filter Rotator Project: University of Vermont Center for Biomedical Innovation (UVM CBI) SEED Project Research Award, 2021-2022. Hemodialysis Filter Rotator Project. This is a two-term Electrical and Biomedical Engineering/Mechanical Engineering Capstone Design UVM Course geared towards the University of Vermont (UVM) College of Engineering and Mathematical Sciences (CEMS) Senior Experience in Engineering Design (SEED) [UVM CEMS – SEED].

Hemodialysis (HD) is the process of cleaning the blood of patients with kidney failure. Blood is pumped through an extracorporeal circuit and the cleaning occurs in a hemodialysis filter. For continuous blood circulation without clotting, anticoagulants - Heparin and regional Citrate - are used. Heparin, the first choice for decades, costs money, and may cause Heparin-induced thrombocytopenia, bleeding complications and other adverse drug reactions. Besides, Citrate protocols are very complex and associated with adverse metabolic complications. In the US, over 400,000 patients are on HD and a good proportion of them sometimes require anticoagulation-free HD. Patients in the ICU, with critical illness and following major surgical operations require anticoagulation-free HD. There is therefore a huge unmet need for a new methodology of anticoagulation-free HD. Our innovative invention is a miniaturized electric motor that would rotate the horizontally placed CAR-170-C NXSTAGE Chronic Cartridge Hemodialysis Filter to-and-fro, back-and-forth, clockwise, then counterclockwise.

On the research front, it is my hope to actualize the dreams of finally actualizing The NxStage Hemodialysis Filter Rotator Project – we had successfully produced a first prototype in the Spring of 2022, working in collaboration with UVM College of Engineering. Subsequently, a second enhanced prototype was designed and developed in 2023 in fulfilment of the requirements for a Master of Science degree in Biomedical Engineering at the University of Vermont. There is currently a Pre-Submission (Pre-Sub) to the US Food and Drug Administration (US FDA) regarding plans for an Investigational Device Exemptions (IDE) determination for the Hemodialysis Dialysis Filter Rotator (HDFR). I completed a UVMCMC/UVMHN Grand Rounds on the HDFR on Friday, February 22, 2025. This followed a successful outing with a poster at the International Society of Nephrology (ISN) World Congress of Nephrology 2025 (WCN'25), held in New Delhi, India, February 6-9, 2025. I have established a HDFR International Consortium with members from Nephrology and Critical Care specialties from the US, India, Nigeria, Kenya, Nepal and Japan. This international consortium, it is hoped, will take on a global multi-center phase 2 and phase 3 trials of the Hemodialysis Filter Rotator (HDFR) after we had completed the planned phase 1 clinical trials here at the UVMCMC Home Dialysis Program.

Moreover, the efforts to secure a University of Vermont Institutional Review Board (UVM IRB) approval for a phase I clinical study of the Hemodialysis Filter Rotator (HDFR) is on hold, pending the ongoing review with the US Food and Drug Administration (US FDA).

Our invention is new and has not been described before. Anticoagulation-free hemodialysis without any other additive constitutes a breakthrough in Clinical Nephrology. This work has been presented at various meetings of the American Society of Nephrology Kidney Week in 2020, 2022, 2023 and 2024, at the National Kidney Foundation Spring Clinical Meeting in 2023, and at the International Society of Nephrology World Congress of Nephrology meetings in Argentina in 2024, and most recently at the International Society of Nephrology 2025 World Congress of Nephrology held in New Delhi, India, February 6-9, 2025.

a. Locke A, Bushey MA, LaCroix C, Deardoff P, Chukwukadibia Onuigbo MA. Timed Controlled Repeated Rotation of the CAR-170-C NXSTAGE Chronic Cartridge Hemodialysis Filter: A Novel Approach to Enabling Heparin-Free Frequent Daily Home Hemodialysis. Mayo Clin Proc Innov Qual Outcomes. 2020 Nov 6;5(1):219-224. doi: 10.1016/j.mayocpiqo.2020.08.003. PMID: 33718796; PMCID: PMC7930779.

SUMMARY OF ACCOMPLISHMENTS

- ❖ I was the best all-round graduating student in my medical school class in 1981.
- ❖ We described in 2002, for the first time, the first case of CMV glomerulopathy, in a renal transplant recipient.
- ❖ In 2005, I described, for the first time, the new syndrome of late onset renal failure from angiotensin blockade (LORFFAB).
- ❖ In 2009, we introduced the concept of Renoprevention, as distinct from Renoprotection into General Nephrology practice.
- ❖ In 2010, we described, for the first time, the new syndrome of rapid onset end stage renal disease (SORO-ESRD).
- ❖ In 2013, we described, for the first time, the new syndrome, Quadruple Whammy.
- ❖ In 2012, we in an MBA class developed a new IT software, the CKD Express ©, a product that I am developing here at UVM into an IT Software to improve population-wide CKD care delivery at the same time as introducing the concept of “Ethicomedicinomics” in the field of Healthcare Economics.
- ❖ In 2015, we published data to implicate intraoperative hypotension as a potent yet neglected, unrecognized and preventable causative factor in postoperative acute kidney injury.
- ❖ National (Academic) Merit award – Ministry of Education, Nigeria (1978)
- ❖ Best Graduating Medical Student Prize Award (1981)
- ❖ Fellowship of the American Society of Nephrology (FASN) in 2007
- ❖ Mayo Health System MacMillan Management Scholarship Award in 2009
- ❖ Mayo Health System (MHS) Education System Oriented Application Research (SOAR) Grant Award in 2010
- ❖ University of Wisconsin MBA Consortium Most Outstanding Graduate in 2012
- ❖ “Best Abstract” Award, at the 16th International Conference on Dialysis/Renal Research Institute, NY in February 2014
- ❖ Mayo Clinic 2014 Division of Hypertension and Nephrology Integration Research Award in June 2014
- ❖ Election to the membership of the MAYO CLINIC O’Brien Kidney Research Center, Rochester, MN, USA in September 2016.

- ❖ Election to Expert Teacher, The Robert Lerner, M.D. College of Medicine Teaching Academy, University of Vermont, Burlington, VT. Effective 12-11-2019 through 12-30-2024.
- ❖ Member, National Expert Consensus Panel on Hyperkalemia Meeting. AstraZeneca. February 13, 2019, in Miami, FL.
- ❖ Member, AstraZeneca Virtual Advisory Board on Farxiga; September 2020 – 2021.

PROFESSIONAL SERVICE

DEPARTMENTAL SERVICE (Prior to UVM at Mayo Clinic/Mayo Clinic Health System)

Years	Department	Committee	Role
2008 – 2018	Medicine	Clinical Research Steering Committee	Member: IRB approval, Mayo Clinic Health System
2002 – 2010	Medicine	Diabetes Clinical Expert Team	Member: Mayo Clinic Health System
2002 – 2004	Medicine	EMR Clinical Evaluation Workgroup	Physician Champion: Mayo Clinic Health System
2003 – 2010	Medicine	Guidelines and Protocol Group	Member: Mayo Clinic Health System
2009 – 2010	Medicine	Heart Failure Expert Team	Member: Mayo Clinic Health System
2002 – 2012	Medicine	Infection Control Committee	Member: Mayo Clinic Health System
2003	Medicine	Leadership Meeting, Hillcrest	Mayo Clinic Health System Leadership Retreat Member
2003 - 2006	Medicine	Management of Information, Process Management Team	Physician Champion: Mayo Clinic Health System
2004 – 2006	Medicine	Process Management Forum Mayo Health System	Member: Mayo Clinic Health System
2008 – 2011	College of Medicine, Mayo Clinic, Rochester	Practice-Based Research Network (PBRN)	Regional Director: Mayo Clinic, Rochester/Mayo Clinic Health System

COLLEGE SERVICES (UVM/UVM HEALTH NETWORK)

Years	Service Committee	Role
2018 – 2025	Diversity and Inclusion, Department of Medicine, The Robert Larner, M.D. Larner College of Medicine, University of Vermont.	Departmental Champion
2018 – 2023	Department of Medicine QI Program: Scholarly QI Interest Group	Member
2018 – 2023	Department of Medicine Quality Assurance & Improvement (QA&I) Committee	Member

2019 – 2022	The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT Admissions team Multi Mini Interview (MMI) Interviewer.	MMI Interviewer
2020 – Present	UVM LCOM Teaching Academy Educational Scholar Mentoring Group.	Mentor
2020 - 2025	Larner College of Medicine Dean's Advisory Committee on Diversity, Equity and Inclusion (DACDEI).	Member
2020 - Present	Larner College of Medicine Teaching Academy Mentoring Committee.	Member
2022 - 2025	Larner College of Medicine Department of Medicine Diversity, Equity and Inclusion (DEI)	Co-Chairman
2022 - 2025	OneCare Vermont Health Equity and Access Workgroup; under OneCare's Quality and Care Models Subcommittee.	Member
2021 - 2024	Division of Rheumatology, Department of Medicine, The Robert Larner, M.D. College of Medicine, Burlington, VT Faculty Search Committee	Member
March – June 2023	The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT Search Committee for the Chair, Department of Medicine Chair	Member
July 2022 - Present	The Robert Larner, M.D. College of Medicine Teaching Academy Advisory Council	Member
October 2021 - Present	The Robert Larner, M.D. College of Medicine, University of Vermont, LCOM Curriculum Services. Acid-Base Small Groups Session. Cardiac, Respiratory Renal Systems - CRR Sessions. LCOM Second Year Medical Students Classes Every October. October 2021 – Present.	

MEDICAL CENTER SERVICE (UVM)

Years	Service Committee	Role
2018 – 2024	University of Vermont Medical Center Pharmacy & Therapeutics Committee.	Member
2018-2024	Medical Records Committee	Member

UNIVERSITY SERVICE (UVM)

Years	Service Committee	Role
2018 – 2025	Diversity and Inclusion, Department of Medicine, The Robert Larner, M.D. Larner College of Medicine, University of Vermont.	Departmental Champion and later Departmental Co-Chair
2018 – 2023	Department of Medicine QI Program: Scholarly QI Interest Group	Member
2018 – 2023	Department of Medicine Quality Assurance & Improvement (QA&I) Committee	Member
March 29, 2019	Facilitator of Active Learning at the 2019 UVM Mud Season on “Diagnosing and Remediating the Clinical Learner” at The UVM Teaching Academy 2019 Mud Season Education Retreat, Hilton Hotel and Conference Center, Burlington, Vermont.	Conference/Retreat Facilitator
June 2025	Hyperkalemia Order Set Review, University of Vermont Health Network (UVMHN) Division of Hospital Medicine Work Group.	Order Set review Committee Member
Annual Review on 6/19/2025	The Robert Larner, M.D., College of Medicine, University of Vermont Department of Internal Medicine Residency Program Evaluation Committee.	Internal Medicine Residency Program Evaluation Committee Member
Annual Program Next due course on 10/23/2025.	CRR 2025 Acid-Base Small Group - 2nd year medical students in CRR (LCOM heart/lung/kidney pathophys course) 2025 in the Acid-Base Small Groups. Andrew Hale MD FIDSA, Course Director, Cardiac, Respiratory, and Renal Systems LCOM	Course faculty

GOVERNMENT - None to date

SOCIETY MEMBERSHIPS

Years	Society
1997-Present	American Medical Association
2002-Present	American Society of Nephrology
2002-2018	Wisconsin Medical Society
2018-Present	Vermont Medical Society

01/15/2018-Present	European Society of Cardiology/European Association of Preventative Cardiology
2021 - Present	European Renal Association (ERA)

SERVICE TO PROFESSIONAL ORGANIZATIONS

Years	Service Committee	Role
2009-Present	Journal of the American Society of Nephrology NephSAP	Reviewer
2008-Present	American Society of Nephrology (ASN) Kidney Week 2018 Abstract Reviewer, Geriatric Nephrology	Reviewer
2014-Present	Association of Nigerian Physicians in the Americas (ANPA) Bylaws Committee	Member
2015 – Present	Association of Nigerian Physicians in the Americas (ANPA) Speed Mentoring Program of the younger physicians	Mentor
2020 – Present	Association of Nigerian Physicians in the Americas (ANPA; anpa.org) Constitution and Bylaws Committee. July 2020 – June 2022.	Chairman
2020 - Present	Nigerian Physicians Advocacy Group (NPAG) Board of Directors	Member (ANPA Representative)
2021 - Present	Vermont Biomedical Research Network. VT IDeA Retreat 2021 Group 5.	Member
2021 - Present	UVMMC BIPOC Employee Resource Group (ERG)	Member
2022 - 2026	American Society of Nephrology (ASN) Self-Assessment Program Review Panelist, NephSAP), 2022-2026 (Appointed 12-10-2021).	Review Panelist
2021	Netter Book Editor, 9-12-2021. The Netter Collection of Medical Illustrations, Volume 3: Respiratory System. 3rd ed/Vol. 3 Respiratory. Elsevier Publishers, 2022.	Editor
2022 - Present	The Cathedral Church of St. Paul, Burlington, VT Election to the Vestry	Vestry Member

SERVICE TO PROFESSIONAL PUBLICATIONS

Years	Journal/Publication/Board
--------------	----------------------------------

International Journal of Clinical Practice: Editorial Board Member

2013 – Present	BioMed Research International: Editorial Board Member
2013 – Present	Journal of Renal Injury Prevention: Editorial Board Member (Section Editor: Renoprevention)
2014 – Present	Nigerian Journal of Clinical Practice: Editorial Board Member
2018 - Present	Journal of Renal Endocrinology (JRE) Editorial Board Member
2003 – Present	American Board of Internal Medicine (Nephrology Section): Reviewer
2007 – Present	American Journal of Hypertension: Reviewer
2012 – Present	American Journal of Kidney Disease: Reviewer
2003 – Present	American Journal of Transplantation: Reviewer
2011 – Present	BioMed Central Nephrology (BMC Nephrology): Reviewer
2014 – Present	Nature Reviews – Nephrology: Reviewer
2018 – Present	American Society of Nephrology (ASN) Kidney Week 2018 Abstract Reviewer, Geriatric Nephrology
2009 – Present	Journal of the American Society of Nephrology NephSAP: Reviewer
2009 – Present	Kidney International: Reviewer
2009 – Present	Renal Failure Journal: Reviewer
2013 – Present	Nigerian Journal of Clinical Practice: Reviewer
2014 – Present	Cleveland Clinic Journal of Medicine: Reviewer
2014 – Present	American Heart Journal: Reviewer
2015 – Present	Mayo Clinic Proceedings: Reviewer

2016 – Present	Critical Care Medicine: Reviewer
2016 – Present	British Medical Journal Open, BMJ Open: Reviewer
2016 – Present	Canadian Medical Association Journal, CMAJ: Reviewer
2016 – Present	Clinical Journal of the American Society of Nephrology (CJASN): Reviewer
2016	American Society of Nephrology (ASN) Board Review Course & Update (BRCU) 2016: Reviewer
2016 - Present	The American Journal of the Medical Sciences: Reviewer
2020 - Present	Associate Editor, Frontiers in Medicine.
2021 - Present	Medical Principles and Practice – Reviewer.
2021 - Present	Editorial Adviser, Editorial Board, Journal of the Nigerian Academy of Medicine (JNAM). https://www.jnamed.com/editorialboard.asp
2021 - Present	Saudi Journal of Kidney Diseases and Transplantation – Reviewer.
July 2022 - Present	Transplant International https://www.frontierspartnerships.org/journals/transplant-international , Official journal of the European Society for Organ Transplantation (ESOT) - Reviewer.
2022 - Present	Frontiers in Bioengineering and Biotechnology – Reviewer.

July 2022 - Present	Member, Editorial Board, International Journal of Medicine & Health Development.
July 2022 - Present	Current Medical Research & Opinion – Reviewer.
August 2022 - Present	Review Editor, Member Editorial Board, Frontiers in Nephrology – Cardioneurology.
August 2022 - Present	American Journal of Case Reports - Reviewer.
August 2022 - Present	Annals of Internal Medicine, Clinical Cases (AIMCC) - Reviewer.
December 2022 - Present	Editor, Evercare ClinicoPathologic Conferences. CASE RECORDS AT THE EVERCARE HOSPITAL LEKKI, LAGOS, NIGERIA. Nigerian-American Medical Foundation International (NAMFI). December 2022 – Inaugural Edition.

PUBLIC SERVICE

Years	Service Role
2014 – 2018	Member, Eau Claire County Medical Reserve Corps. Assistance to the state in Emergency Preparedness.
2015 – 2018	Certified QPR (Question, Persuade, Refer) Certified Instructor Training, QPR Institute, Eau Claire, Wisconsin. May 7, 2015 (Question, Persuade, Refer).
2015 - Present	BlackHealthOnline TeleMedicine Project for patients in the developing world. I am working on this project with a group of three other US-based physicians and an IT team.
2018 – Present	Physician Representative, Vermont Kidney Association.
2020 – Present	Member, (HEALTHSENS S.L. Biomedical Research) HEALTHSENS S.L. Advisory Board. March 24, 2020 to Present. https://healthsens.com/en/md-phd-macaulay_onuigbo/

May 2019	I completed Crucifier training at The Cathedral of St. Paul, Burlington, Vermont on Thursday, May 2, 2019 under the tutelage of Susan McMillan.
July 16, 2022	Member, Northeast Regional Medical Affairs Advisory Board, Travers: Treatment in IgA Nephropathy, in Philadelphia, Pennsylvania.
10/20/2023 – 10/21/2023	Member, Rare Kidney Disease (RKD) Scientific Network. Travers Therapeutics.

SUMMARY OF SERVICE ACTIVITIES

I have over the past thirty years and counting, since leaving medical school in Nigeria in 1981, been involved in a long list of professional and social endeavors in Nigeria, sometime in the United Kingdom, and in the last 24 years here in the United States of America. While I was in Wisconsin with the Mayo Clinic Health System and with Mayo Clinic, Rochester, MN, I participated in several professional bodies to contribute to medical science and to improve community physicians' participation in medical research and the quest for improved healthcare delivery through research. For the latter mission, I served as the Northwestern Regional Director of the Mayo Clinic, Rochester, MN Practice-Based Research Network (PBRN) between 2008 and 2011. I also served on various Mayo Clinic Health System Committees including Diabetes Clinical Expert Team, Clinical Research Steering Committee, Guidelines and Protocol Group, Infection Control Committee and the EMR Clinical Evaluation Work Group. I was a member of the Eau Claire County Medical Reserve Corps, a County-based volunteer corps dedicated to assistance in Emergency Preparedness from 2014 – 2018. Additionally, between 2014 and 2018, I was an active volunteer member of the Eau Claire, WI, Certified QPR (Question, Persuade, Refer) Certified Instructor Training Program that was dedicated to reducing suicide in the community. For three years now, I have volunteered to assist Garki Hospital, Abuja, Nigeria, in their efforts to establish a functional and sustainable kidney transplantation program as a Consulting Nephrologist. I presented a poster/abstract on their 3-year kidney transplantation experience at the 2017 International Society of Nephrology World Congress in Nephrology held in Mexico City, Mexico. At the global level, about 2015-2018, I had worked with three other Nigerian physicians with a vision to set up BlackHealthOnline, a convenient, affordable, and prompt TeleMedicine portal geared towards delivering a robust, portable, reliable, convenient, affordable and patient-centered medical care to the underserved patients in the developing world especially in Sub-Saharan Africa. We collaborated with an international consortium of IT engineers (Nigeria, Sierra Leone, and India) to complete this project. Most fortuitously, despite the vast amount of effort, time and resources put into this project, due to unforeseen circumstances, regrettably, we never were able to launch this program. Furthermore, in the summer of 2018, I had started a new collaboration effort with Zenith Hospital, Abuja, Nigeria to help enhance its renal transplantation services to the thousands of underserved Nigerians with end stage renal disease. Since arriving here at the University of Vermont, Burlington, VT, I have joined the effort at enhancing and enabling Diversity and Inclusion as the Departmental Champion, Diversity and Inclusion, Department of Medicine, UVM. I am an active member of the Vermont Kidney Association with the mission of improving the care of the patient with

kidney disease in all its ramifications here in Vermont. Furthermore, I have joined, and I am actively serving on several committees of the UVM/UVMMC to contribute to the growth and enrichment of the system. I have been very active on the following UVM/UVMMC committees – the University of Vermont Medical Center Pharmacy & Therapeutics Committee, the Department of Medicine QI Program - Scholarly QI Interest Group, and the Department of Medicine Quality Assurance & Improvement (QA&I) Committee.

TEACHING

FORMAL SCHEDULED CLASSES – At UVM Larner College of Medicine.

CURRICULUM DEVELOPMENT

MAYO CLINIC HEALTH SYSTEM, EAU CLAIRE, WI: SEPTEMBER

2002 – 2018

- Peritoneal Dialysis University. Hands-on Practical Peritoneal Dialysis Course under the auspices of the Wake Forest University School of Medicine. Wake Forest University School of Medicine. Chicago, Illinois - 08/2004.
- Hypertension and Cardiovascular Disease in People with Kidney Disease. Hypertension management course under the auspices of the American Society of Nephrology (ASN). American Society of Nephrology (ASN) Renal Week, St Louis, MO - 10/2004.
- Prevention in Renal Disease: 4th Annual Conference. Royal College of Physicians & Surgeons of Canada. Toronto, Canada - 09/2005.
- Annual Update in Nephrology and kidney/Pancreas Transplantation, Mayo Clinic College of Medicine. Minneapolis, Minnesota - 10/2005.
- Cardiology for the Practicing Clinician 2007. Luther Midelfort, Mayo Health System. Eau Claire, Wisconsin - 10/2007.
- Peritoneal Dialysis course under the auspices of the International Conference on Dialysis, the Renal Research Institute, New York, USA. The Renal Research Institute, New York, USA. Cancun, Mexico - 01/2008.
- Metabolism and Nutrition in Renal Disease. International Society of Renal Nutrition and Metabolism. International Society of Renal Nutrition and Metabolism. Merida, Mexico – 06/2009.
- Online MBA Program, University of Wisconsin Consortium. University of Wisconsin Consortium. Eau Claire, Wisconsin – 10/2009 to 05/2012
- “Winning Grants”. National Institutes of Health Version. (Stephen W. Russell, D.V.M. and David C. Morrison Ph.D). Mayo Clinic, Rochester. November 12, 2010
- “Writing for Biomedical Publication”. (Dr. Chris Papasian and David C. Morrison Ph.D). Mayo Clinic, Rochester. March 11, 2011.
- Fundamental Critical Care Support Provider Course. Society of Critical Care Medicine. November 20, 2015. Fairview University Medical Center, Minneapolis, MN, USA.
- Point-of-Care Ultrasound Workshop. Update in Nephrology and Transplantation Course. Mayo Clinic Division of Hypertension and Nephrology. Scottsdale, AZ, USA. February 11, 2017.
- 15th Annual Update in Nephrology and Transplantation Course, Mayo Clinic Division of Hypertension and Nephrology, Scottsdale, AZ, USA. February 10-11, 2017.

UNIVERSITY OF VERMONT: 2018 - PRESENT

- Baxter PD Webinar: Management of Non-Infectious Complications in Peritoneal Dialysis
- Home Therapies. Tuesday, April 3, 2018.
- I2V_UVM INNOVATION 2 VENTURES CONFERENCE _APRIL 5, 2018. 1-5 pm. Dudley H. Davis Center, 590 Main Street, Burlington, VT 05401.
- I-Trep BioMedical Entrepreneurship Summer Course. 2018 Seminar Series. June 14th – June 22nd, 2018. University of Vermont, Burlington, VT.
- **NIH-NIDDK Workshop Committee Participant: Chronic Kidney Diseases in Agricultural Communities. Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD. June 25-26, 2018. An NIH Study Section Workshop. An NIDDK-NIEHS Workshop on Chronic Kidney Diseases in Agricultural Communities. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Environmental Health Sciences (NIEHS).**
- UVM Faculty of Color Writing Retreat. Inkwell Academic Writing Retreats. All-day workshop. I worked on a manuscript on Book Faction Novel. Supervision and teaching by Michelle Boyd PhD. Retired Associate Professor, Departments of American Studies & Political Science, UIC. Friday, May 10, 2019 (Professional Development).
- Onuigbo MAC. The CKD Express © App – A new disruptive yet utilitarian new approach to Population Chronic Kidney Disease (CKD) Management. Innovative Idea Pitch Presentation and Discussion at the University of Vermont Center for Biomedical Innovation (CBi) 1st Workshop. UVM Innovation Building, Burlington, VT. Tuesday, November 26, 2019.

POSTGRADUATE AND OTHER COURSES

Years	Department	Responsibility
10/2009 - 05/2012	Business Administration	MBA Program

PREDOCTORAL STUDENTS SUPERVISED OR MENTORED – None to date

DISSERTATION/THESIS COMMITTEE MEMBERSHIP – None to date

POSTDOCTORAL FELLOWS AND RESIDENTS DIRECTLY SUPERVISED OR MENTORED – None to date

INFORMAL TEACHING

Year	One Sentence Description of Information Teaching
09/2002 – 01/2018	Class-based and medical floor-based teaching of rotating medical students, rotating medical students from University of Wisconsin, School of Medicine and Public Health, Madison, WI, as well as Dialysis Nurses and Technicians, and other Advanced Care Practitioners at Mayo Clinic Health System, Eau Claire, WI.
02/2018 - Present	Nephrology fellows teaching at UVMMC and the UHC Nephrology Office. Medical students and Residents teaching on the UVMMC Nephrology Consult Service.

UVM FACULTY MENTORED

i. Nina Narasimhadevera MD. Assistant Professor, Department of Medicine, Division of Nephrology, The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT. (Research Grant Application): We subsequently were recipients of the University of Vermont Health Network Medical Group UVMHNMG Research Award Grant: **“A pilot crossover study of the impact of increased urine flow rate by oral hydration versus bolus intravenous furosemide infusion on urinary oxygen tension”**. The grant period is 01/01/2019 to 12/31/2020. Research Grant amount - \$50,000. Grant/project code: MG191.

ii. Chidinma Enyinna MD. Assistant Professor, Department of Medicine, Division of Nephrology, The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT.

OTHER VISITING FACULTY SUPERVISED/MENTORED

Years	Names	University/College
04/2011 – 06/2012	Obinna Onodugo MD	Department of Medicine, University of Nigeria College of Medicine (Consultant Nephrologist).
09/2010 - 09/2012	Ejikeme Arodiwe MD	Department of Medicine, University of Nigeria College of Medicine (Consultant Nephrologist).
07/2009 – 06/2011	Kayode Lawrence MD	Nephrology Fellowship, Mount Sinai Services of the Mount Sinai School of Medicine, NY, USA.
2009	Jennifer Stephani MSIV	MSIV student from the School of Medicine and Public Health, University of Wisconsin, Madison, WI.
2009	Joseph Skalski MSIV (Case Report Education)	MSIV student from the School of Medicine and Public Health, University of Wisconsin, Madison, WI.
2017	Eileen Samuel MSIV (Case Report Education)	MSIV student from the School of Medicine and Public Health, University of Wisconsin, Madison, WI.

TEACHING AIDS

CURRICULUM DEVELOPMENT

2019 – The Robert Larner, M.D. College of Medicine, University of Vermont The Teaching Academy Medical Education Fellowship Program Certificate. September 2018 – May 2019.

Curriculum Development: As part of the The Teaching Academy Medical Education Fellowship Program Certificate. September 2018 – May 2019, I developed a pedagogic adaptation of the “Case Analysis” paradigm as applied in the Social Sciences to the application of the art and science of “History & Physical” in Clinical Clerkship. The title of the work is **“Case Analysis – A UVM New Pedagogy Methodology for History & Physical Medical Clerkship”**. The work was completed in May 2019 and it is hoped to be rolled out sometime in 2019-2020 at The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT as part of new innovative techniques of teaching the art and science of Medicine to medical students, resident doctors and fellows at UVMHC.

TEACHING AWARDS AND NOMINATIONS – None to date

SUMMARY OF TEACHING ACTIVITIES

Since 1990, when I was appointed an Attending Nephrologist and Senior Lecturer at the University of Nigeria Teaching Hospital, Enugu, Nigeria, I have conducted teaching services to medical students, residents, fellows, nurses and other healthcare personnel. Between September

2002 and January 2018, at the Mayo Clinic Health System, Eau Claire, Wisconsin, I have participated in formal lectures involving medical students and residents from the University of Wisconsin School of Medicine and Public Health, Madison, WI. We did not however have access to the evaluations they submitted on their return to Madison, WI. This was on the average of 2-6 students/medical residents a year, each completing usually a 2-4 week's rotation in Nephrology with me. Indeed, on a few occasions, I was able to complete work on patients seen together with these students/residents and to publish case reports with these students/residents as co-authors. Furthermore, I offered formal lectures to Dialysis Nurses and Dialysis technicians on the various concepts and tenets of renal replacement therapy that was pertinent to their job descriptions at the Mayo Clinic Health System, Eau Claire, WI. I have carried out teaching lectures and Grand Rounds at Mayo Clinic, Rochester, MN, USA, and affiliated medical centers within the Mayo Clinic Health System and in various medical schools here in the USA between 2003 and 2017. Similarly, I have completed teaching lectures and Grand Rounds in the last 10 years to various international audiences including the National University Health System (NUHS), Division of Nephrology, Singapore, Singapore, at Instituto Mexicano de Investigaciones Nefrológicas. Instituto Nacional de Ciencias Medicas y Nutrition (Salvador Zubiran), Mexico City, Mexico, at the Garki Hospital, Abuja, Nigeria, and at the Nnamdi Azikiwe Teaching Hospital, Nnewi, Nigeria. Since joining The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, in February 2018, I have continued with teaching Nephrology fellows at the UHC Nephrology Office during the Thursday Fellow's Clinics. I have had various medical residents and observers in attendance while on Nephrology Consult Service, and in the Nephrology outpatient office. While working with the medical students, observers and Internal Medicine residents on the Consult Service, I have been able to mentor and coach them in medical writing and in the last one year, we have produced several published case reports including one titled "A Novel Diagnostic Approach for Suspected Icodextrin Pleural Effusion in a Peritoneal Dialysis Patient", published in Mayo Clinic Proceedings Innovations Quality Outcomes in 2019. I have completed several lectures on "Acute Kidney Injury in the Hospital" to 3rd Year Medical Students, Morning Report/Academic Half Day lectures to UVMHC Internal Medicine residents and "Acute Kidney Injury in the ICU" to UVMHC Pulmonary/Critical Care fellows. Additionally, since 2016, I have served as a Professor/Instructor at the College of Business, University of Wisconsin MBA Consortium. I teach an online 8-week Fall Semester course to the MBA students titled "Health Care Human Resources & Organizations". To further my teaching capabilities and to align myself more closely with the cultures and practices here at UVM, I quickly completed the UVM Mentoring the Mentor Workshop (August 22, 2018) and I subsequently successfully completed the 2018-2019 The Teaching Academy Medical Education Fellowship Program of the Robert Larner, M.D. College of Medicine, at the University of Vermont.

RESEARCH AND SCHOLARLY ACTIVITIES

RESEARCH AWARDS AND GRANTS

University of Vermont Health Network Medical Group UVMHNMG Research Award Grant: "A pilot crossover study of the impact of increased urine flow rate by oral hydration versus bolus intravenous furosemide infusion on urinary oxygen tension". The grant period is 01/01/2019 to 12/31/2020. Research Grant amount - \$50,000. Grant/project code: MG191.

University of Vermont Center for Biomedical Innovation (UVM CBI) SEED Project Research Award, 2021-2022. Hemodialysis Filter Rotator/Manipulator. March 9, 2021. This is a two-term Electrical and Biomedical Engineering/Mechanical Engineering Capstone Design UVM Course. University of Vermont (UVM) College of Engineering and Mathematical Sciences (CEMS) Senior Experience in Engineering Design (SEED) UVM CEMS – SEED: \$2000.00.

Ongoing Research Support

Study #: BXU519739

04/2018-04/2019

PD Baxter study titled “A Retrospective Chart Review Study of Patients Using Automated Peritoneal Dialysis (APD) With or Without Remote Monitoring”.

The goal of this study is to compare the effects of two different night cycled APD machine systems on patient and dialysis outcomes. **This was subsequently withdrawn by Baxter.**

Role:

PI

Completed Research Support

2010-2011

1. System Oriented Application Research SOAR Grant Award, Mayo Health System (MHS) Education: 2010-2011. We completed work on the dynamics of Hepatitis B Virus serology testing in ESRD patients on chronic maintenance outpatient hemodialysis. We investigated De-Novo Hepatitis B Virus Infection Versus Transient Vaccine-Related Recombinant HBsAgemia in a Mayo Clinic Hemodialysis Population. Our work was presented in several international dialysis conferences and was published in the journal Hemodialysis International [Hemodial Int 2012; 16(1):162].

Role: PI

2. Mayo Clinic 2014 Division of Hypertension and Nephrology Integration Research Award – 06/2014. We investigated the incidence of the syndrome of rapid onset ESRD among incident ESRD patients on chronic maintenance hemodialysis in a Mayo Clinic cohort, 2001-2013. We presented our findings at the 2015 European Renal Association Annual Congress and the 18th International Conference on Dialysis (2016), and have published our findings in the journals Renal Failure (2015), JAMA Surgery (2016) and in Hemodialysis International [Hemodial Int 2017; 21(Suppl 2):S33-S40].

Role: PI

Ongoing Research Grants & Co-Investigator of Ongoing Clinical Trials.

1. University of Vermont Health Network Medical Group UVMHNMG Research Award Grant: “A pilot crossover study of the impact of increased urine flow rate by oral hydration versus bolus intravenous furosemide infusion on urinary oxygen tension”. The grant period is 01/01/2019 to 12/31/2020. Research Grant amount - \$50,000. Grant/project code: MG191 (**Principal Investigators**: Macaulay Onuigbo MD, Nina Narasimhadevera MD. Division of Nephrology, UVMMC, Burlington, VT).

2. Clinical Trial Investigator – REATA Pharmaceuticals: RTA 402. 402-C-1808. US IND NUMBER: 140817. EUDRACT NUMBER:2018-004651-20. A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease. Version 2.0-04 March 2019. Participation as **Co-investigator** in Site Initiation Visit: June 20, 2019 1030 am – 1115 am with Richard Solomon MD as PI.

3. Clinical Trial Investigator – Corivdia Therapeutics, Inc. RESCUE Site Initiation Visit (SIV). COR-001-02. July 2, 2019. Participation as **Co-investigator** in Site Initiation Visit: July 2, 2019 10:00 am – 1145 am with Richard Solomon MD as PI. This is a Phase 2, Randomized, double-Blind, Placebo-Controlled Trial to Evaluate Reduction in Inflammation in Patients with advanced Chronic Renal Disease Utilizing Antibody mediated IL-6 inhibition (RESCUE).

4. Clinical Trial Investigator - IDORSIA PHASE III RESISTANT HYPERTENSION STUDY – APROCITENTAN INSPIRE-CKD & PRECISION STUDIES_IDORSIA. Participation as a **Sub-investigator**. Dr. Richard Solomon is the Principal Investigator for the UVMMC site.

5. Plans to start phase 1 clinical trials with the Hemodialysis Filter Rotator (HDFR) studies as a novel innovative approach to achieving anticoagulation-free hemodialysis using the NxStage Hemodialysis Machine and the NxSTAGE CAR-170-C Cartridge. Currently as of June 6, 2025, I have a Pre-Submission before the US Food and Drug Administration regarding the newly designed and prototyped medical device.

SCHOLARSHIP

Peer Reviewed Publications

Original Research

Peer-reviewed Articles in journals

My NCI Bibliography Link:

https://www.ncbi.nlm.nih.gov/myncbi/1Z_8wlyOQwHAcG/bibliography/public/

1. **Onuigbo MA.** The ESR: Facts and fallacies. Medicine Digest 1988; 14(7):9-12.
2. **Onuigbo MA,** Otti TIP, Okolo PI, Anyoku O, Ubaka A. The liver in malaria: Can it be hepatitis? Orient Journal of Medicine 1989; 1:22-4.
3. **Onuigbo MA.** Typhoid fever epidemic in Nigeria. The abuse of Widal test and the antibiotic chloramphenicol. Nigeria Medical Practitioner 1989; 18(2):23-5.
4. Ibeachum GI, **Onuigbo MA,** Osefo A. Dermal myiasis by cordylobia anthropophaga in Nigeria male. A case report. Orient Journal of Medicine 1990; 2:142-4.
5. Mezue ME, Ozoh JO, **Onuigbo MA.** Management of problems of symptomatic giant intracranial aneurysms: illustration with a case of multiple giant aneurysms in a Nigerian female. Orient Journal of Medicine 1990; 2(4):212-5.

6. **Onuigbo MA**, Ideyi S, Osunkwo IC. Fatal hypothermia in erythema multiforme exudativum (Steven-Johnson Syndrome). A case report *Orient Journal of Medicine* 1990; 2(2):88-92.
7. **Onuigbo MA**. Fracture of bone with an aneurysmal bone cyst during lactation. *Cent Afr J Med* 1990; 36(3):84-7.
8. **Onuigbo MA**. Diagnosis of typhoid fever in Nigeria: misuse of the Widal test. *Trans R Soc Trop Med Hyg.* 1990 Jan-Feb;84(1):129-31.
9. **Onuigbo MA**. Relevance of the Widal test in typhoid fever. A reply. *Trans R Soc Trop Med Hyg* 1990; 85(1):137-8.
10. Ozoh JO, **Onuigbo MA**, Nwankwo N, Ukabam SO, Umerah BC, Emeruwa CC. "Vanishing" of vertebra in a patient with sickle cell haemoglobinopathy. *BMJ.* 1990 Dec 15;301(6765):1368-9.
11. Okoye IJ, Offodile A, Ozoh JO, **Onuigbo MA**, Umerah BC, Nwagbo DFE. Estimation of gestational age by fetal ultrasonic femoral length measurements. *Orient Journal of Medicine* 1991.
12. Okoye IJ, Offodile AA, Ozoh O, Udeh AC, Umerah BC, Nwagbo DFE, **Onuigbo MA**. Improved accuracy in assessment of gestational age combining ultrasonic femoral and biparietal measurements. *Nigerian Medical Journal* 1991.
13. Okoye LI, Nwankwo N, Umerah BC, Udeh AC, Ozoh O, **Onuigbo MA**. Congenital penoscrotal urethral diverticulum, MCU Diagnosis. *Orient Journal of Medicine* 1991; 3(1):60-1.
14. **Onuigbo MA**, Chikwendu VC. Fatal spontaneous rupture of mitral valve leaflet chordae tendineae in Marfan's syndrome. A case report and a review of the literature. *Nigerian Medical Practitioner* 1991; 2(6):67-71.
15. **Onuigbo MA**, Egwim PO, Ibeachum GI. Aminoglycoside nephrotoxicity. An animal model for gentamicin-induced nephropathy. *Orient Journal of Medicine* 1991; 3(2):76-81.
16. **Onuigbo MA**, Ozoh JO, Egbuji T, Ijeoma CK, Chukwuka C, Offodile AA, Obianigwe V. Adult polycystic kidney disease. A Nigerian family study. *Niger Med J* 1991; 3 & 4:71-3.
17. **Onuigbo MA**, Ozoh JO, Nusiemi CA, Onyeagocha AC, Nwaneri O, Offodile AA, Ijeoma CK. Combined ascitic--fluid and furosemide infusion: a therapeutic option for massive diuretic-resistant ascites and severe oliguria of hepatic cirrhosis. *Cent Afr J Med.* 1991 Aug;37(8):244-7.
18. **Onuigbo MA**. Intravascular volume depletion and preexisting azotemia in non-diabetic nephritic syndrome: risk factors for acute renal shutdown. *Nigerian Journal Medicine* 1991; 21:129.

19. Ozoh JO, **Onuigbo MA**, Awogu AU, Juwah AI. Unusual spine changes in sickle cell hemoglobinopathy. A review of two cases Nigerian Journal of Medicine 1991; 1:69-71.
20. Ozoh JO, **Onuigbo MA**, Okoye I, Umerah, Nwagbo DFE. Correlation of renal lengths with heights of Nigerians. Nigerian Medical Journal 1991.
21. Ozoh JO, **Onuigbo MA**, Okoye IJ, Umerah BC, Nwagbo DFE. Age and sex distribution of normal renal sizes in Southeastern Nigeria. Orient Journal of Medicine 1991; 3(3):146-9.
22. **Onuigbo MA**, Ozoh JO, Onuigbo WI, Ibeachum GI. Chronic Gaucher's disease masquerading as tropical splenomegaly syndrome in a Nigerian woman. Trans R Soc Trop Med Hyg. 1991 Nov-Dec;85(6):834-5.
23. Okoye IJ, Offodile AA, Osoh O, Udeh AC, Umerah BC, Nwagbo DFE, **Onuigbo MAC**. An evaluation of biparietal diameter as a predictor of gestational age. West African Journal of Radiology 1992; 2(1):11-4.
24. Okoye IJ, Okereke OUI, Ozoh JO, Udeh AC, Umerah BC, **Onuigbo MA**. Intracavitary cardiac metastasis from hepatoma. West African Journal of Radiology 1992; 2(1):19-21.
25. **Onuigbo MA**, Anusiem CA, Ijoma CK, Obinna A, Omeche KO. Unusual tetanus with multiple cranial nerve palsies A case report Orient Journal of Medicine 1992.
26. **Onuigbo MA**, Ogbonna A, Ozoh JO. Probable adrenocortical failure following suramin administration. A case report. Niger Med J 1992; 23(1):28-30.
27. **Onuigbo MA**, Wamuo I, Ifebunandu N. Proptotic panophthalmitis and bilateral supraclavicular lymph node metastases from prostatic carcinoma. A case report and literature review. Medicare Journal 1992; 5(4):20-5.
28. **Onuigbo MA**. Hemodialysis: A modality of renal substitution therapy. Medicare Journal 1992; 5(3):23-8.
29. **Onuigbo MAC**, Okafor PIS, Ibeachum GI. Bilateral granulomatous tuberculous epididymitis and male infertility. A case report. Medicare Journal 1992; 5(5):21-2.
30. Ozoh JO, **Onuigbo MA**, Okoye IJ, Umerah BC, Nwagbo DFE. Normal renal sizes. West African Journal of Radiology 1992; 2(1):3-7.
31. Ozoh JO, **Onuigbo MA**, Udeh FN. Hypernephroma complicating pregnancy. Nigerian Journal of Surgical Sciences 1992; 2:29-31.
32. Ozoh JO, **Onuigbo MA**, Ukabam SO, Umerah BC, Onuigbo WIB, Mba I. Gaucher's disease: Progressive osseous changes in a West African Nigerian. West African Journal of Radiology 1992.
33. **Onuigbo MA**, Mbah AU. Tropical splenomegaly syndrome in Nigerian adults. West Afr J Med. 1992 Jan-Mar;11(1):72-78.

34. Ozoh JO, **Onuigbo MA**, Umerah BC, Mgbor SO. Hepatoma in pregnancy. *Trop Geogr Med*, 1992 vol. 44(1-2) pp. 72-74.
35. **Onuigbo MA**. Hypertensive Nephropathy – A prospective UNTH perspective. *Medikka Journal The International Journal of the University of Nigeria Medical Students Special Edition* October 1992-September 1993:31-37.
36. Ibeachum GI, **Onuigbo MA**. Dermal myiasis by *cordylobia rhodaini* in Nigerian Children. *Orient Journal of Medicine* 1993; 5:148-50.
37. **Onuigbo MA**, Ijoma CK, Aduba O. Acute peritoneal dialysis using ordinary dextrose-saline solutions, prospects and problems. *Medicare Journal* 1993; 5(9):11-4.
38. **Onuigbo MA**, Ozoh JO, Ejike O. The vanishing vertebra syndrome: Two missing lumbar vertebrae complicating Pott's disease of the spine. *Nigerian Medical Journal* 1993; 24(1):26-7.
39. **Onuigbo MA**, Ukpaka C, Ibeku C, Nneji B. Small urine samples, specific gravity determinations: how far can serial dilutions go? *Orient Journal of Medicine*. 1993; 5(1):27-9.
40. **Onuigbo MA**. Acute renal failure in Southeastern Nigeria: A 24-month prospective review. *Medical Update Journal* 1993; 1(2):19-25.
41. Guntupalli J, **Onuigbo M**, Wall S, Alpern RJ, DuBose TD. Adaptation to low K⁺ media increases H⁺ K⁺-ATPase but not H⁺-ATPase-mediated pHi recovery in OMCD1 cells. *American Journal of Physiology* 1997; 273(2 pt 1):C558-71.
42. **Onuigbo MA**, Alikhan M. Over-the counter sympathomimetics: A risk factor for cardiac arrhythmias in pregnancy *Southern Medical Journal* 1998; 91:1153-5.
43. **Onuigbo MA**. Angiotensin II receptor antagonists. What Future? *Biomedicine* 1998; 7(7).
44. **Onuigbo MA**, Alikhan M. Cold medications can have unwanted results. *Southern Medical Journal* 1998 Dec.
45. **Onuigbo MA**, Cuffy-Hallam M, Mangano A, Schwartz M, Alikhan M. Successful thrombolytic therapy for massive pulmonary embolism: A case report. *Southern Medical Journal* 2000; 93:327-9.
46. **Onuigbo MA**, Yin R. Macro-aspartate transaminasemia: The macroenzyme phenomenon as a diagnostic dilemma. *Mayo Clinic Proceedings* 2000; 72:1223-4.
47. **Onuigbo MA**. Inherited thrombophilia, hypercoagulability, and risk factors for atherosclerosis. *Mayo Clinic Proceedings* 2000; 75:870-1.
48. **Onuigbo MAC**, Cuffy-Hallam ME, Wiley KJ, McClelland PA. Painless Thyroiditis: the rare phenomenon of lithium-associated thyrotoxicosis. *Hospital Physician* 2000 Sep;36(9)-48-50.

49. **Onuigbo MA**, Cuffy-Hallam M, Dunsmore N, Zinreich E. Mammography reveals a 2 mm sized intraductal breast carcinoma. A case report. *Hospital Physician* 2001;61-4.
50. **Onuigbo MA**, Lawrence K, Park, S. Retroperitoneal Fibrosis: Unusual cause of low back pain. *Southern Medical Journal* 2001; 94(7):735-7.
51. **Onuigbo MA**, Washington C. Glycosuria in alcoholics: Alcohol diabetes, transient hyperglycemia, renal tubular syndrome or factitious dipstick test result? *Nephron* 2001; 3:287-8.
52. **Onuigbo MA**, Haririan A, Ramos E, Klassen D, Wali R, Drachenberg C. Cytomegalovirus-induced glomerular vasculopathy in renal allografts; A report of two cases. *American Journal of Transplantation* 2002; 2(7):684-8.
53. **Onuigbo MA**. Gender differences in responsiveness to erythropoietin. *American Journal of Kidney Diseases* 2002; 39(2):442-3.
54. Fink JC, **Onuigbo MA**, Blahut SA, Christenson RH, Mann D, Bartlett ST, Weir MR. Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study. *Am J Kidney Dis* 2002 May; 39(5):1096-101. PMID:11979355.
55. **Onuigbo M**, Weir M. Evidence-based treatment of hypertension in patients with diabetes mellitus. *Diabetes Obesity and Metabolism* 2003; 5:13-26.
56. **Onuigbo MA**, Onuigbo NT. Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience. *Med Sci Monit* 2005 Oct; 11(10):CR462-9. Epub 2005 Sep 26. PMID:16192897.
57. **Onuigbo MA**, Onuigbo NT. Renal failure and concurrent RAAS blockade in older CKD patients with renal artery stenosis: an extended Mayo Clinic prospective 63-month experience. *Ren Fail* 2008; 30(4):363-71. PMID:18569908. DOI:10.1080/08860220801947363.
58. **Onuigbo MA**, Onuigbo NT. Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors. *Ren Fail* 2008; 30(1):73-80. PMID:18197547. DOI:10.1080/08860220701742161.
59. **Onuigbo MA**, Onuigbo NT. Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study. *Ren Fail* 2008; 30(1):67-72. PMID:18197546. DOI:10.1080/08860220701742153.
60. **Onuigbo MA**, Onuigbo NT. Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. *Int Urol Nephrol* 2008; 40(1):233-9. Epub 2008 Jan 15. PMID:18196471. DOI:10.1007/s11255-007-9299-2.
61. **Onuigbo MA**, Onuigbo NT. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis. *QJM* 2008 Jul; 101(7):519-27. Epub 2008 Mar 28. PMID:18375475. DOI:10.1093/qjmed/hcn039.

62. **Onuigbo MA**, Nye D, Iloanya PC. Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients. *Adv Perit Dial* 2009; 25:89-91. PMID:19886325.
63. **Onuigbo MA**. The natural history of chronic kidney disease revisited--a 72-month Mayo Health System Hypertension Clinic practice-based research network prospective report on end-stage renal disease and death rates in 100 high-risk chronic kidney disease patients: a call for circumspection. *Adv Perit Dial* 2009; 25:85-8. PMID:19886324.
64. **Onuigbo MA**. Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution. *Nephron Clin Pract* 2009; 113(2):c63-9, discussion c70. Epub 2009 Jul 14. PMID:19602900. DOI:10.1159/000228536.
65. **Onuigbo MAC**. Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET--a call for more circumspection. *QJM. South African Excerpts Edition*. 2009; 8(3):169-181.
66. **Onuigbo MAC**. Symptomatic uraemia from bilateral obstructive uropathy secondary to metastatic urinary bladder cancer showing only unilateral hydronephrosis: A case report. *NDT Plus* 2009; 2(5):387-9.
67. **Onuigbo MA**. Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET--a call for more circumspection. *QJM* 2009 Mar; 102(3):155-67. Epub 2008 Dec 19. PMID:19098074. DOI:10.1093/qjmed/hcn142.
68. **Onuigbo M**. A Downside to Angiotensin Blockade? *Renal and Urology News* 2009 Jun 18.
69. **Onuigbo MA**. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice. *Hemodial Int* 2009 Oct; 13 Suppl 1:S24-9. PMID:19775421. DOI:10.1111/j.1542-4758.2009.00416.x.
70. **Onuigbo MA**, Lawrence K, Onuigbo NT. Non-dilated obstructive uropathy - an unrecognized cause of acute renal failure in hospitalized US patients: three case reports seen over 6 months in a northwestern Wisconsin Nephrology practice. *Ren Fail* 2010; 32(10):1226-9. PMID:20954986. DOI:10.3109/0886022X.2010.517343.
71. **Onuigbo MA**. Bilateral lower extremity sequential compression devices (SCDs): a novel approach to the management of intra-dialytic hypotension in the outpatient setting--report of a case series. *Ren Fail* 2010 Jan; 32(1):32-5. PMID:20113263. DOI:10.3109/08860220903367478.
72. **Onuigbo MA**. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. *Nephrol Dial Transplant* 2010 Apr; 25(4):1344-5. Epub 2009 Dec 27. PMID:20037177. DOI:10.1093/ndt/gfp678.

73. **Onuigbo MA**, Skalski J. Newly symptomatic central diabetes insipidus in ESRD with adult polycystic kidney disease following intracranial hemorrhage: the first reported case. *Med Sci Monit* 2010 Feb 26; 16(3):CS29-32. PMID:20190689.
74. **Onuigbo M**, Frenandes R, Nijhawan V. The ASTRAL trial results revisited--to stent or not to stent in renal artery stenosis? *QJM* 2010 May; 103(5):357. Epub 2010 Jan 21. PMID:20093328. DOI:10.1093/qjmed/hcp202. (Editorial Commentary)
75. **Onuigbo MA**, Nesbit A, Weisenbeck J, Hurlburt J. Hepatitis B surface antigenemia following recombinant Engerix B hepatitis B vaccine in an 81-year-old ESRD patient on hemodialysis. *Ren Fail* 2010 May; 32(4):531-2. PMID:20446799. DOI:10.3109/08860221003637369.
76. **Onuigbo MA**. Relation between kidney function, proteinuria, and adverse outcomes--a critical look at the application of medical statistics in the Nephrology literature. *QJM* 2010 Jul; 103(7):537-8. Epub 2010 Apr 11. PMID:20385569. DOI:10.1093/qjmed/hcq053.
77. **Onuigbo MA**. Nephrotoxic effects of water-soluble B-vitamin therapy in diabetic nephropathy?--How true can this be? *QJM* 2010 Jul 14. [Epub ahead of print] PMID:20630906. DOI:10.1093/qjmed/hcq120.
78. **Onuigbo MA**. Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far? *Int J Clin Pract* 2010 Sep; 64(10):1341-6. PMID:20716141. DOI:10.1111/j.1742-1241.2010.02448.x.
79. **Onuigbo MA**. Syndrome of rapid-onset end-stage renal disease: a new unrecognized pattern of CKD progression to ESRD. *Ren Fail*. 2010;32(8):954-8.
80. **Onuigbo MAC**, Onuigbo N. Syndrome of rapid onset end-stage renal disease revisited – Observations from two chronic kidney disease populations in two continents. *US Nephrology*, 2010;5(2): 81-5.
81. **Onuigbo MA**. Can ACE Inhibitors and Angiotensin Receptor Blockers Be Detrimental in CKD Patients? *Nephron Clin Pract*. 2011 Mar 7;118(4):c407-c419. [Epub ahead of print].
82. **Onuigbo MA**, Onuigbo NT. Variability in CKD stage in outpatients followed in two large renal clinics – Implications for CKD trials and the status of current knowledge of patterns of CKD to ESRD progression. *Int Urol Nephrol*. 2011 Aug 30. [Epub ahead of print].
83. **Onuigbo MA**, Onuigbo NT. Predialysis Nephrology Care of Older Patients Approaching End-stage Renal Disease. *Arch Intern Med*. 2011 Dec 12;171(22):2066.
84. **Onuigbo M**. Association between glycemic control and adverse outcomes in diabetic CKD patients. Letter to the Editor, *Arch Intern Med*. *Arch Intern Med*. 2012 Apr 9;172(7):596.
85. **Onuigbo MA**. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose containing intravenous immunoglobulins. A case-control study. *Pharmacoepidemiol Drug Saf*. 2012 Mar;21(3):320-2. doi: 10.1002/pds.2273. Epub 2012 Jan 12. [Epub ahead of print]. (Editorial Commentary).

86. **Onuigbo M.** Long inter-dialytic interval and mortality among patients receiving maintenance hemodialysis for end-stage renal disease – A call for more studies on the right amount or frequency of maintenance hemodialysis for end stage renal disease. *Int J Clin Pract.* 2012 Mar;66(3):327. doi: 10.1111/j.1742-1241.2011.02874.x
87. **Onuigbo MA.** Healthcare expenditure in the United States of America in the last year of life - where ethics, medicine and economics collide - *Int J Clin Pract.* 2012 Feb;66(2):226-7. doi: 10.1111/j.1742-1241.2011.02846.
88. **Onuigbo M.** Bend Health Cost Curve. *Leader-Telegram, Eau Claire, WI. Opinions - Voice of the People.* June 18, 2012. P 8A. (Newspaper).
89. **Onuigbo MAC, Onuigbo NTC.** De novo HBV infection in a Mayo Clinic hemodialysis population: Economic impact of reduced HBV testing and a call for changes in current US CDC guidelines on HBV testing protocols. *Hemodial Int.* 2012 Oct; 16 Suppl 1:S32-8. Article first published online: 4 OCT 2012. DOI: 10.1111/j.1542-4758.2012.00748.x
90. **Onuigbo MA.** Increasing trends in acute dialysis after elective surgery, 1995-2009: How often does AKI directly lead to irreversible ESRD all in one fell swoop? *CMAJ.* Published Online, July 13, 2012.
91. **Onuigbo MAC.** CKD Express © - A New IT-Software Proposed for a Paradigm Change in CKD Care. *Open Med Inform J.* 2012 vol. 6 pp 26-27.
92. **Onuigbo MA, Onuigbo NT.** Variability in CKD stage in outpatients followed in two large renal clinics – Implications for CKD trials and the status of current knowledge of patterns of CKD to ESRD progression. Letter to the Editor. *International Urology and Nephrology;* 2012, 44 (5): 1589-1590.
93. **Onuigbo MAC.** Physician “cognitive drift” and medication errors – Unintended consequences of the modern EMR. *WMJ.* 2012;111(5):198 (Letter to the Editor).
94. **Onuigbo MA.** Renoprevention: A New Concept for Reengineering Nephrology Care-An Economic Impact and Patient Outcome Analysis of Two Hypothetical Patient Management Paradigms in the CCU. *Ren Fail.* 2013;35(1):23-8. doi: 10.3109/0886022X.2012.741644. Epub 2012 Nov 15.
95. **Onuigbo MAC.** Is combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade associated with increased risk of cardiovascular death in hemodialysis patients? *Current Hypertension Reviews;* 2012; 8 (4): 256-266 (eBook).
96. **Onuigbo MAC.** Syndrome of rapid onset end-stage renal disease in two consecutive renal transplant recipients. *Indian J Nephrol.* 2013 May;23(3):222-5. doi: 10.4103/0971-4065.111861.
97. **Onuigbo MA.** The CKD Enigma with Misleading Statistics and Myths about CKD, and Conflicting ESRD and Death Rates in the Literature: Results of a 2008 US Population-Based Cross-Sectional CKD Outcomes Analysis. *Ren Fail.* 2013;35(3):338-43. doi: 10.3109/0886022X.2013.764272. Epub 2013 Feb 8.

98. **Onuigbo MA.** Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. *BMJ* January 2013: Rapid Response, Published online January 17 2013. <http://www.bmj.com/content/346/bmj.e8525/rr/625431>.
99. **Onuigbo MA.** The nephrotoxic "triple whammy" of combining diuretics, ACE inhibitors, and diuretics. *BMJ*. 2013; 346:f678. Epub 2013 Feb 19. [Letter. Polypharmacy and acute kidney injury]. Corrected in *BMJ* to read: "The nephrotoxic 'triple whammy' of combining diuretics, ACE inhibitors, and NSAIDs". (<http://www.bmj.com/content/346/bmj.f678>.)
100. **Onuigbo MA, Onuigbo NTC.** Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomized trials. *BMJ* 2013: Rapid Response, Published online February 6, 2013. <http://www.bmj.com/content/346/bmj.f360/rr/629350>.
101. **Onuigbo MA, Onuigbo NTC.** "Quadruple Whammy", a new syndrome of potentially preventable yet iatrogenic acute kidney injury in the ICU. *BMJ* 2013: Rapid Response, Published online February 25, 2013. <http://www.bmj.com/content/346/bmj.f678/rr/632570>.
102. **Onuigbo MA, Onuigbo NTC.** A second case of "Quadruple Whammy" in a week in a Northwestern Wisconsin hospital. *BMJ* 2013: Rapid Response, Published online March 1, 2013. <http://www.bmj.com/content/346/bmj.f678/rr/633687>.
103. **Onuigbo M, Onuigbo N.** Aliskiren in Type 2 Diabetes and Cardiorenal End Points. *N Engl J Med*. 2013 Mar 14;368(11):1064-5. doi: 10.1056/NEJMc1300257#SA1. (<http://www.nejm.org/doi/pdf/10.1056/NEJMc1300257>).
104. **Onuigbo MAC.** Renoprotection and the Bardoxolone Methyl Story - Is this the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A new classification scheme for renoprotective agents. *Nephron Extra* 2013;3:36-49 (DOI: 10.1159/000351044).
105. **Onuigbo MA.** Evidence of the syndrome of rapid onset end-stage renal disease (SORO-ESRD) in the acute kidney injury (AKI) literature - Preventable causes of AKI and SORO-ESRD – A Call for Re-engineering of Nephrology Practice Paradigms. *Ren Fail*. 2013 Jul;35(6):796-800. doi: 10.3109/0886022X.2013.800459. Epub 2013 Jun 3.
106. **Onuigbo M, Onuigbo N, Bellasi A, Russo D, Di Iorio B.** Penultimate pulse wave velocity, better than baseline pulse wave velocity, predicted mortality in italian ESRD cohort study - a case for daily hemodialysis for ESRD patients with accelerated pulse wave velocity changes. [La penultima Pulse Wave Velocity è un predittore migliore di mortalità rispetto alla Pulse Wave Velocity di base in una coorte italiana di pazienti affetti da ESRD – L'emodialisi a sedute quotidiane potrebbe aiutare pazienti ESRD con variazioni accelerate della PWV] . *G Ital Nefrol*. 2013 Mar-Apr;30(2). pii: gin/30.2.22.
107. **Ulasi I, Tzur S, Wasser WG, Shemer R, Kruzel E, Feigin E, Ijoma CK, Onodugo CD, Okoye JU, Arodiwe EB, Ifebunandu NA, Chukwuka CJ, Onyedum CC, Ijoma UN, Nna E, Onuigbo M, Saharon Rosset S, Skorecki K.** High Population Frequencies of APOL1 Risk Variants are Associated with Increased Prevalence of Non-Diabetic Chronic Kidney Disease in the Igbo People from South-eastern Nigeria. *Nephron Clin Pract*. 2013 Jul 13;123(1-2):123-128. [Epub ahead of print].

108. **Onuigbo MAC.** Nondialytic Therapy for End-Stage Renal Disease Is an Underutilized Care Paradigm in the United States: Time for a More Robust Reappraisal of This Treatment Option. *Adv Perit Dial.* 2013; 29:73-76.
109. **Onuigbo MAC,** Onuigbo NT, Musso CG. Syndrome of rapid onset end stage renal disease in incident Mayo Clinic chronic hemodialysis patient. *Indian J Nephrol* 2014;24:75-81.
110. **Onuigbo MA.** Chronic kidney disease controversy: how expanding definitions are unnecessarily labeling many people as diseased. *BMJ* 2013 (Rapid Response, October 2 2013). www.bmj.com/content/347/bmj.f4298/rr/664777.
111. **Onuigbo MA.** Too much angioplasty. *BMJ* 2013. <http://www.bmj.com/content/347/bmj.f5741/rr/669420> (Rapid Response, October 30, 2013).
112. **Onuigbo M,** Agbasi N. ""Quadruple whammy" - A Preventable Newly Described Syndrome of Post-operative AKI in CKD II and CKD III Patients on Combination "Triple Whammy" Medications: A Mayo Clinic Health System, Eau Claire, Wisconsin Experience." *Niger J Clin Pract* 2014; 17(5): 649-654.
113. **Onuigbo MAC.** Comment on: Have we reached the limits for the treatment of diabetic nephropathy? Expert Opin Investig Drugs Posted online on May 6, 2014. (doi:10.1517/13543784.2014.912376) Letter to the Editor.
114. **Onuigbo MAC.** Unexplained hypotension and exertional dyspnea in a night cycled peritoneal dialysis patient - A rare form of Icodextrin hypersensitivity. *Adv Perit Dial* 2014. 30: 87-89.
115. **Onuigbo MAC,** Agbasi N. Too much coronary angioplasty in the USA?: Less may be better – The conflicting roles of inexactness of medicine as a science, asymmetric information, technologic imperative, unnecessary care and ethicomedicomics in US healthcare. *Int J Clin Pract*, September 2014, 68, 9, 1056–1059. doi: 10.1111/ijcp.12446
116. **Onuigbo MA.** Preoperative angiotensin axis blockade therapy, intraoperative hypotension, and the risks of postoperative acute kidney injury. *J Hosp Med.* 2014 Jun 16. doi: 10.1002/jhm.2229. [Epub ahead of print].
117. **Onuigbo M,** Agbasi N. ‘Escalating Cost of Pre-dialysis Chronic Kidney Disease Care in the US: The Introduction of an Innovative Chronic Kidney Disease Care Paradigm Using “The CKD Express © IT Software Program” - A New Recommended Tool for Medicare and the Affordable Care Act.’ *The Open Open Med Inform J*, 2014.
118. **Onuigbo M,** Agbasi N. Chronic kidney disease prediction is an inexact science: The concept of “progressors” and “nonprogressors”. *World J Nephrol.* 2014, 3(3): 31-49. <http://www.wjnet.com/2220-6124/pdf/v3/i3/31.pdf>.
119. **Onuigbo MA.** Renoprevention Revisited - The Impact of Preemptive Withdrawal of RAAS Blockade prior to Iodinated Contrast Exposure in Older CKD Patients: Results of a New Meta-Analysis. *Cardiology* 2015;130:25-26. [Epub ahead of print].

120. **Onuigbo MA.** Reduction of angiotensin inhibition in older CKD patients with heart failure led to improved renal and mortality outcomes - the results of a Spanish open RCT. *Int J Clin Pract.* 2015 May;69(5):510-3. doi: 10.1111/ijcp.12595 (Editorial).
121. Musso CG, Vilas M, **Onuigbo M.** Nephroprotection in the oldest old with chronic kidney disease: Special considerations. *World J Nephrol* 2015; 4(1):1-5. Published online 2015 February 06. doi: 10.5527/wjn.v4.i1.1 (Editorial).
122. **Onuigbo MAC.** Stenting may benefit select patients with severe renal artery stenosis. *Cleve Clin J Med.* 2015; 82(8): 495-7. (Editorial).
123. **Onuigbo M,** Agbasi N. Diabetic Nephropathy and CKD - Analysis of individual patient serum creatinine trajectories: A forgotten diagnostic methodology for diabetic CKD prognostication and prediction. *J. Clin. Med.* 2015, 4(7), 1348-1368; doi:10.3390/jcm4071348.
124. **Onuigbo MA,** Agbasi N. Intra-operative Hypotension - A Neglected Causative Factor in Hospital-Acquired Acute Kidney Injury: A Mayo Clinic Health System Experience Revisited. *J Renal Inj Prev.* 2015; 4(3): 61-67.
125. **Onuigbo M,** Agbasi N. Syndrome of rapid onset ESRD accounted for high hemodialysis catheter use - results of a 13-year Mayo Clinic incident hemodialysis study. *Ren Fail.* 2015, 37(9): 1486-91.
126. **Onuigbo MA.** Major Effect of the Syndrome of Rapid-Onset End-Stage Renal Disease on the Use of Arteriovenous Fistulas: High Rates of Initiation of Hemodialysis With Hemodialysis Catheter in the United States. *JAMA Surgery* 2016, 151(1): 96. Published Online October 7, 2015. (Letter to the Editor).
127. **Onuigbo MA.** What's new in emergencies, trauma and shock? Acute renal failure and intra-abdominal hypertension in acute compartment syndrome: Any corollaries with acute renal failure in cardiorenal syndrome? *Journal of Emergencies, Trauma, and Shock.* 2016; 9 (2):49-50 (Editorial).
128. **Onuigbo M,** Agbasi N. Association of Intraoperative Hypotension with acute kidney injury after elective non-cardiac surgery – prevention is better than cure. *Ren Fail* 2016, 38(1): 168-9.
129. Hamadah AM, Beaulieu LM, Wilson JW, Aksamit TR, Gregoire JR, Williams AW, Dillon JJ, Albright RC, **Onuigbo M,** Iyer VK, Hickson LJ. Tolerability and Healthcare Utilization in Maintenance Hemodialysis Patients Undergoing Treatment for Tuberculosis-Related Conditions. *Nephron.* 2016, 132(2).
130. Hickson LJ, Negrotto SM, **Onuigbo M,** Scott CG, Rule AD, Norby SM, Albright RC et al. Echocardiography Criteria for Structural Heart Disease in Patients with End-Stage Renal Disease Initiating Hemodialysis. *J. Am. Coll. Cardiol.* 2016, 67(10): 1173-82.
131. **Onuigbo M.** Leveraging the Electronic Health Record to Optimize Chronic Kidney Disease Care. *Am J Med. The American Journal of Medicine* **129** (2016) p. e65. 10.1016/j.amjmed.2015.12.033

132. **Onuigbo MAC.** Perioperative Acute Kidney Injury. Prevention Rather Than Cure. *JAMA Surg.* 2016.0455. 2016 Aug 1;151(8):782-3. doi: 10.1001/jamasurg.2016.0455
133. **Onuigbo M,** Agbasi N, Achebe J, Odenigbo C, Oguejiofor F. Pleuritic chest pain from portal hypertensive gastropathy in an end-stage renal disease patient with autosomal dominant polycystic kidney disease misdiagnosed as pericarditis. *J Renal Inj Prev.* 2016; 5(1): 48-52.
134. **Onuigbo MA,** Agbasi N. Comment on; post-transcatheter aortic valve replacement acute kidney injury; prevention rather than cure. *J Renal Inj Prev.* 2017;6(2):12-15. DOI: 10.15171/jrip.2017.02 (Letter to Editor).
135. **Onuigbo MA,** Agbasi N, Oguejiofor F, Odenigbo C. A curious case of persistently relapsing hyperkalemia in an ESRD patient on maintenance hemodialysis following bioprosthetic aortic valve replacement – a potential case for the use of the new agent, patiomer, for hyperkalemia management. *J Renal Inj Prev.* 2017;6(1):30-34. DOI: 10.15171/jrip.2017.06.
136. **Onuigbo MA,** Agbasi N. Severe symptomatic acute hyponatremia in traumatic brain injury responded very rapidly to a single 15 mg dose of oral tolvaptan; a Mayo Clinic Health System hospital experience – need for caution with tolvaptan in younger patients with preserved renal function. *J Renal Inj Prev.* 2017;6(1):26-29. DOI: 10.15171/jrip.2017.05
137. **Onuigbo M.** The neglected role of intraoperative hypotension in causing postoperative acute kidney injury – A mandatory need for more preventative nephrology in general medical practice. *Orient Journal of Medicine*, Vol 28 [Issues 3-4], Jul-Dec, 2016:iv-v. EDITORIAL.
138. **Onuigbo M,** Agbasi N. Prevention of post-operative AKI during cardiothoracic surgery - Intraoperative hypotension is a neglected culprit. *Niger J Cardiovasc Thorac Surg* 2016;1:59-63. DOI:10.4103/2468-7391.195952
139. **Onuigbo M.** Re: Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. *BMJ* 2017;356:j791 (eLetter).
140. **Onuigbo MA,** Agbasi NC. A call for more adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin–angiotensin system blockade. *BMJ Open*; Published April 7, 2017 (eLetter).
141. **Onuigbo MAC,** Agbasi N, McDermott W, Rentzepis M. Unintentional ipsilateral ureteral cannulation causing bilateral obstructive uropathy and azotemia in multiple sclerosis. *J Nephropharmacol.* 2017;6(2):65-67. DOI: 10.15171/npj.2017.06 (IN PRESS).
142. **Onuigbo MA,** Samuel E, Agbasi N. Hospital-acquired nephrotoxic exposures in the precipitation of acute kidney injury – A case series analysis and a call for more preventative nephrology practices. *J Nephropharmacol.* 2017;6(2):90-97. DOI: 10.15171/npj.2017.11.

143. Rafique Z, Weir MR, **Onuigbo M**, Pitt B, Lafayette R, Butler J, Lopes M, Farnum C, Peacock WF. Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure. *J Manag Care Spec Pharm*. 2017 Apr;23(4-a Suppl):S10-S19. doi: 10.18553/jmcp.2017.23.4-a.s10.
144. **Onuigbo MA**, Agbasi N. Reversible personality changes caused by brain nocardiosis in a 74-year old Caucasian male renal transplant recipient following disease-specific antimicrobial therapy. *J Renal Inj Prev*. 2018;7(3):211-214. doi: [10.15171/jrip.2018.49.c](https://doi.org/10.15171/jrip.2018.49.c)
145. **Onuigbo MA**, Agbasi N. A Mayo Clinic 13-year investigation of the syndrome of rapid onset ESRD among renal transplant recipients: An analysis of the implications of renal allograft biopsy results. *Hemodialysis International* 2017; 21:S33–S40.
146. **Onuigbo M**, Samuel E, Agbasi N. Late onset renal failure from angiotensin blockade (LORFFAB) and the syndrome of rapid onset end-stage renal disease (SORO-ESRD) revisited – Two case reports from Mayo Clinic Health System, Northwestern Wisconsin, USA; a review paper. *J Renal Inj Prev*. 2018;7(2):58-63. doi: [10.15171/jrip.2018.15](https://doi.org/10.15171/jrip.2018.15)
147. **Onuigbo MA**, Agbasi N. A three-year renal transplantation in a Nigerian public-private partnership program in Abuja, Nigeria, 2013-2016. *J Nephropharmacol*. 2017 (IN PRESS).
148. **Onuigbo MAC**. End Stage Renal Disease—A Nephrologist’s Perspective of Two Different Circumstances as Typified by Kidney Transplantation Experience in a Nigerian Hospital Versus a Large US Medical School. *Healthcare* 2017, 5, 31; doi:10.3390/healthcare5030031.
149. **Onuigbo MAC**, Kress C, Webb C, Agbasi N. Transient asymptomatic hepatitis B surface antigenemia following recombinant Recombivax B hepatitis B vaccine in a 42-year-old ESRD patient on maintenance hemodialysis. *J Nephropharmacol*. 2017;7(1):43-45. DOI: 10.15171/npj.2018.10.
150. **Onuigbo MA**. The problem with US Healthcare: It ain’t Obamacare! *WMJ*, 2017, 116(3) pp. 148 (Letter to the Editor).
151. **Onuigbo MA**. The STOP-ACEi Trial - Apt timing for this long awaited randomised controlled trial - Validation of the syndrome of late-onset renal failure from angiotensin blockade (LORFFAB)? *Int J Clin Pract*. 2017 Jan;71(1). doi: 10.1111/ijcp.12916. Epub 2016 Dec 9.
152. **Onuigbo MAC**, Agbasi N, Sengodan M, Rosario KF. Acute Kidney Injury in Heart Failure Revisited—The Ameliorating Impact of ‘Decongestive Diuresis’ on Renal Dysfunction in Type 1 Acute Cardiorenal Syndrome: Accelerated Rising Pro B Natriuretic Peptide Is a Predictor of Good Renal Prognosis. *J. Clin. Med*. 2017, 6, 82; doi:10.3390/jcm6090082.
153. **Onuigbo MAC**, Agbasi N, Khan A, Nijhawan V, Jiang Z. Superior vena cava syndrome complicating calcific uremic arteriolopathy in an ESRD male patient on maintenance hemodialysis following failed kidney transplantation *J Parathyroid Dis*. 2018;6(2):68-71. DOI: 10.15171/jpd.2018.21.

154. Golestaneh L, Alvarez PJ, Reaven NL, Funk SE, McGaughey KJ, Romero A, Brenner MS, **Onuigbo M**. All-cause costs increase exponentially with increased chronic kidney disease stage. *Am J Manag Care*. 2017 Jun; 23 (10 Suppl):S163-S172.
155. **Onuigbo MAC**, Agbasi N. The Ignored Role of Intraoperative Hypotension in Producing Postoperative Acute Kidney Injury-An Obligatory Appeal for More Preventative Nephrology. *Curr Hypertens Rev*. 2017;13(1):71-78. doi: 10.2174/1573402112666161229125455.
156. Golestaneh L; Alvarez PJ, MBA; Reaven NL; Funk SE; McGaughey KJ; Romero A; **Onuigbo M**. Longitudinal Study of Chronic Kidney Disease Progression and Associated Costs. *Journal of Clinical Pathways* 2017; 3(9): 40-48.
<https://www.journalofclinicalpathways.com/article/longitudinal-study-chronic-kidney-disease-progression-and-associated-costs?page=0>
157. Hickson L, Thorsteinsdottir B, Ramar P, Reinalda M, Crowson C, Williams A, Albright R, **Onuigbo M**, Rule AD, Shah N. Hospital readmission among new dialysis patients associated with young age and poor functional status. *Nephron*. 2018 Jan 9. doi: 10.1159/000485985. [Epub ahead of print].
158. **Onuigbo MA**, Samuel E, Agbasi N, Zurob A. Proposed laboratory surrogate markers for the management of acute kidney injury in ethylene glycol poisoning in resource-challenged countries; a Mayo Clinic Health System, Wisconsin, case analysis. *J Nephropharmacol*. 2018;7(x):x-x. DOI: 10.15171/npj.2018.xx.
159. **Onuigbo MA**, Samuel E, Agbasi N. The demise of contrast nephropathy; can this be true? A contrarian view; a representative case report of contrast nephropathy from Mayo Clinic Health System in Northwestern Wisconsin. *J Nephropharmacol*. 2018;7(2):68-73.
160. **Onuigbo MAC**. The guiding evidence based therapy using biomarker intensified treatment in heart failure (GUIDE-IT) study; the utility of decongestive diuresis in type 1 cardiorenal syndrome with rising pro-BNP levels. *J Nephropharmacol*. 2018; 7(2):66-67.
161. **Onuigbo MAC**, Agbasi N, Amadi EJ, Okeke UC, Khan A. Sequential cerebral salt wasting complicating SIADH in a patient following head trauma. *J Renal Inj Prev*. 2018;7(1):49-52. doi: 10.15171/jrip.2018.12.
162. **Onuigbo MAC**. Acute Kidney Injury Following Cardiopulmonary Bypass Surgery: Challenges of Acute Kidney Injury after Open Heart Surgery in Sub-Saharan Africa. *Nig J of Cardiovascular & Thoracic Surgery*, 2017; 2(2): 44-45.
163. **Onuigbo MAC**, Mohammed R, Agbasi N, Henry Alon MH, Sammour Y, Culver T, et al. Symptomatic life-threatening hyponatremia complicating sever COPD exacerbation, pulmonary edema and pulmonary hypertension-a critical role for conivaptan. *J Renal Inj Prev*. 2018;7(2):98-102. doi: 10.15171/jrip.2018.23
164. **Onuigbo MAC**. End-Stage Renal Disease Risk in Different Glomerulonephropathies. *Mayo Clin Proc*. 2018 Jul;93(7):958-959. doi: 10.1016/j.mayocp.2018.05.003.

165. Chen J, Thorsteindottir B, Vaughan L, Feely M, Albright R, **Onuigbo M**, Norby S, Gossett C, D'Uscio M, Williams A, Dillon J, Hickson L. End of Life, Withdrawal and Palliative Care Utilization among Patients Receiving Maintenance Hemodialysis Therapy. *Clin J Am Soc Nephrol*, 2018; 13(8): 1172-1179.
166. **Onuigbo MAC**, Agbasi N, Wahlberg K, Karki B, Khan S. A Novel Diagnostic Approach for Suspected Icodextrin Pleural Effusion in a Peritoneal Dialysis Patient. *Mayo Clin Proc Inn Qual Out* 2019;3(2):238-240.
167. **Onuigbo MAC**. Intermittent pneumatic compression in patients with ESRD. *Hemodial Int*. 2019 Aug 19. doi: 10.1111/hdi.12777. [Epub ahead of print] No abstract available.
168. **Onuigbo MAC**, Engesser M, Susarla S. Spleno-renal anastomotic bypass revascularization for worsening renal failure and uncontrolled hypertension in bilateral calcific atherosclerotic renal artery stenosis. *J Renal Inj Prev*. 2019;8(4):253-256. DOI: 10.15171/jrip.2019.48.
169. **Onuigbo MAC**, Sharma V, Balogun OO, Ghimire A. Post-Renal Biopsy Acute Kidney Injury and Page Kidney from Intra-Renal Hematoma Aggravated by Reversible Contrast-Induced Nephropathy Following Renal Arterial Embolization. *Am J Case Rep*, 2020; 21: e919701.
170. **Onuigbo MA**, Agbasi N, Sarki B, Khan S, Wahlberg K. Pseudo-arterial temporary hemodialysis catheter placement in the left internal jugular vein ipsilateral to a preexisting brachio-axillary arteriovenous graft. *Indian J Nephrol*. 2020 Jan-Feb;30(1):29-31. doi: 10.4103/ijn.IJN_389_18. Epub 2019 Dec 27.
171. Palmer BF, Carrero JJ, Clegg DJ, Colbert GB, Emmett M, Fishbane S, Hain DJ, Lerma E, **Onuigbo M**, Rastogi A, Roger SD, Spinowitz BS, Weir MR. Clinical Management of Hyperkalemia. *Mayo Clin Proc*. 2020 Nov 4:S0025-6196(20)30618-2. doi: 10.1016/j.mayocp.2020.06.014. Epub ahead of print. PMID: 33160639.
172. **Onuigbo MA**, Sharma V, Balogun O, Ghimire A. Page kidney complicating kidney biopsy after stopping Apixaban: A physician's dilemma. *Indian J Nephrol* 2020;30:201-203.
173. **Onuigbo MAC**. Decongestive diuresis using combination intravenous loop diuretics plus chlorothiazide in type 1 acute cardiorenal syndrome and worsening acute kidney injury; a neglected paradigm in resource-poor settings. *J Nephropharmacol*. 2020;9(2):e13. DOI: 10.15171/npj.2020.13.
174. **Onuigbo MAC**, Muhammad T, Jordan Bruno X, Mahurin C, Tibernii V, Hingre J, Muchmore B. Polyuric acute kidney injury complicating non-dilated obstructive uropathy from abdominopelvic sarcoma – A physician's diagnostic nightmare. *J Renal Inj Prev*. 2020, In Press.
175. **Onuigbo MAC**. Cytomegalovirus glomerulopathy in renal allografts. *J Nephropathol*. 2020;9(1): e01. doi: 10.15171/jnp.2020.01

176. **Onuigbo MA**, Agbasi N, Sarki B, Khan S, Wahlberg K. Pseudo-arterial temporary hemodialysis catheter placement in the left internal jugular vein ipsilateral to a preexisting brachio-axillary arteriovenous graft. *Indian J Nephrol*. 2020 Jan-Feb;30(1):29-31. doi: 10.4103/ijn.IJN_389_18. Epub 2019 Dec 27.
177. **Onuigbo MAC**, Seok J, Anyamene I, Ejimone F, Eze-Raphael C, Park VI. Rituximab in ANCA-associated vasculitis presenting with severe acute kidney injury: A case report. *J Nephropharmacol*. 2019;8(1): e13. doi: 10.15171/npj.2019.13
178. **Onuigbo MAC**. The use of modified Ponticelli regimens for primary membranous nephropathy. *J Nephropathol*. 2019;8(4): e34. doi: 10.15171/jnp.2019.34
179. **Onuigbo MAC**, Sharma V, Balogun OO, Ghimire A. Post-Renal Biopsy Acute Kidney Injury and Page Kidney from Intra-Renal Hematoma Aggravated by Reversible Contrast-Induced Nephropathy Following Renal Arterial Embolization. *Am J Case Rep*, 2020; 21: e919701.
180. **Onuigbo MAC**, Tayyeb M. Severe rhabdomyolysis complicated by acute kidney injury requiring dialysis after an elderly fall at home – A call for enhanced elderly care with daily phone calls and falls prevention. *J Renal Inj Prev*. 2020, In Press.
181. **Onuigbo MAC**. Persistence of coronavirus disease 2019 (COVID-19) in patients with end-stage renal disease; An unrecognized phenomenon? *J Renal Inj Prev*. 2021; 10(1): e07.
182. Locke A, Bushey MA, LaCroix C, Deardoff P, **Onuigbo MAC**. Timed Controlled Repeated Rotation of the CAR-170-C NXSTAGE Chronic Cartridge Hemodialysis Filter – A Novel Approach to Enabling Heparin-Free Frequent Daily Home Hemodialysis. *Mayo Clin Proc Inn Qual Out Mayo Clin Proc Inn Qual Out* 2021, 5(1): 219-224.
183. **Onuigbo MA**, Tan H, Sherman SE. Alternating and Concurrent True Hyperkalemia and Pseudohyperkalemia in Adult Sickle Cell Disease. *Rambam Maimonides Med J*. 2021 Apr 29;12(2). doi: 10.5041/RMMJ.10439. PMID: 33938804; PMCID: PMC8092952.
184. **Onuigbo MAC**. Stopping RAS Inhibitors in Advanced CKD Chronic Kidney Disease and Cardiorenal Outcomes - Several Unanswered Questions Remain. *Am J Med*. 2021 May 4:S0002-9343(21)00273-4. doi: 10.1016/j.amjmed.2021.03.031. Epub ahead of print. PMID: 33961836.
185. **Onuigbo, M.A.C**. Postoperative Acute Kidney Injury in Abdominal Operations: a Critical Appraisal. *Indian J Surg* (2021). <https://doi.org/10.1007/s12262-021-03031-6>
186. **Onuigbo, M.**, & Izuora, A. (2021). The Impact of Elective Withdrawal of Long-Term Renin Angiotensin Aldosterone System Blockade in Chronic Kidney Disease Patients with Progressive Acute Kidney Injury: A Prospective 40-Months' Single-Unit Cohort Study. *Medical Research Archives*, 9(9). <https://doi.org/10.18103/mra.v9i9.2549>
187. **Onuigbo MA**. COVID-19 infection recurrence in ESRD. *Indian J Nephrol* 2022;32:184-5

188. **Onuigbo M A**, Ross A (August 14, 2021) Pseudohyperkalemia and the Need for Imperative Caution With the Newly Introduced Potent Potassium Binders: Two Cases. *Cureus* 13(8): e17179. DOI 10.7759/cureus.1717
189. **Onuigbo MAC**, Libman B, Lazarovich M. Benralizumab substitution monotherapy in symptomatic relapsing asthma dominant eosinophilic granulomatosis with polyangiitis. *Immunopathol Persa*. 2022;x(x):e0x. DOI:10.34172/ipp.2022. xx. [<http://immunopathol.com/Files/Inpress/ipp-31373.pdf>]
190. Bahadoram M, Labaykee S, Lakkakula BVKS, Keikhaei B, Nekouei Shahraki M, Mohammadi Jouabadi S, **Onuigbo M**, Ahmadizar S, Mahmoudian-Sani MR, Peymani P. World Kidney Day 2021 with the theme of living well with kidney disease; a review of current concepts. *J Prev Epidemiol*. 2021;6(1):e08. doi: 10.34172/jpe.2021.08.
191. **MACAULAY ONUIGBO**. Mask Up America!!! - Stop This Deceptive Self-Destructive COVID-19 CHARADE!!!: The rantings of a perplexed US Nephrologist!!!. Authorea. March 30, 2022. DOI: 10.22541/au.164864293.36799088/v1.
192. **Onuigbo MA**. A Four-Year Report on Renal Outcomes Following the Elective Withdrawal of Long-Term Renin-Angiotensin-Aldosterone Blockade in a Cohort of Patients With Otherwise Inexplicable New-Onset and Progressive Acute Kidney Injury. *Cureus*, 2022. 14(10): e30794. doi:10.7759/cureus.30794
193. Ulasi II, Awobusuyi O, Nayak S, Ramachandran R, Musso CG, Depine SA, Aroca-Martinez G, Solarin AU, **Onuigbo M**, Luyckx VA, Ijoma CK. Chronic Kidney Disease Burden in Low-Resource Settings: Regional Perspectives. *Semin Nephrol*. 2023 Apr 12;42(5):151336. doi: 10.1016/j.semnephrol.2023.151336. Epub ahead of print. PMID: 37058859.
194. **Onuigbo MA**. Renin-Angiotensin-Aldosterone System Blockade (RAASB) After Acute Kidney Injury: The Controversy Thickens on If and When to Discontinue RAASB. *Cureus*, 2023. DOI: 10.7759/cureus.49571
195. de Waal D, **Onuigbo M**, Golper TA. Case Study: The Weighty Issue of Treatment Options for Obese Dialysis Patients. *J Ren Nutr*. 2024 Apr 27:S1051-2276(24)00065-7. doi: 10.1053/j.jrn.2024.04.004. Epub ahead of print. PMID: 38685393.
196. **Onuigbo M**. Comment on Non-dilated Obstructive Nephropathy – *Clinical Kidney Journal* – published October 16, 2024. <https://doi.org/10.1093/ckj/sfae249>
197. **Onuigbo M**. Post-Transplantation Hypervolemia and Renal Allograft Outcomes. *Indian J Nephrol*. doi: 10.25259/IJN_48_2025 (Letter to the Editor, *Indian Journal of Nephrology*, Published Online 4-15-2025).
198. **Onuigbo MAC**. eGFR Decline at Initiation of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i). *Mayo Clinic Proc* 2025 (100) pp. 1670-1671.
199. **Onuigbo M**. CKD-associated pruritus in haemodialysis: A road map for diagnosis and treatment - A very unusual and expected etiology. Comment on CKD-associated pruritus in

haemodialysis: a road map for diagnosis and treatment – Clinical Kidney Journal – published April 24, 2025. <https://academic.oup.com/ckj/article/18/5/sfaf096/8119397>
<https://doi.org/10.1093/ckj/sfaf096>

200. **Onuigbo M A**, Balonfentse O (November 21, 2025) Anuria Following Solitary Left Renal Vein Ligation: An Old Surgery Myth Is Rigorously Challenged. *Cureus* 17(11): e97430. doi:10.7759/cureus.97430.

In Preparation - N/A

Non-Peer Reviewed Publications

Review Articles - N/A

Books and Chapters

Books (Editor):

https://www.amazon.com/Macaulay-Amechi-M.D.-Onuigbo/e/B00I4H9DD6%3Fref=dbs_a_mng_rwt_scns_share?camp=1789&creative=9325&linkCode=ur2&tag=iphone0dce-20&linkId=OMBRYAX56M45VB35

1. **Onuigbo M** & Onuigbo N. (Eds.) (2011). *Chronic Kidney Disease and RAAS Blockade: A New View of Renoprotection*. London, England. Lambert Academic Publishing GmbH 11 and Co. KG.
2. Di Iorio B, Heidland A, **Onuigbo M**, & Ronco C (Eds.). (2012). *HEMODIALYSIS: When, How, Why*. New York, NY. NOVA Science Publishers. 32 chapters; 611 pages.
3. **Onuigbo MAC**, Editor. ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics. New York, NY. NOVA Publishers, 2013. Volume 1.
4. **Onuigbo MAC**, Editor. ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics. New York, NY. NOVA Publishers, 2013. Volume 2.

Book Chapters:

1. Ballerman BJ, **Onuigbo MAC**. (2000). Chapter 4: Angiotensins. In: Fray J CS. *Handbook Of Physiology: Section 7: The Endocrine System. Volume III: Endocrine Regulation of Water and Electrolyte Balance*. New York: Oxford. Oxford University Press; p. 104-54.
2. **Onuigbo MAC**, Onuigbo NTC. (2009). Chapter 1: Angiotensin Converting Enzyme Inhibitors. In: DeBrue, AN. *Angiotensin Converting Enzyme Inhibitors* New York: Nova Biomedical Books. Published by Nova Science Publishers; p. 1-41.
3. **Onuigbo MAC**, Onuigbo NTC. (2012). De novo Hepatitis B virus infection in a Mayo Clinic hemodialysis population, 2000-2010: Practical lessons – the economic impact of reduced HBV testing and a call for paradigm changes in current US CDC guidelines on HBV testing protocols. In Di Iorio B, Heidland A, Onuigbo M, & Ronco C (Eds.), *HEMODIALYSIS: When, How, Why*. New York, NY. NOVA Publishers. p. 111-130. 109 refs.

4. **Onuigbo MA**, Onuigbo NT. (2012). The Syndrome of Rapid Onset End-Stage Renal Disease (SOROESRD) – A New Mayo Clinic Dialysis Services Experience, January 2010-February 2011. In Di Iorio B, Heidland A, Onuigbo M, & Ronco C (Eds.), *HEMODIALYSIS: When, How, Why*. New York, NY. NOVA Publishers. p. 443-485. 159 refs.
5. **Onuigbo MAC**. Is combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade associated with increased risk of cardiovascular death in hemodialysis patients? *Current Hypertension Reviews*; 2012; 8 (4): 256-266 (eBook).
6. **Onuigbo MAC**. Angiotensin Blockers and Renoprotection in Diabetic Chronic Kidney Disease is a Failed Paradigm? – A Revisionist View of Renoprotection in Diabetic Chronic Kidney Disease and A Novel Classification Scheme for Renoprotective Agents. *Frontiers in Clinical Drug Research - Diabetes & Obesity*, 2012, 3-31. eBook. In Print, August 2012. Bentham Science Publishers.
7. **Onuigbo MA**, Achebe NJ. The introduction of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) into clinical medicine and the mechanisms of actions of ACEIs and ARBs. In: Macaulay Amechi Chuka Onuigbo, Editor. *ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics*. Volume 1. New York, NY. NOVA Publishers, 2013: 3-12.
8. **Onuigbo MA**. The Abuse of Renal Surrogates and Combination Renal Endpoints in Nephrology RCTs. In: Macaulay Amechi Chuka Onuigbo, Editor. *ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics*. Volume 1. New York, NY. NOVA Publishers, 2013: 35-40.
9. **Onuigbo MA**, Onuigbo C, Onuigbo V, Onuigbo M, Onuigbo N, Joshi M, Egbuniwe O. The CKD enigma, reengineering CKD care, narrowing asymmetric information and confronting ethicomedicinomics in CKD care: The introduction of the new 'CKD express©' IT software program. In: Macaulay Amechi Chuka Onuigbo, Editor. *ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics*. Volume 1. New York, NY. NOVA Publishers, 2013: 41-56.
10. **Onuigbo MA**, Roman-Maradiaga BP, Achebe NJ. “Quadruple Whammy” – A Newly Described Preventable Syndrome of Peri-operative AKI on CKD in Patients on Concurrent “Triple Whammy” Medications. In: Macaulay Amechi Chuka Onuigbo, Editor. *ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics*. Volume 1. New York, NY. NOVA Publishers, 2013: 63-74.
11. **Onuigbo MA**, Achebe NJ. Late Onset Renal Failure From Angiotensin Blockade (LORFFAB) – The Results of a Mayo Clinic Health System Angiotensin Inhibition Withdrawal Study: A Clarion Call For More Preventative Nephrology, Also Called Renoprevention. In: Macaulay Amechi Chuka Onuigbo, Editor. *ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics*. Volume 1. New York, NY. NOVA Publishers, 2013: 75-90.
12. **Onuigbo MA**, Achebe NJ. Acute Kidney Injury on Chronic Kidney Disease - The Rainbow Syndrome of Too Many Colors: A Mayo Clinic Health System Case Series Report. In: Macaulay

Amechi Chuka Onuigbo, Editor. ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics. Volume 1. New York, NY. NOVA Publishers, 2013: 91-108.

13. **Onuigbo MA**, Achebe NJ, Musso CG. The syndrome of rapid onset ESRD in the last 100 consecutive incident Northwestern Wisconsin Mayo Clinic chronic hemodialysis patients, 2010-2011: Results of the analysis of individual patient-level serum creatinine trajectories to ESRD – Can there be a link with angiotensin inhibition and renal senescence in older CKD patients? In: Macaulay Amechi Chuka Onuigbo, Editor. ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics. Volume 1. New York, NY. NOVA Publishers, 2013:109-125.

14. **Onuigbo MA**. Geriatric Nephrology Debate: Angiotensin Inhibition Should be Withdrawn In Older Adults with Later Stage CKD – A 2013 Mayo Clinic Health System Nephrologist's Perspective and The Unmet Need For Newer Kidney-Friendly Renoprotective Agents For the 21st Century. In: Macaulay Amechi Chuka Onuigbo, Editor. ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics. Volume 1. New York, NY. NOVA Publishers, 2013: 127-145.

15. **Onuigbo MA**. Epilogue - Bold Predictions and The Future of Renoprotection: The Way Forward with Multiple Pathway Blockers – Making a Case For Novel Non-Angiotensin Inhibiting Renoprotective Agents like Corticotropin and Pentoxifylline. In: Macaulay Amechi Chuka Onuigbo, Editor. ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics. Volume 2. New York, NY. NOVA Publishers, 2013: 335-344.

16. **Onuigbo M**, Agbasi N. Medicare and the Escalating Costs of US ESRD Care Compared with the United Kingdom National Health Service: A Case Study of Reengineering Current US CDC Hepatitis B Virus Testing Protocols among Hemodialysis Patients to Achieve Cost Savings - The Use of a New IT Software Program, The CKD Express ©, to Achieve Cost-effective CKD Care for the US Medicare. In: Leon V. Berhardt, Editor. Advances in Medicine and Biology. Volume 76. New York, NY. NOVA Publishers, 2014: 21-38.

17. **Onuigbo M**. Angiotensin Blockers and Renoprotection in Diabetic Chronic Kidney Disease is a Failed Paradigm? – A Revisionist View of Renoprotection in Diabetic Chronic Kidney Disease and A Novel Classification Scheme for Renoprotective Agents”. Chapter 1, eBook. Frontiers in Clinical Drug Research: Diabetes and Obesity, Vol. 1, 2014, 3-32.

18. **Onuigbo M**, Agbasi N, Oguejiofor O, Okocha E, Aneke C, Odenigbo C. Serum Creatinine Trajectories in Kidney Disease. In: V.B. Patel, V.R. Preedy (eds.), Biomarkers in Disease: Methods, Discoveries and Applications. Biomarkers in Kidney Disease. DOI 10.1007/978-94-007-7699-9_9. Springer Science + Business Media Dordrecht 2016, pp 139-170.

19. **Onuigbo MAC**, Agbasi N. Frailty Among Elderly Patients on Chronic Maintenance Hemodialysis for ESRD: Not Simply a Matter of Chronological Age. In: Musso, C.G., Jauregui, J.R., Macías-Núñez, J.F., Covic, A. (Eds.). Clinical Nephrogeriatrics - An Evidence-Based Guide. Switzerland: Nature Springer; 2019. P 163-169.
<https://link.springer.com/book/10.1007%2F978-3-030-18711-8>.

20. **Onuigbo M**. Section, In: Netter Book Editor. The Netter Collection of Medical Illustrations, Volume 3: Respiratory System. 3rd ed/Vol. 3 Respiratory. Elsevier Publishers, 2022. Editor, Kaminsky D. This item will be released on 05-03-2024.

Other Scholarly Publications

Conference Abstracts and Letters

1. **Onuigbo MA.** Atherosclerotic multi-infarct syndrome. A predisposition to methyldopa-induced psychosis. *Nigeria Medical Practitioner* 1989; 18(1):19. (Letter)
2. **Onuigbo MA.** Creatinine clearance revisited: Simplified formula for calculation. *East African Journal of Medicine* 1989; 66(12):856-9. (Letter)
3. **Onuigbo MA.** Problems arising from non-standardization of insulin preparations and insulin syringes. *Orient Journal of Medicine* 1990; 2(3):148. (Letter)
4. **Onuigbo MA.** Creatinine clearance revisited: a simplified formula for derivation of renal clearance. *Orient Journal of Medicine* 1990; 2(4):224. (Letter)
5. **Onuigbo MAC, Egwim PO.** Probable correlation between high intake of vitamin D3 and pathogenesis of intimal atherosclerosis from animal studies. 2nd African Conference on the Biochemistry of lipids University of Nigeria, Enugu Campus, Nigeria 1990 Nov 6. (Abstract)
6. **Onuigbo MA.** Blood parasites in blood donors: The probable strongyloides stercoralis risk. *Orient Journal of Medicine* 1991; 3(1):66. (Letter)
7. **Onuigbo MA, Ibeachum GI.** Strongyloides stercoralis larvae in peripheral blood. *Tropical Diseases Bulletin* 1992; 89:317. (Abstract)
8. **Onuigbo MA.** Aids and Nigerians: Ignorance, Intransigence or both? *Orient Journal of Medicine* 1992; 4:88. (Letter)
9. **Onuigbo MA.** Diabetes mellitus following stroke: A case presentation. *International Diabetes Digest (UK)* 1993; 4(1):132. (Letter)
10. **Onuigbo MA.** Renal glycosuria: A neglected abnormality in nephrotic syndrome. *International Diabetes Digest (UK)* 1993; 4(2):36. (Letter)
11. **Onuigbo MA, Guntupalli J, DuBose, Jr TD.** Regulation of Na⁺-independent pHi recovery by H⁺-K⁺ ATPase and H⁺-ATPase in outer medullary collecting duct (OMCDi) cells in culture. *Journal of Investigative Medicine* 1995; 43(2 Suppl 2):353A. (Abstract)
12. **Onuigbo MA, Guntupalli J, Wall S, DuBose, Jr TD.** Adaptation to low potassium in vitro enhances H⁺-K⁺-ATPase-mediated pHi regulation in the outer medullary collecting duct cell line. *Journal of the American Society of Nephrology* 1995; 6(3):313. (Abstract)

13. **Onuigbo MA**, Sansom S, DuBose, Jr TD. Mouse outer medullary collecting duct (OMCD) cells possess a KATP channel. *Journal of Investigative Medicine* 1996; 44(3):228A. (Abstract)
14. **Onuigbo MA**, Sansom S, Codina J, DuBose, Jr TD. Mouse outer medullary collecting duct (mOMCD) cells possess a KATP channel. Cloning of ROMK equivalents in mOMCD TXSAN Book of Abstracts 1996 May. (Abstract)
15. **Onuigbo MA**. Residual HIV-1 RNA after highly active antiretroviral therapy. *JAMA* 2000 Mar 1; 283(9):1138-9. PMID:10703769. (Letter)
16. **Onuigbo MA**, Blahut S, Christenson R, Weir MR, Fink JC, Giutierrez M. Pretransplant C-reactive protein (CRP) as a predictor of chronic allograft nephropathy (CAN): A case-control study. #615 *American Journal of Transplantation* 2001; 1(Suppl 1):290. (Abstract)
17. **Onuigbo MA**, Weir MR, Bartlett ST, Ramos E, Wali R. Sirolimus rescue therapy in renal transplantation. #A4755 *Journal of the American Society of Nephrology* 2001; 12:909A-10A. (Abstract)
18. **Onuigbo MA**. Sick cell disorders and the skeletal system. *Hospital Physician* 2001; 37(2):25. (Letter)
19. **Onuigbo M**, Hise M, Ramos E, Traong N, Amelung P, Drachenberg C. Fatal granulomatous bronchopneumonia complicated by acute renal failure. *Southern Medical Journal* 2002; 95(8):947-9. (Letter)
20. **Onuigbo M**, Lacey B, Ricely J. Right atrial mobile thrombus and pulmonary thromboembolism complicating hemorrhagic *Campylobacter jejuni* colitis. *Southern Medical Journal* 2002; 95(9):1107-9. (Letter)
21. **Onuigbo M**, Qu X, Obah E. Unilateral hyperlucency and lung abscess in a 20-year old woman. *Southern Medical Journal* 2002; 95(9):1109-10. (Letter)
22. **Onuigbo MA**, Wali R, Ramos E, Cangro C, Klassen D, Bartlett ST, Weir MR. Sirolimus rescue therapy in renal transplant recipients receiving tacrolimus, mycophenolate mofetil and corticosteroids. (abstract #PUB510) *Journal of the American Society of Nephrology* 2002; 13:773A. (Abstract)
23. **Onuigbo MA**, Weir MR. Sirolimus rescue: A novel therapeutic approach to calcineurin inhibitor-associated thrombotic microangiopathy in renal allograft recipients. (abstract #PUB511) *Journal of the American Society of Nephrology* 2002; 13:774A. (Abstract)
24. Wali RK, Brace K, Ngan G, Bakshi A, Unterman M, Dowling T, **Onuigbo M**, Hamze O, Briglia A, Salzberg D, Henrich W. Prognosis of acute renal failure (ARF) in medical intensive care unit versus surgical intensive care units; Preliminary report of an ongoing prospective study. (abstract #SU-P0846). *Journal of the American Society of Nephrology* 2002; 13:692A. (Abstract)

25. Wali RK, Marin H, **Onuigbo M**, Hamze O, Salzberg D, Briglia A, Ramos E, Weir M, Weinman E, Henrich W. Prevalence of markers of acute phase reactants in the incident population of hemodialysis patients: Preliminary results of the Cohort study. #SA-P0962. Journal of the American Society of Nephrology 2002; 13:463A. (Abstract)
26. Wali RK, Marin H, Simon C, **Onuigbo M**, Hamze O, Joseph A, Briglia A, Ramos E, Weir M, Weinman E, Henrich W. Processes of care for patients with CKD and progression to ESRD. (abstract #PUB035) Journal of the American Society of Nephrology 2002; 13:677A. (Abstract)
27. **Onuigbo MA**. Causes of renal failure in patients with type 2 diabetes mellitus. JAMA 2003 Oct 8; 290(14):1855; author reply 1855-6. PMID:14532312. DOI:10.1001/jama.290.14.1855-b. (Letter)
28. **Onuigbo MA**. Achieved vs initial blood pressure in predicting renal outcomes. Arch Intern Med 2004 Jan 26; 164(2):223; author reply 223-4. PMID:14744850. DOI:10.1001/archinte.164.2.223-a. (Letter)
29. **Onuigbo MA**, Onuigbo NT. Late onset renal failure from angiotensin blockade (LORFFAB): A Prospective Thirty-month Mayo Health System Clinic Experience. (abstract - PUB 501). Journal of the American Society of Nephrology 2005 Oct; 16:891A. (Abstract)
30. **Onuigbo MA**, Onuigbo NT. Renal failure from RAAS blockade: Need for increased physician awareness: Time for paradigm shifts in the application of RAAS blockade. (abstract #PUB361) Journal of the American Society of Nephrology 2006; 17:892A. (Abstract)
31. **Onuigbo MA**, Onuigbo NT. Use of ultrahigh RAAS blockade: implications for exacerbation of renal failure. Kidney Int 2006 Jan; 69(1):194-5. PMID:16374445. DOI:10.1038/sj.ki.5000068. (Letter)
32. **Onuigbo M**, Onuigbo NT. Early- and late-onset renal failure from angiotensin blockade: A coat of many colors – Need for increased physician awareness.(abstract #122) Am J Kidney Dis 2006 Apr; 47(4):A49. (Abstract)
33. **Onuigbo M**, Onuigbo NT. Late-onset renal failure from angiotensin blockade (LORFFAB): Extended observations. Implications for late onset accelerated loss of GFR in susceptible patients on RAAS blockade - Time for a paradigm shift in use of RAAS blockade? (abstract #123). Am J Kidney Dis 2006 Apr; 47(4):A49. (Abstract)
34. **Onuigbo MA**, Onuigbo NT. Late-onset renal failure from RAAS blockade. Kidney Int 2006 Oct; 70(7):1378-9. PMID:16988746. DOI:10.1038/sj.ki.5001648. (Letter)
35. **Onuigbo MA**, Onuigbo NT. Renal failure from RAAS blockade? Sustained improved eGFR following withdrawal of RAAS blockade in 100 CKD patients presenting with accelerated renal failure - A 50-month Mayo Health System Hypertension Clinic Experience. J Am Soc Nephrol 2007; 18:629A. (Abstract)

36. **Onuigbo MA**, Onuigbo NT. Renal failure associated with RAAS blockade in CKD patients with renal artery stenosis: Results of a 50-month Mayo Health System Hypertension Specialist Clinic Study. *J Am Soc Nephrol* 2007; 18:630A. (Abstract)
37. **Onuigbo MA**, Onuigbo NT. Late onset renal failure from angiotensin blockade (LORFFAB) in CKD patients with normal renal arteries and absent precipitating risk factors – Five patients followed over 50 months in a Mayo Health System Hypertension Clinic. *J Am Soc Nephrol* 2007; 18:846A. (Abstract)
38. **Onuigbo MA**, Onuigbo NT. RAAS blockade accelerates loss of eGFR in contrast-induced nephropathy? - A 50-month Mayo Health System Hypertension Clinic Experience. *J Am Soc Nephrol* 2007; 18:846A. (Abstract)
39. **Onuigbo MA**, Onuigbo NT. RAAS blockade causing renal failure in CKD patients with renal artery stenosis: A prospective Mayo Health System Clinic 50-month analysis.(abstract #158) *Am J Kidney Dis* 2007 Apr; 49(4):A64. (Abstract)
40. **Onuigbo MA**, Onuigbo NT. Renal failure from RAAS blockade in CKD patients: A prospective 50-month analysis – A call for pragmatic caution to optimize cardiorenal protection with RAAS blockade. (abstract #159) *Am J Kidney Dis* 2007 Apr; 49(4):A64. (Abstract)
41. **Onuigbo MAC**, Onuigbo NTC. Renal failure from RAAS blockade in patients with chronic kidney disease (CKD): A prospective 50-month analysis – A call for pragmatic caution to further optimize cardiorenal protection with RAAS blockade. S-FC-024. *World Congress of Nephrology abstract book Free Communications* 2007 Apr 22:45-6. (Abstract)
42. **Onuigbo MAC**, Onuigbo NTC. Renal failure from RAAS blockade in patients with chronic kidney disease and hemodynamically significant renal artery stenosis (RAS): A prospective Mayo Health System Clinic 50-month experience. T-PO-1226. *World Congress of Nephrology abstract book Poster Communications* 2007 Apr 24:401. (Abstract)
43. **Onuigbo MAC**, Onuigbo NTC. Contrast-induced nephropathy in patients with chronic kidney disease (CKD) concurrently on RAAS blockade: A prospective Mayo Health System Clinic 50-month analysis. T-PO-1318 *World Congress of Nephrology abstract book Poster Communications* 2007 Apr 24:426. (Abstract)
44. **Onuigbo M**, Onuigbo N. “RAAS blockade accelerates loss of eGFR in contrast-induced nephropathy? A 50-month Mayo Health System Hypertension Clinic experience” 26th Annual Meeting of the North American Society for Dialysis and Transplantation 2007 July 7. (Abstract)
45. **Onuigbo M**, Onuigbo N. "Does Renin-Angiotensin Aldosterone Blockade Exacerbate Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease: A Prospective 50-Month Mayo Clinic Study". *Blood Purif* 2008; 26(1):126. (Abstract)

46. **Onuigbo M**, Onuigbo N. Late Onset Renal Failure From Angiotensin Blockade (LORFFAB) – Sustained Improved eGFR Following Withdrawal of RAAS blockade in 100 CKD Patients Presenting with Accelerated Renal Failure; A Subgroup Analysis of Five Patients with Normal Renal Arteries and No Precipitating Risk Factors: Results of A Prospective 50-Month Mayo Health System Hypertension Clinic Study. *Blood Purif* 2008; 26(1):126-7. (Abstract)
47. **Onuigbo M**, Onuigbo N. RAAS Blockade and Worsening Azotemia in CKD Patients with Hemodynamically Significant Renal Artery Stenosis: Results of A Prospective 50-Month Mayo Health System Clinic Study. *Blood Purif* 2008; 26(1):127-8. (Abstract)
48. **Onuigbo MA**, Onuigbo NT. Renal Failure from Angiotensin Blockade in Older CKD Patients with Renal Artery Stenosis (RAS) – A Mayo Health System Hypertension Clinic Prospective 68-Month Follow-Up Report [PUB578] *Journal of the American Society of Nephrology* 2008; 19:941A. (Abstract).
49. **Onuigbo MA**, Nye D. Gabapentin Neurotoxicity with Generalized Myoclonus and Encephalopathy in a Diabetic ESRD Patient on Peritoneal Dialysis (PD) – A Case Report. [PUB784] *Journal of the American Society of Nephrology* 2008; 19:991A. (Abstract)
50. **Onuigbo MA**, Onuigbo NT. Late Onset Renal Failure from Angiotensin Blockade (LORFFAB) in 5 CKD Patients: An Extended 68-Month Report from a Mayo Health System Hypertension Clinic. [PUB579]. *Journal of the American Society of Nephrology* 2008; 19:942A. (Abstract)
51. **Onuigbo MA**, Rosado A, Nordstrom C, Rucker-Keegan R, Macken P. Nonoliguric Acute Renal Failure (ARF) in an Obese Hypertensive but Dehydrated Caucasian Female Less Than 24 Hours Following Multiple Intravenous Gadolinium Exposure. [PUB733] *Journal of the American Society of Nephrology* 2008; 19:979A. (Abstract)
52. **Onuigbo MA**, Rozich J, Howard M, Kayode L, Kincaid D. Conivaptan in the Management of Moderately Severe Symptomatic Hyponatremia Complicating Intravenous Furosemide Therapy in the Acutely Decompensated Heart Failure Patient. A Case Report [PUB024] *Journal of the American Society of Nephrology* 2008; 19:818A-9A. (Abstract)
53. **Onuigbo MA**, Shuja S. Changing Patterns of Presentation of Symptomatic Acute Kidney Infarction in the US: Three Cases Seen over a 12-Month Period in a Suburban Northwestern Wisconsin Nephrology Practice. [PUB729] *Journal of the American Society of Nephrology* 2008; 19:978A. (Abstract)
54. **Onuigbo MA**. Generalized Angioedema with 20-lb Weight Gain Persisting Nearly Two Months Following a 4-Week Course of Atovaquone-Proguanil Antimalarial Prophylaxis. [PUB785] A Case Report *Journal of the American Society of Nephrology* 2008; 19:991A. (Abstract)

55. **Onuigbo MA.** Increasing Acute Renal Failure (ARF) in US Hospitals: Does Concurrent RAAS Blockade in Older CKD Patients Have a Causative Role? - 3 Cases of Severe ARF in 3 Days in a Northwestern Nephrology Practice [PUB728] Journal of the American Society of Nephrology 2008; 19:978A. (Abstract)
56. **Onuigbo MA.** eGFR vs Serum Creatinine in CKD Monitoring for Acute Renal Failure Exacerbation: Is the Acceptable 30% or Less Non-Progressive Increase in Baseline Serum Creatinine at Initiation of RAAS Blockade Applicable to a Similar Decrease in Baseline eGFR? [PUB628] Journal of the American Society of Nephrology 2008; 19:954A. (Abstract)
57. **Onuigbo MA.** RAAS Blockade Antagonizes Recovery of Renal Function after Acute Renal Failure in Obstructive Uropathy with a Single Functioning Kidney. [PUB727] Journal of the American Society of Nephrology 2008; 19:977A. (Abstract)
58. **Onuigbo MA.** Bilateral Lower Extremity Deep Vein Thrombosis: An Unusual and Under-Recognized Pattern of Presentation of Wegener's Granulomatosis – Implications for Diagnosis, Management and Pathogenesis. A Review of Two Cases [PUB782] Journal of the American Society of Nephrology 2008; 19:990A-1A. (Abstract)
59. **Onuigbo MA.** RAAS blockade, renal failure, ESRD, and death among African Americans in the AASK Posttrial Cohort Study. Arch Intern Med 2008 Nov 24; 168(21):2383-4. PMID:19029505. DOI:10.1001/archinternmed.2008.510. (Letter)
60. **Onuigbo MA.** Radiographic contrast-induced nephropathy and patient mortality. Mayo Clin Proc 2008 Dec; 83(12):1412-3; author reply 1413. PMID:19046563. (Letter)
61. **Onuigbo M, Onuigbo N.** The Natural History of chronic Kidney Disease (CKD) Revisited: A 72-month Mayo Health System Hypertension Clinic Practice-Based Research Network Prospective Report on ESRD and Death Rates in 100 High-Risk CKD Patients: A Call for Circumspection? Hemodialysis International 2009; 13(1):110. (Abstract)
62. **Onuigbo M.** Bilateral Lower Extremity Sequential Compression Devices, A Novel Approach to the Management of Intradialytic Hypotension in the Outpatient Setting: A Luther Hospital Mayo Health System Dialysis Unit Experience with Three Consecutive Patients. Hemodialysis International 2009; 13(1):100. (Abstract)
63. **Onuigbo M.** Does Concurrent RAAS Blockade in Older CKD Patients Play a Role in the Acute Renal Failure Epidemic in US Hospitalized Patients? Three Cases of Severe ARF Encountered Over Three Days in a Northwestern Wisconsin Nephrology Practice. Hemodialysis International 2009; 13(1):121. (Abstract)
64. **Onuigbo M.** Reno-Prevention vs. Reno-Protection: A Critical Reexamination of the Evidence-Base From the Large RAAS Blockade Trials Is it Time for a Paradigm Shift? Hemodialysis International 2009; 13(1):121. (Abstract)

65. **Onuigbo M.** Drug-induced Encephalopathy Secondary to Non-renal Dosing of Common Medications in Two Dialysis Patients. *Peritoneal Dialysis International* 2009; 29(Suppl 1):S5. (Abstract)
66. **Onuigbo MA, Skalski J.** Newly symptomatic central diabetes insipidus in ESRD with adult polycystic kidney disease following intracranial hemorrhage: The first reported case. [PUB515]. *Journal of the American Society of Nephrology* 2009. (Abstract)
67. **Onuigbo MA.** Bilateral lower extremity sequential compression devices (SCDs) for the treatment of intra-dialytic hypotension: A new solution to an old problem – A Mayo Health System Luther Hospital Pilot Study. [PUB327]. *Journal of the American Society of Nephrology* 2009. (Abstract)
68. **Onuigbo MA.** CKD progression as we know it in 2009: Can nephrologists predict renal outcomes? - Results of an 82-month PBRN-based community-level patient-level-data prospective analysis of 100 high risk CKD patients? [PUB539] *Journal of the American Society of Nephrology* 2009. (Abstract)
69. **Onuigbo MA.** ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. *Arch Intern Med* 2009 Oct 26; 169(19):1810; author reply 1810-1. PMID:19858442. DOI:10.1001/archinternmed.2009.371. (Letter)
70. **Onuigbo M, Onuigbo N, Nijhawan V.** To stent or not to stent: renal artery stenosis - a Mayo Health System hypertension clinic 82-month pbrn-based patient-level prospective: data analysis of 26 high-risk CKD patients with renal artery stenosis presenting with acute kidney injury. *Am J Kidney Dis* 2010 Apr; 55(4):B87. (Abstract).
71. **Onuigbo M, Lawrence K.** Nondilated Obstructive Uropathy – An Unrecognized Cause of Acute Renal Failure in Hospitalized US Patients: Three Case Reports Seen Over Six Months in a North-Western Wisconsin Nephrology Practice. *Am J Kidney Dis* 2010 Apr; 55(4): B87. (Abstract).
72. **Onuigbo M, Onuigbo N.** Chronic Kidney Disease Progression to ESRD: Smooth and Progressive Vs Uneven and Staccato Patterns? – A Mayo Clinic PBRN-Based 82-Month Analysis of 100 High-Risk CKD Patients – Implications for a Paradigm Change in Reno-Protection. Macaulay Onuigbo. *Am J Kidney Dis* 2010 Apr; 55(4): B87. (Abstract).
73. **Onuigbo M.** Bilateral Lower Extremity Sequential Compression Devices (SCDS) for the Management of Intra-Dialytic Hypotension – A New Approach to an Old Problem. *Am J Kidney Dis* 2010 Apr; 55(4): B87. (Abstract).
74. **Onuigbo MA.** The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. *Nephrol Dial Transplant* 2010 Apr; 25(4):1344-5. Epub 2009 Dec 27. PMID:20037177. DOI:10.1093/ndt/gfp678. (Letter).
75. **Onuigbo MA.** Syndrome of rapid onset end-stage renal disease (SORO-ESRD): A new unrecognized pattern of CKD progression to ESRD. *J Am Soc Nephrol* 2010;21:614A (SA-PO2198).

76. **Onuigbo MA**, Kayode CL, Onuigbo NT. Non-dilated obstructive uropathy An unrecognized cause of acute renal failure in hospitalized US patients. *J Am Soc Nephrol* 2010;21:845A (PUB 156).
77. **Onuigbo MA**. A 120-month retrospective analysis of De novo HBV infection in a Mayo Clinic Hemodialysis System - A comparative effectiveness review and a call for change in current US CDC guidelines for HBV immuno-surveillance and immuno-prophylaxis. *J Am Soc Nephrol* 2010;21:951A (PUB 628).
78. **Onuigbo M**, Zeman J, Alexander L, Schrader K, Marfilus T. Two consecutive health-related quality of life (KDQOL-SF) surveys in a stable hemodialysis population – Present and past scores compared. The International Society of Nephrology (ISN). World Congress of Nephrology 2011, Vancouver, Canada. (Abstract) (Poster presentation).
79. **Onuigbo M**, Onuigbo N, Onwubere B, Ulasi I, Ijoma C, Arodiwe A. The syndrome of rapid onset end stage renal disease (SORO-ESRD) revisited across two continents: A transcontinental experience from Eau Claire, WI, USA, and from Enugu, Nigeria: What lessons can be learnt? The International Society of Nephrology (ISN). World Congress of Nephrology 2011, Vancouver, Canada. (Abstract) (Poster presentation).
80. **Onuigbo M**. A 120-month retrospective analysis of de novo HBV infection versus recombinant HBsAgemia in a US mid-western Mayo Clinic hemodialysis population – A comparative effectiveness review and a call for changes in current US CDC guidelines for HBV immune-surveillance and immune-prophylaxis. The International Society of Nephrology (ISN). World Congress of Nephrology 2011, Vancouver, Canada. (Abstract) (Poster presentation).
81. **Onuigbo M**, Onuigbo N. Syndrome of rapid onset end stage renal disease (SORO-ESRD): A new unrecognized pattern of progression of CKD to ESRD. The International Society of Nephrology (ISN). World Congress of Nephrology 2011, Vancouver, Canada. (Abstract) (Poster presentation).
82. **Onuigbo M**. Non-dilated obstructive uropathy – An often unrecognized cause of acute kidney injury in US hospitalized patients: Three consecutive cases seen over six months in a mid-western US Nephrology practice. The International Society of Nephrology (ISN). World Congress of Nephrology 2011, Vancouver, Canada. (Abstract) (Poster presentation).
83. **Onuigbo M**. Bilateral lower extremity sequential compression devices (SCDs) for the prevention of intra-dialytic hypotension – A new therapy for an old problem. The International Society of Nephrology (ISN). World Congress of Nephrology 2011, Vancouver, Canada. (Abstract) (Poster presentation).
84. **Onuigbo M**. Lessons Learnt from Consecutive Health-Related Quality of Life (KDQOL-SF) Surveys in a Mayo Clinic Stable Hemodialysis Patient Population. *J Am Soc Nephrol* 2011; 22: 263A (TH-PO651).

85. **Onuigbo MA.** The Validity of Current CKD Staging Paradigms Revisited and Disputed: A 2-Year Snap Shot of Stage IV CKD Patients in a Mayo Clinic Laboratory Database: A Call for Process Reengineering in Nephrology Practice. J Am Soc Nephrol 2011; 22: 686A (SA-PO2472).
86. **Onuigbo MA, Onuigbo NT.** Economic Impact of Reduced HBV Testing among Hemodialysis Patients in the New Environment of Bundling: Results of a Study of De Novo HBV Infection Rates in a Mayo Clinic Hemodialysis Population – A Call for Changes in Current US CDC Guidelines on HBV Testing Protocols. J Am Soc Nephrol 2011; 22: 815A (SA-PO3028).
87. **Onuigbo MA, Onuigbo NT.** Reno-Prevention: A New Concept for Re-Engineering of Nephrology Practice: An Economic Impact and Patient Outcome Analysis of Two Hypothetical Patient Scenarios in the CCU. J Am Soc Nephrol 2011; 22: 873A (PUB 124).
88. **Onuigbo MA.** Relapsing Central Diabetes Insipidus Following Renal Transplantation in an ADPKD ESRD Patient. J Am Soc Nephrol 2011; 22: 878A (PUB 149).
89. **Onuigbo MA, Nasr SH.** IgA-Dominant Post-Infectious Glomerulonephritis – An Unrecognized Cause of Reversible Acute Kidney Injury in a Diabetic CKD Patient. J Am Soc Nephrol 2011; 22: 878A (PUB 150).
90. **Onuigbo MA, Martin SA.** Cutaneous Capillary Calciphylaxis – A New Variant of Calciphylaxis in End Stage Renal Disease. J Am Soc Nephrol 2011; 22: 878A (PUB 151).
91. **Onuigbo MA, Onuigbo NT.** Evidence of the Syndrome of Rapid Onset End-Stage Renal Disease (SOROESRD) in the Acute Kidney Injury (AKI) Literature – Preventable Causes of AKI and SORO-ESRD – A Call for Re-Engineering of Nephrology Practice Paradigms. J Am Soc Nephrol 2011; 22: 886A (PUB 183).
92. **Onuigbo MA.** Syndrome of Rapid Onset End-Stage Renal Disease (SORO-ESRD) Described in Two Consecutive Renal Transplant Recipients over a Period of Six Months in a Mayo Clinic Renal Unit. J Am Soc Nephrol 2011; 22: 953A (PUB 477).
93. **Onuigbo M, Onuigbo N.** Evidence of the Syndrome of Rapid Onset End stage Renal Disease (SOROESRD) in the Acute Kidney Injury (AKI) Literature - Preventable Causes of AKI and SORO-ESRD - A Call for Re-engineering of Nephrology Practice Paradigms. Perit Dial Int 2012; 32, Suppl. 1: S4.
94. **Onuigbo M, Onuigbo N.** Reno-Prevention: A New Concept For Re-engineering Nephrology Care: An Economic Impact and Patient Outcome Analysis of Two Hypothetical Patient Management Paradigms in the CCU. Perit Dial Int 2012; 32, Suppl. 1: S4.
95. **Onuigbo M, Onuigbo N.** The Syndrome of Rapid Onset End-stage Renal Disease (SORO-ESRD) Described in Two Consecutive Renal Transplant Recipients Seen Over Six Months. Hemodial Int 2012; 16(1):133.

96. **Onuigbo M**, Onuigbo N. De Novo Hepatitis B Virus Infection in a Mayo Clinic Hemodialysis Population: Practical Lessons - Economic Impact of Reduced HBV Testing and A Call for Changes in Current US CDC Guidelines on HBV Testing Protocols. *Hemodial Int* 2012; 16(1):162.
97. **Onuigbo M**, Onuigbo N. A 120-month retrospective analysis of de-novo Hepatitis B virus infection versus transient vaccine-related recombinant HBsAgenemia in a Mayo Clinic hemodialysis population. Online ISSN 1753-0792 - Print ISSN 1753-0784. Copyright © 2012 European Renal Association - European Dialysis and Transplant Assoc. [Abstract]. This article appears in: Abstracts from the 48th ERA-EDTA Congress, June 23-26 2011, Prague, Czech Republic. *NDT Plus* (2011) 4 (suppl 2): doi: 10.1093/ndtplus/4.s2.50.
98. **Onuigbo MA**, Onuigbo NT. Variability in CKD stage in outpatients followed in two large renal clinics – Implications for CKD trials and the status of current knowledge of patterns of CKD to ESRD progression. Letter to the Editor. *International Urology and Nephrology*; 2012, 44 (5): 1589-1590.
99. **Onuigbo M**. Serum creatinine trajectories to end-stage renal disease: The path to ESRD – The syndrome of rapid onset end-stage renal disease – A 100 consecutive cohort analysis in a Mayo Clinic dialysis population. *J Nephrol Therapeut.* 2012;2(5): 30 (Abstract).
100. **Onuigbo MAC**. Physician “cognitive drift” and medication errors – Unintended consequences of the modern EMR. *WMJ.* 2012;111(5):198 (Letter to the Editor).
101. **Onuigbo M**. De novo HBV infection in a Mayo Clinic hemodialysis population: Economic impact of reduced HBV testing and a call for changes in current US CDC guidelines on HBV testing protocols. www.Hemodialysis.com Author Interview.
102. **Onuigbo M**, Onuigbo M, Onuigbo N, Egbuniwe O. Process Management Reengineering in Healthcare: Why Old and New Paradigms Have Failed - The Roles of Critical Healthcare-Specific Complex Unidentified Bottlenecks in a Complex Adaptive System: Do We Need More MD MBAs? *J Am Soc Nephrol* 2012: FR-PO069.
103. **Onuigbo M**, Onuigbo N. Cognitive Drift in The Electronic Medical Record System: An Unrecognized Source of Physician Stress and a Silent Cause of Medication Errors - Results of a Small Physician Survey. *J Am Soc Nephrol* 2012: FR-PO070.
104. **Onuigbo M**, Onuigbo N. The CKD Express © - A New Effective, Efficient and Cost-saving IT-based Program to Expedite CKD Care Among Large Populations: Results of a Pre-design CKD Survey. *J Am Soc Nephrol* 2012: FR-PO162.
105. **Onuigbo M**, Bellasi A, Russo D, Di Iorio B. Penultimate Pulse Wave Velocity, More Than Baseline Pulse Wave Velocity, Predicted Mortality in Italian ESRD Cohort Study. *J Am Soc Nephrol* 2012: SA-PO602.
106. **Onuigbo M**, Onuigbo N. Transient Post-vaccination Recombinant HBsAgenemia among ESRD patients – How Common is This Phenomenon? What Implications for Dialysis Care? *J Am Soc Nephrol* 2012: SA-PO817.

107. **Onuigbo M.** Nondialytic Therapy (NDT) is a Neglected Paradigm in US Nephrology Practice: It's Time for a Robust Reappraisal – This is not Rationing! J Am Soc Nephrol 2012: (PUB).
108. **Onuigbo M.** Syndrome of Rapid Onset ESRD Versus Classic ESRD – A Tale of Two Different Cities – A New Unrecognized Syndrome and Implications for Improved Dialysis Care. J Am Soc Nephrol 2012: (PUB).
109. **Onuigbo M.** Stress and Burnout Among Nephrology-Dialysis Staff – Results of a 2012 Survey in A Mayo Clinic HD Unit. J Am Soc Nephrol 2012: (PUB).
110. **Onuigbo M.** The CKD enigma - statistics and myths: Conflicting ESRD-death rates: A revisionist Mayo Clinic perspective of CKD non-progressors vs progressors. 7th International DIP Symposium – Diabetes, Hypertension, Metabolic Syndrome & Pregnancy, scheduled to take place in Florence, Italy, March 13-16, 2013 (Accepted abstract_Did not attend).
111. **Onuigbo M.** Stress and Burnout Among Nephrology-Dialysis Staff – Results of a 2012 Survey in a Mayo Clinic HD Unit. Perit Dial Int 2013; 33, Suppl. 1: S4 (Abstract).
112. **Onuigbo M.** Cost-Cutting Measures to Bend the U.S. Healthcare Cost Curve Without Rationing: “Obamacare” under Siege – How to Make The Affordable Care Act Affordable. Perit Dial Int 2013; 33, Suppl. 1: S4 (Abstract).
113. **Onuigbo M.** Ethicomedicinomics Unfurled - Asymmetric Information, Patient-Physician Trust, Profitability and ‘Choosing Widely Campaign’: Wasteful Unnecessary Tests and Rising US Healthcare Costs: Who’s to Blame?: Wastage in Kidney Transplant Work-Up. Perit Dial Int 2013; 33, Suppl. 1: S5 (Abstract).
114. **Onuigbo M.** Non-dialytic Therapy (NDT) for ESRD: A Neglected Paradigm in US Nephrology Practice: Time for a Robust Reappraisal. Perit Dial Int 2013; 33, Suppl. 1: S22 (Abstract).
115. **Onuigbo M, Foster K.** New PD Starts Per Period – A New PD CQI Continuous Assessment Tool For New PD Programs: An 80-year Old Atherosclerotic Wisconsinian Successfully Transitions from HD to PD in a Mayo Clinic Dialysis Unit. Perit Dial Int 2013; 33, Suppl. 1: S23 (Abstract).
116. **Onuigbo M, Onuigbo N, Egbuniwe O.** Cognitive Drift in the Electronic Medical Record: A Neglected Source of Physician Stress and a Silent cause of Medication Errors - Results of a Small Physician Survey. Hemodial Int 2013; 17(1):148 (Abstract).
117. **Onuigbo M.** Asymmetric information, end-of-life decision making, the elderly patient, futile care and Ethicomedicinomics: The Nephrologists’ dilemma: A Case Presentation. When is Enough, Enough? Hemodial Int 2013; 17(1):161 (Abstract).
118. **Onuigbo M.** The New Syndrome of Rapid Onset ESRD Versus Classic ESRD – A Tale of Two Cities – Implications for Dialysis Planning and Dialysis Care. Hemodial Int 2013; 17(1):162 (Abstract).

119. **Onuigbo M.** The CKD Enigma – Statistics and Myths about CKD: Conflicting ESRD and Death Rates in the Literature: A Revisionist Mayo Clinic Perspective and Implications for CKD Care. The Concept of “Asymptomatic” vs “Symptomatic” CKD – Non-Progressors vs Progressors. *Hemodial Int* 2013; 17(1):162 (Abstract).
120. **Onuigbo M,** Onuigbo N, Egbuniwe O. The CKD Express © - An Innovative Effective, Efficient and Cost-Saving IT-Based Program to Enable Improved CKD care Among Large Populations: Results of a Pre-Design Module. *Hemodial Int* 2013; 17(1):180 (Abstract).
121. **Onuigbo M,** Onuigbo M, Onuigbo N, Egbuniwe O. Process Reengineering in US Healthcare: Why old Paradigms Have Failed – The Impacts of Critical Healthcare-Specific Complex and Unidentified Bottlenecks in a Complex Adaptive System – Do We Need More MD MBAs?. *Hemodial Int* 2013; 17(1):181 (Abstract).
122. **Onuigbo MA.** The nephrotoxic "triple whammy" of combining diuretics, ACE inhibitors, and diuretics. *BMJ.* 2013; 346:f678. Epub 2013 Feb 19. [Letter. Polypharmacy and acute kidney injury]. Corrected in *BMJ* to read: “The nephrotoxic ‘triple whammy’ of combining diuretics, ACE inhibitors, and NSAIDs”.
(<http://www.bmj.com/content/346/bmj.f678>.)
123. **Onuigbo M,** Onuigbo N. Aliskiren in Type 2 Diabetes and Cardiorenal End Points. *N Engl J Med.* 2013 Mar 14;368(11):1064-5. doi: 10.1056/NEJMc1300257#SA1.
(<http://www.nejm.org/doi/pdf/10.1056/NEJMc1300257>).
124. **Onuigbo M.** The Newly Described Syndrome of Rapid Onset ESRD (SORO–ESRD) Versus Traditional ESRD - A Tale of Two Cities - Implications for Dialysis Planning and Dialysis Care, Worldwide. Moderated Poster Abstract. [SA544]. World Congress of Nephrology, Hong Kong. May 31-June 4, 2013.
125. **Onuigbo M.** Asymmetric information in the practice of medicine, over diagnosis, unnecessary tests, unnecessary procedures and futile care – \$750 billion blown annually in US healthcare _ Blame the doctors!: How to make The Affordable Care Act affordable; Yes we can! Moderated Poster Abstract. [MO470]. World Congress of Nephrology, Hong Kong. May 31-June 4, 2013.
126. **Onuigbo M.** Nondialytic Therapy (NDT) for US ESRD patients: An Ignored Paradigm in US Nephrology Practice: A Call for a Robust Reappraisal. Moderated Poster Abstract. [MO466]. World Congress of Nephrology, Hong Kong. May 31-June 4, 2013.
127. **Onuigbo M,** Onuigbo N, Egbuniwe O. The CKD Express © Software Program - A novel effective, efficient and cost-containing IT-based program to extend improved CKD care to large populations: Results of a Mayo Clinic Health System pre-production analysis. Moderated Poster Abstract. [MO103]. World Congress of Nephrology, Hong Kong. May 31-June 4, 2013.

128. **Onuigbo M.** The CKD Enigma – Statistics and Myths about CKD: Conflicting ESRD and Death Rates in the Literature: Do they all really die before reaching ESRD?: A Revisionist Mayo Clinic Perspective and Implications for CKD care. The Concept of Asymptomatic vs Symptomatic CKD - Non-Progressors vs Progressors. Moderated Poster Abstract. [SU356]. World Congress of Nephrology, Hong Kong. May 31-June 4, 2013.
129. **Onuigbo M,** Onuigbo M (Jr.), Onuigbo N, Egbuniwe O. Process Reengineering in US Healthcare: Why Old Paradigms Have Failed – The Impacts of Critical Healthcare-specific Complex yet Unidentified Bottlenecks in a Complex Adaptive System. Moderated Poster Abstract. [MO461]. World Congress of Nephrology, Hong Kong. May 31-June 4, 2013.
130. **Onuigbo M,** Foster K. New PD Starts Per Period – A New PD CQI Tool: An 80-year Old Atherosclerotic Man Successfully Transitions from HD to PD in a Mayo Clinic Dialysis Unit. Moderated Poster Abstract. [MO457]. World Congress of Nephrology, Hong Kong. May 31-June 4, 2013.
131. **Onuigbo MA,** Roman-Maradiaga BP, Achebe NJ. Quadruple whammy - A New Preventable Syndrome of Peri-Operative AKI on CKD in Patients on Concurrent Combination Triple Whammy Medications. (ASN 2013 Published Abstract). American Society of Nephrology (ASN) Kidney Week, Atlanta, GA. November 5-10, 2013. J Am Soc Nephrol 24: 2013: PUB011.
132. **Onuigbo MA,** Achebe NJ. The Rainbow Syndrome of AKI on CKD: From Full Recovery to Acute Irreversible Renal Failure or the Syndrome of Rapid Onset End-Stage Renal Disease - A Mayo Clinic Perspective. (ASN 2013 Published Abstract). American Society of Nephrology (ASN) Kidney Week, Atlanta, GA. November 5-10, 2013. J Am Soc Nephrol 24: 2013: PUB010.
133. **Onuigbo MA,** Achebe NJ. A New Step-Ladder Approach to Treating Severe Symptomatic Chronic Hyponatremia To Mitigate Catastrophic Cerebral Events. (ASN 2013 Published Abstract). American Society of Nephrology (ASN) Kidney Week, Atlanta, GA. November 5-10, 2013. J Am Soc Nephrol 24: 2013: PUB270.
134. **Onuigbo MA.** Chronic kidney disease controversy: How expanding definitions are unnecessarily labeling many people as diseased. BMJ 2013 (Rapid Response, October 2 2013). www.bmj.com/content/347/bmj.f4298/rr/664777.
135. **Onuigbo MA.** “Individual patient-level serum creatinine trajectories from CKD to ESRD: The path from CKD to ESRD - The results of a retrospective cohort analysis of 100 consecutive ESRD patients, 2010-2011, in a Northwestern Wisconsin Mayo Clinic Dialysis Services population - The syndrome of rapid onset end stage renal disease (SORO-ESRD) revisited”. Lecture presented at the Seventh Congress of Nephrology in Internet CIN'2013, November 15-30, 2013. <http://cin2013.uninet.edu/>.

136. **Onuigbo MA.** “Quadruple whammy”: A Preventable Newly Described Syndrome of Post-operative AKI in CKD Patients on Combination ‘Triple Whammy’ Medications: A Mayo Clinic Health System, Eau Claire, Wisconsin Experience. Lecture presented at the Seventh Congress of Nephrology in Internet CIN'2013, November 15-30, 2013. <http://cin2013.uninet.edu/>.
137. **Onuigbo M,** Achebe N, Musso C. Individual Patient-Level Serum Creatinine Trajectories from CKD to ESRD: The Path from CKD to ESRD – The Syndrome of Rapid Onset End Stage Renal Disease Revisited – The Results of a Retrospective Cohort Analysis of 100 Consecutive ESRD Patients, 2010–2011, in a Northwestern Wisconsin Mayo Clinic Dialysis Services Population. *Blood Purif* 2013;36:251-253 (DOI:10.1159/000356547) Published online: December 27, 2013 (Oral Presentation – Best Abstract).
138. **Onuigbo M.** CKD Prediction Is an Inexact Science – A 2008 US CKD Population-Wide ESRD Rates Analysis and a 2011 Cross-Sectional Study of CKD Stage Changes in a Mayo Clinic Laboratory Database: The concept of ‘Progressors’ and ‘Non-Progressors’. *Blood Purif* 2013;36:250-251 (DOI:10.1159/000356547) Published online: December 27, 2013 (Poster).
139. **Onuigbo M.** The Rainbow Spectrum of Renal Outcomes Following AKI-on-CKD: A Call for More Emphasis on Renoprevention. *Blood Purif* 2013;36:253 (DOI:10.1159/000356547) Published online: December 27, 2013 (Poster).
140. **Onuigbo M,** Roman-Maradiaga B, Achebe N. ‘Quadruple Whammy’ – A Preventable Newly Described Syndrome of Post-Operative AKI in CKD Patients on Combination ‘Triple Whammy’ Medications: A Mayo Clinic Health System, Eau Claire, Wisconsin Experience. *Blood Purif* 2013;36:254 (DOI:10.1159/000356547) Published online: December 27, 2013 (Poster).
141. **Onuigbo M,** Achebe N. The Rainbow Spectrum of Renal Outcomes Following AKI on-CKD: The Need for More Emphasis on Renoprevention. *Hemodial Int* 2014; 18:226 (Poster).
142. **Onuigbo M.** A Novel Step-Ladder Approach of Safely Managing Severe Symptomatic Chronic Hypermnatremia to Prevent Catastrophic Cerebral Events Due to Cerebral Edema. *Hemodial Int* 2014; 18:242 (Poster).
143. **Onuigbo M.** CKD Prediction and Prognostication is an Inexact Science - A 2008 US CKD Population-Wide ESRD Rates Analysis and a 2011 Cross-sectional Study of CKD Stage Changes in a Mayo Clinic Laboratory Database: The Concept of "Progressors" and "Nonprogressors". *Perit Dial Int* 2014; 34: Suppl 1: S3 (Poster).
144. **Onuigbo M.** “Quadruple whammy” – A Newly Described Preventable Syndrome of Post-operative AKI in CKD Patients on Combination “Triple Whammy” Medications: A Mayo Clinic Health System Experience. *Perit Dial Int* 2014; 34: Suppl 1: S3 (Poster).
145. **Onuigbo M.** Unexplained Hypotension and Exertional Dyspnea in a Night-cycled PD Patient - A Case of Icodextrin Hypersensitivity. *Perit Dial Int* 2014; 34: Suppl 1: S9 (Poster).

146. **Onuigbo M**, Agbasi N. Giant paraesophageal hernia presenting as acute episodic dyspnea in an ESRD patient - A diagnostic quagmire. *Perit Dial Int* 2014; 34: Suppl 1: S9 (Poster).
147. **Onuigbo M**, Agbasi N. Severe symptomatic acute hyponatremia in traumatic brain injury responds very rapidly to a single 15 mg dose of oral Tolvaptan: A Mayo Clinic Health System hospital experience - Need for caution with Tolvaptan in younger patients with preserved renal function. *Nephrol Dial Transplant*. 2014 May; 29:70.
148. **Onuigbo M**, Agbasi N. The pathway from CKD to ESRD: The syndrome of rapid onset end stage renal disease in the last consecutive 100 adult ESRD patients in a Mayo Clinic dialysis services maintenance outpatient in-center hemodialysis unit. *Nephrol Dial Transplant*. 2014 May; 29:369.
149. **Onuigbo M**, Agbasi N. The rainbow continuum of renal outcomes in CKD patients following AKI-on-CKD: A plea for more emphasis on renoprevention. *Nephrol Dial Transplant*. 2014 May; 29:359-60.
150. **Onuigbo M**, Agbasi N. CKD prediction and prognostication: An inexact science - A 2008 US population-wide CKD to ESRD rates analysis and a 2011 cross-sectional study of CKD stage translations in a Mayo Clinic Health System laboratory database: The concept of "progressors" and "non-progressors". *Nephrol Dial Transplant*. 2014 May; 29:139.
151. Hickson LJ, Thorsteinsdottir B, Reinalda M, Ramar P, Williams AW, Albright RC, **Onuigbo MA**, Rule AD, Shah ND. Predictors of 30-Day Readmissions among Incident Dialysis Patients: Registry Linkage to United States Renal Database System (USRDS) Data. *J Am Soc Nephrol* 25, 2014. TH-PO863 (Abstract – Poster).
152. **Onuigbo MA**, Abbas I, Maierhofer WJ, Shuja SB, Agbasi N. Mortality and Causes of Death in Patients with the Syndrome of Rapid Onset End Stage Renal Disease versus “Classic” ESRD in a Mayo Clinic Northwestern Wisconsin Hemodialysis Unit. *J Am Soc Nephrol* 25, 2014. PUB147 (Abstract).
153. **Onuigbo MA**, Agbasi N. Rapid Normalization of Post-Traumatic Severe Symptomatic Acute Hyponatremia after a Lone 15 mg Tolvaptan Dose: A Mayo Clinic Health System Trauma Unit Experience – A Call for Caution with Tolvaptan in Younger Patients with Preserved Renal Function. *J Am Soc Nephrol* 25, 2014. PUB523 (Abstract).
154. **Onuigbo M**, Agbasi N. Rapid Normalization of Severe Hyponatremia Following Single 15 mg Dose of Oral Tolvaptan in Post-Traumatic Brain Injury: A Mayo Clinic Health System Experience – Call For Caution with Tolvaptan in Younger Patients with Preserved Renal Function. *Perit Dial Int* 2015, 35; Suppl . 1: S9 (Abstract).
155. **Onuigbo M**, Abbas I, Shuja S, Maierhofer W, Agbasi N. Mortality Outcomes and Causes of Mortality Among Patients with the Syndrome of Rapid-Onset End-Stage Renal Disease Compared to Patients with “Classic” ESRD in a Mayo Clinic Northwestern Wisconsin Hemodialysis Unit. *Perit Dial Int* 2015, 35; Suppl . 1: S10 (Abstract).

156. **Onuigbo M**, Agbasi N. Rapid normalization of severe hyponatremia after a single 15 mg dose of oral tolvaptan: Need for caution in younger patients with preserved renal function. Moderated poster abstract. World Congress of Nephrology, Cape Town, South Africa. March 13-17, 2015. [SUN-001].
157. **Onuigbo M**, Abbas I, Maierhofer W., Agbasi N. Mortality outcomes and causes of mortality in patients with the syndrome of rapid onset ESRD compared with "classic" ESRD in a Mayo Clinic Hemodialysis Unit. Moderated poster abstract. World Congress of Nephrology, Cape Town, South Africa. March 13-17, 2015. [SUN-418].
158. **Onuigbo M**, Agbasi N, Maierhofer W, Shuja S, Abbas I, Hickson L. A Mayo Clinic Rochester thirteen-year retrospective investigation of the syndrome of rapid onset end stage renal disease (SORO-ESRD) in an incident adult hemodialysis cohort, 2001–2013. *Nephrol. Dial. Transplant.* (2015) 30 (suppl 3): iii496 doi:10.1093/ndt/gfv192.19.
159. **Onuigbo M**, Agbasi N. Syndrome of Rapid Onset ESRD Accounted for High Hemodialysis Catheter Use – Results of a 13-Year Mayo Clinic Incident Hemodialysis Study. Abstract presented at the 18th International Conference on Dialysis. *Advances in Chronic Kidney Disease* 2016. January 20–22, 2016, Miami, FL. *Blood Purif* 2016; 41:225–245. Published online: January 15, 2016. DOI: 10.1159/000442341.
160. Golestaneh L, Alvarez PJ, Reaven N, Funk S, Mcgaughey KJ, Sproles CA, Benton W, **Onuigbo MA**. Healthcare Cost Rises Exponentially by Stage of Chronic Kidney Disease. *J Am Soc Nephrol.*, Nov 2016, 27:SA-PO911 (Abstract).
161. Golestaneh L, Alvarez PJ, Reaven NL, Funk SE, McGaughey KJ, Romero A, Brenner MS, **Onuigbo M**. “Healthcare Cost Rises Exponentially by Stage of Chronic Kidney Disease” has been accepted for an Encore presentation at the AMCP Managed Care Specialty Pharmacy Annual Meeting 2017, Denver, Colorado, March 27-30, 2017 (Abstract).
162. **Onuigbo M**, Agbasi N. Poster presentation. A Mayo Clinic Thirteen-Year Retrospective Investigation of the Syndrome of Rapid Onset ESRD Among Renal Transplant Recipients, 2001-2013. 15th Mayo Clinic Update Course in Nephrology and Transplantation, Scottsdale, AZ, February 10-11, 2017.
163. **Onuigbo M**, Agbasi N. Poster presentation. Intraoperative Hypotension is a Neglected Causative Factor in Precipitating Post-Operative Acute Kidney Injury. 15th Mayo Clinic Update Course in Nephrology and Transplantation, Scottsdale, AZ, February 10-11, 2017.
164. **Onuigbo M**, Agbasi N. Poster presentation. An Unusual Case of Persistently Recurrent Hyperkalemia in an ESRD Patient After Bioprosthetic Aortic Valve Replacement – Can This Be a Case For The New Potassium Binder, Patiromer? 15th Mayo Clinic Update Course in Nephrology and Transplantation, Scottsdale, AZ, February 10-11, 2017.

165. **Onuigbo M**, Agbasi N, McDermott W, Rentzepis M. Poster presentation. A Rare Complication of Transurethral Foley Catheterization Causing Distal Right Ipsilateral Ureteric Obstruction, Contralateral Left Ureteric Obstruction and Acute Kidney Injury. 15th Mayo Clinic Update Course in Nephrology and Transplantation, Scottsdale, AZ, February 10-11, 2017.
166. **Onuigbo M**, Agbasi N. A Mayo Clinic Thirteen-Year Retrospective Study of the Syndrome of Rapid Onset ESRD Among Renal Transplant Recipients 2001-2013. Oral Presentation at the 2017 Annual Dialysis Conference, Long Beach, CA, USA: Slide Forum III – Clinical Experiences. Monday, March 13, 2017.
167. **Onuigbo M**, Agbasi N. Intra-operative Hypotension is a Neglected but Preventable Causative Factor in Hospital-Acquired Acute Kidney Injury. Oral Presentation at the 2017 Annual Dialysis Conference, Long Beach, CA, USA: Slide Forum V – AKI/RKF. Monday, March 13, 2017.
168. **Onuigbo M**, Agbasi N. A Thirteen-Year Mayo Clinic Retrospective Study of the Syndrome of Rapid Onset ESRD Among Renal Transplant Recipients, 2001-2013. [abstract]. Am J Transplant. 2017; 17 (suppl 3). <http://atcmeetingabstracts.com/abstract/a-thirteen-year-mayo-clinic-retrospective-study-of-the-syndrome-of-rapid-onset-esrd-among-renal-transplant-recipients-2001-2013/>. Accessed March 30, 2017.
169. **Onuigbo M**, Agbasi N, Egbuna O, Atim T, Manmak H, Galadanci H, Ibrahim Wada I, Miner E. A Three-year Kidney Transplant Experience at Garki Hospital, Abuja, Nigeria, 2013-2016. Poster presented at the World Congress of Nephrology, International Society of Nephrology (ISN) Meeting, Mexico City, Mexico. April 21-25, 2017 (Abstract).
170. **Onuigbo M**, Agbasi N. A Mayo Clinic 13-year Retrospective Investigation of the Syndrome of Rapid Onset ESRD Among Renal Transplant Recipients, 2001-2013. Poster presented at the World Congress of Nephrology, International Society of Nephrology (ISN) Meeting, Mexico City, Mexico. April 21-25, 2017 (Abstract).
171. Golestaneh L , Alvarez P, Reaven N, Funk S, McGaughey K, Romero A, **Onuigbo M**. Healthcare Costs Accelerate With Chronic Kidney Disease Progression. Poster presented at the World Congress of Nephrology, International Society of Nephrology (ISN) Meeting, Mexico City, Mexico. April 21-25, 2017 (Abstract).
172. David M, Sengodan M, Sachak S, **Onuigbo M**, Hanna R. Implications of Intravenous Contrast Use in Patients Admitted with Acute Decompensated Heart Failure. Journal of Cardiac Failure, Vol. 23, Issue 8, S111. Published in issue: August 2017. [Heart Failure Society of America (HSFA) 21st Annual Scientific Meeting. September 16-19, 2017; Dallas, TX (Poster Presentation)].
173. **Onuigbo M**, Agbasi N. The Value of Intravenous Decongestive Diuresis in Type 1 Acute Cardiorenal Syndrome: Acutely Rising Pro B Natriuretic Peptide (BNP) Is a Prognosticator for Good Renal Outcomes. Advances in CKD. Accepted for Poster presentation at the 20th International Conference on Dialysis – Advances in Kidney Disease, January 31 – February 2, 2018. Lake Buena Vista, FL.

174. **Onuigbo M**, Agbasi N. The Utility of Intravenous Decongestive Diuresis in Type 1 Acute Cardiorenal Syndrome: Accelerated Rising Pro B Natriuretic Peptide At Presentation Is a Prognosticator for Good Renal Outcomes. Poster presentation at the 2018 Annual Dialysis Conference, March 3 – March 6, 2018. Orlando, FL.
175. Golestaneh L, Alvarez PJ, Reaven NL, Funk SE, McGaughey KJ, Romero A, Brenner MS, **Onuigbo M**. Healthcare Costs Accelerate With Chronic Kidney Disease Progression. J Manag Care Spec Pharm 2017 Oct 23 (10-a Suppl0;S1-S92. Poster presentation at AMCP Nexus 2017 in Dallas, Texas, October 16-19, 2017.
176. **Onuigbo M**. The Ameliorating Effect of “Decongestive Diuresis” on Renal Dysfunction in Type-1 Acute Cardiorenal Syndrome: A Prognostic Role For Rising BNP. World Congress of Internal Medicine (WCIM) 2018 – The 34th World Congress of Internal Medicine, Cape Town, South Africa (Poster Abstract).
177. **Onuigbo M**. Intraoperative Hypotension – A Neglected Modifiable Risk Factor in Postoperative Acute Kidney Injury: Need For Preventative Nephrology in Sub-Saharan Africa. World Congress of Internal Medicine (WCIM) 2018 – The 34th World Congress of Internal Medicine, Cape Town, South Africa (Poster Abstract).
178. **Onuigbo M**. A Mayo Clinic 13-Year Study of the Syndrome of Rapid Onset ESRD in Renal Transplantation: The Implications of Renal Allograft Pathologic Findings. World Congress of Internal Medicine (WCIM) 2018 – The 34th World Congress of Internal Medicine, Cape Town, South Africa (Oral Presentation Abstract).
179. **Onuigbo M**. The utility of the bedside nephrologist urine deposit microscopy in the management of acute kidney injury: A review of two cases. World Congress of Internal Medicine (WCIM) 2018 – The 34th World Congress of Internal Medicine, Cape Town, South Africa (LECTURE).
180. **Onuigbo M**. Classification and diagnostic criteria of glomerulonephritis. How does this inform management? World Congress of Internal Medicine (WCIM) 2018 – The 34th World Congress of Internal Medicine, Cape Town, South Africa (KEYNOTE LECTURE). YOUTUBE RECORDING - [WCIM 2018: Macaulay Onuigbo - Classification and diagnostic criteria of glomerulonephritis.](https://www.youtube.com/watch?v=nhtmBtWJoB4); <https://www.youtube.com/watch?v=nhtmBtWJoB4>
181. **Onuigbo M**. 34th World Congress of Internal Medicine (WCIM 2018) Congress Ambassador (July 11, 2018 – October 21, 2018).
182. **Onuigbo M**. 34th World Congress of Internal Medicine (WCIM 2018) Congress Ambassador (July 11, 2018 – October 21, 2018). Session Chair: Renal Failure: Clinical Settings of Interest. Friday, October 19, 2018.
183. **Onuigbo M**. 34th World Congress of Internal Medicine (WCIM 2018) Interview Video on the classification and diagnostic criteria for acute glomerulonephritis with emphasis on resource-poor settings: <https://www.youtube.com/watch?v=nhtmBtWJoB4>
184. **Onuigbo M**. "Postoperative Acute Kidney Injury: A Prospective Randomized Controlled Trial of The Impact of Two Different Intraoperative Systolic Blood Pressure Levels on Renal

Outcomes". American Society of Nephrology (ASN) Kidney Week 2018, San Diego, CA. ASN's 2018 Abstract Supplement - Abstract #3007193.

185. **Onuigbo M.** "The Value Contribution of an Innovative Remote Monitoring of Longitudinal Estimated Glomerular Filtration Rate Trajectories in CKD Patients". American Society of Nephrology (ASN) Kidney Week 2018, San Diego, CA. ASN's 2018 Abstract Supplement - Abstract # 3001366.

186. **Onuigbo M,** Khan S, Vecchio M, Karki B, Agbasi N. "Symptomatic Icodextrin Right Pleural Effusion From Suspected Pleuroperitoneal Communication: The Utility of Simultaneous Biochemical Fingerprint Analysis of Drained Pleural Fluid and Peritoneal Dialysis Fluid". Abstract accepted for Poster Presentation. 39th Annual Dialysis Conference, Dallas, TX. March 16-19, 2019.

187. **Onuigbo M,** Agbasi N. "A prospective randomized double-blind controlled trial of the effect of two intraoperative systolic blood pressure levels on postoperative acute kidney injury". Abstract accepted for Poster Presentation. 39th Annual Dialysis Conference, Dallas, TX. March 16-19, 2019.

188. **Onuigbo MAC,** Agbasi N. The CKD Express ©: The value contribution to chronic kidney disease care using an innovative remote EMR-Based monitoring system - A Vermont population health initiative, Neph Dial Transpl, Vol 34, Issue Supplement 1, June 2019, gfz106.FP412, <https://doi.org/10.1093/ndt/gfz106.FP412>.

189. **Onuigbo M,** Khan S, Karki B, Agbasi N. Symptomatic Icodextrin Right Pleural Effusion From Suspected Pleuro-peritoneal Communication: The Utility of Simultaneous Biochemical Fingerprint Analysis of Drained Pleural Fluid and Peritoneal Dialysis Fluid. WCN19-0082. Abstract accepted for poster presentation at the International Society of Nephrology (ISN) World Congress of Nephrology, 2019. Melbourne, Australia. April 12-15, 2019.

190. **Onuigbo M,** Agbasi N, Karki B, Wahlberg K, Khan S. Symptomatic Icodextrin Right Pleural Effusion From Suspected Pleuroperitoneal Communication: The Utility of Simultaneous Chemical Fingerprinting Analysis of Drained Pleural Fluid and Peritoneal Dialysis Fluid. Accepted for poster abstract presentation at the National Kidney Foundation (NKF) 2019 Spring Clinical Meetings (SCIM19), Boston, MA, USA.

191. Karki B, **Onuigbo M,** Khan S, Wahlberg K, Agbasi N. Symptomatic Icodextrin Right Pleural Effusion From Suspected Pleuro-peritoneal Communication: The Utility of Biochemical Fingerprint Analysis of Drained Pleural Fluid and Peritoneal Dialysis Fluid. Accepted for poster presentation at The 2019 Mayo Research Fellows' Association Research Day, 3/14/2019, Mayo Clinic, Rochester, MN.

192. **Onuigbo MAC.** The CKD Express © App – A new disruptive yet utilitarian new approach to Population Chronic Kidney Disease (CKD) Management. Innovative Idea Pitch Presentation and Discussion at the University of Vermont Center for Biomedical Innovation (CBI) 1st Workshop. UVM Innovation Building, Burlington, VT. Tuesday, November 26, 2019.

193. **Onuigbo M,** Agbasi N. The CKD Express ©: The value contribution to chronic kidney disease care using an innovative remote EMR-based monitoring system – A Vermont population health initiative. FP412. Nephrology Dialysis Transplantation, Volume 34, Issue Supplement_1,

June 2019, gzf106.FP412, <https://doi.org/10.1093/ndt/gfz106.FP412>. Abstract poster presentation at the 56th ERA-EDTA Congress - June 13, 2019 - Budapest, Hungary.

194. **Onuigbo M**, Agbasi N, Khan S, Karki B, Wahlberg K. Symptomatic Icodextrin right pleural effusion from suspected pleuroperitoneal communication: The utility of simultaneous biochemical fingerprinting analysis of drained pleural fluid and peritoneal dialysis fluid. FP595. Nephrology Dialysis Transplantation, Volume 34, Issue Supplement_1, June 2019, gzf106.FP595, <https://doi.org/10.1093/ndt/gfz106.FP595>. Abstract poster presentation at the 56th ERA-EDTA Congress - June 13, 2019 - Budapest, Hungary.

195. **M. Onuigbo**, N. Agbasi. THE CKD EXPRESS APP © - An innovative state-of-the-art revolutionary CKD health management system. Kid Int Rep, 2020, 5(3), S247. <https://doi.org/10.1016/j.ekir.2020.02.639>

196. **M. Onuigbo**, N. Agbasi. Pharmacologic decongestive diuresis with intravenous loop and thiazide diuretics in type 1 acute CRS – an underutilized paradigm of care in resource-poor settings. Kid Int Rep, 2020, 5(3), S24–S25.

197. **M. Onuigbo**, T. Muhammad, X. JordanBruno, C. Mahurin, V. Tibernii, J. Hingre. Polyuric acute kidney injury from non-dilated obstructive uropathy complicating recurrent abdominopelvic sarcoma. Kid Int Rep, 2020, 5(3), S23–S24.

198. **Onuigbo MA**, A. Timed Repetitive Controlled Rotations of the CAR-170-C NXSTAGE Chronic Cartridge Hemodialysis Filter: An Original Newfangled Maneuver to Enable Heparin-Free Frequent Daily Home Hemodialysis. An ePoster abstract presented at the American Society of Nephrology (ASN) 2020 Kidney Week, Thursday, October 22, 2020. PO1244 — 2020. <https://asn.scientificposters.com/epsAbstractASN.cfm?id=1>

199. **M. Onuigbo**, T. Muhammad, JordanBruno X, Mahurin C, V. Tibernii, J. Hingre. SAT-054. Polyuric acute kidney injury from non-dilated obstructive uropathy complicating recurrent abdominopelvic sarcoma. KI Reports. 5 (3), Suppl S23-S24. Open Access. DOI:<https://doi.org/10.1016/j.ekir.2020.02.059> (Abstract accepted for presentation at the ISN WCN, Abu Dhabi, UAE, March 2020 – Postponed due to COVID-19 Pandemic).

200. **M. Onuigbo**, Agbasi N. SAT-055. Pharmacologic decongestive diuresis with intravenous loop and thiazide diuretics in type 1 acute cardiorenal syndrome – An underutilized paradigm of care in resource-poor settings. KI Reports. 5 (3), Suppl S24-S25. doi.org/10.1016/j.ekir.2020.02.060 (Abstract accepted for presentation at the ISN WCN, Abu Dhabi, UAE, March 2020 – Postponed due to COVID-19 Pandemic).

201. **Macaulay Onuigbo**, Kolade Olabode, Mohan Sengodan, MO170. “SWEET HYPOXIA” WITH ACUTE KIDNEY INJURY: THE UNPREDICTABILITY OF ACUTE HYPOXIC RESPIRATORY FAILURE IN COVID-19 INFECTION - A COMMUNITY HOSPITAL EXPERIENCE, Nephrology Dialysis Transplantation, Volume 36, Issue Supplement_1, May 2021, gfab092.0048, <https://doi.org/10.1093/ndt/gfab092.0048>

202. **Macaulay Onuigbo**, Sarah Sherman, Heng Tan, MO218. ALTERNATING EPISODES OF TRUE HYPERKALEMIA AND PSEUDOHYPERKALEMIA IN ADULT SICKLE CELL DISEASE - A NEPHROLOGIST'S DILEMA, Nephrology Dialysis Transplantation, Volume 36, Issue Supplement_1, May 2021, gfab092.0096, <https://doi.org/10.1093/ndt/gfab092.0096>

203. **Onuigbo MA**, Tan H, Sherman SE. Alternating Episodes of True Hyperkalaemia and Pseudohyperkalaemia in Adult Sickle Cell Disease: A Nephrologist's Dilemma. *EMJ Nephrol.* 2021;9[1]:55-57. Abstract Review No. AR6.
204. **Onuigbo MA**, Olabode K, Sengodan M. ‘Sweet Hypoxia’ with Acute Kidney Injury: The Unpredictability of Acute Hypoxic Respiratory Failure in COVID-19 Infection – a Community Hospital Experience. *EMJ Nephrol.* 2021;9[1]:48-49. Abstract Review No: AR2.
205. **Onuigbo, M.** POS-647 COMBINED HOME-HEMODIALYSIS PLUS IN-CENTER HEMODIALYSIS HYBRID REGIMEN AS A FAMILY-FRIENDLY WORK-FRIENDLY OPTION - THE FIRST OF ITS KIND. *Kidney International Reports*, Volume 7, Issue 2, S277, February 2022.
206. **Onuigbo, M.** POS-143 BENRAZILUMAB SUBSTITUTION MONOTHERAPY IS EFFECTIVE IN SYMPTOMATIC ASTHMA EXACERBATIONS OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. *Kidney International Reports*, Volume 7, Issue 2, S61, February 2022.
207. **Onuigbo, M.** POS-094 PSEUDOHYPERKALEMIA AND THE NEWLY INTRODUCED POTENT POTASSIUM BINDERS: A CALL FOR IMPERATIVE CAUTION – TWO CASE SERIES. *Kidney International Reports*, Volume 7, Issue 2, S40, February 2022.
208. **Onuigbo, M.** POS-040 RENAL OUTCOMES FOLLOWING ELECTIVE WITHDRAWAL OF LONG-TERM STABLE RAAS-BLOCKADE IN CHRONIC KIDNEY DISEASE PATIENTS PRESENTING WITH PROGRESSIVE ACUTE KIDNEY INJURY. *Kidney International Reports*, Volume 7, Issue 2, S16 - S17, February 2022.
209. **Onuigbo M**, de Waal D. Family-Friendly & Work-Friendly Hybrid Hemodialysis: Combination Home Hemodialysis and In-Center Hemodialysis Regimen. Poster presented at the National Kidney Foundation Spring Meeting, April 2022, Boston, MA.
210. Bowman N, Cobb N, George A, O’Driscoll S, Thomas K with **Onuigbo M.** Hemodialysis Filter Rotator. Poster presented at the UVM Departments of Mechanical Engineering and Electrical and Biomedical Engineering (ME 185-186, BME 187-188, EE 187-188) Engineering Design Night, Davis Center, University of Vermont on Thursday, April 28, 2022.
211. **Onuigbo M**, Bowman N, Cobb N, George A, O’Driscoll S, Thomas K, Locke A, Dubief Y. Onuigbo M. Timed Controlled Repeated Rotation of the CAR-170-C NXSTAGE Chronic Cartridge Hemodialysis Filter: A Novel Approach to Enabling Heparin-Free Frequent Daily Home Hemodialysis. European Society of Medicine, ESMED 2022, General Assembly COVID-19 Session Presentation. Madrid, Spain, August 4-6, 2022. Lecture Presentation (Recorded), COVID-19 Section.
212. **Onuigbo MA**, Bowman N, Cobb N, George A, O’Driscoll S, Thomas K, Locke A, Vila-Beamonte P. Mechanical Rotatory Method of Anticoagulation-Free Hemodialysis Using a Hemodialysis Filter Rotator With the NxStage Hemodialysis Machine: A UVM-MC-UVM Burlington VT Research Collaboration Effort. *J Am Soc Nephrol* 33: 2022. PUB084.

213. **Onuigbo MA**, Marineci S, Prikis M. Preemptive Living Kidney Transplantation in Asymptomatic CKD Stage 4 With Autosomal Dominant Polycystic Kidney Disease: To Transplant or Not to Transplant? That Is the Question. *J Am Soc Nephrol* 33: 2022. PUB309.
214. Jensen C, Geraci C, **Onuigbo MA**. Pregnancy-Associated Hemolytic Uremic Syndrome: Two Case Series From the University of Vermont Medical Center. *J Am Soc Nephrol* 33: 2022. PUB309.
215. **Onuigbo MA**. Four-Year Report on Renal Outcomes Following Elective Withdrawal of Long-Term RAAS Blockade in a Cohort of Patients With Otherwise Inexplicable New-Onset and Progressive AKI. *J Am Soc Nephrol* 33: 2022. TH-PO053 Poster.
216. **Onuigbo M**. “Four-Year Renal and Mortality Outcomes After Stopping Long-Term RAAS Blockade in CKD Patients with Otherwise Inexplicable Progressive New-Onset Acute-Kidney-Injury: A Post STOP ACEi Trial Review” WCN23-1002. *Kidney International Reports*, 2023, 8, S37. (ePoster, International Society of Nephrology Congress, Bangkok, Thailand, March 30-April 1, 2023)
217. **Onuigbo MA**. Four-Year Account of Renal and Mortality Outcomes After Elective Discontinuation of Long-Term RAAS Blockade in CKD Patients with Otherwise Inexplicable Progressive New-Onset Acute Kidney Injury. *AJKD* Vol 81, Iss 4, Suppl 1, April 2023 S6-7, #21. (Poster abstract. 2023 National Kidney Foundation Spring Clinical Meeting taking place in Austin, TX, April 11-15, 2023).
218. **Onuigbo M**. The NxStage Hemodialysis Filter Rotator for Anticoagulation-Free Hemodialysis. *AJKD* Vol 81, Iss 4, Suppl 1, April 2023 S105-106, #361. (Poster abstract. 2023 National Kidney Foundation Spring Clinical Meeting taking place in Austin, TX, April 11-15, 2023).
219. **Onuigbo MA**, Houston M, Kagan M, Klauzenberg S. Transient Hepatitis B Surface Antigenemia Following Hepatitis B Immunization - Lessons from a recent case. *AJKD* Vol 81, Iss 4, Suppl 1, April 2023 S69, #237. (Poster abstract. 2023 National Kidney Foundation Spring Clinical Meeting taking place in Austin, TX, April 11-15, 2023).
220. **Onuigbo MA**, Okrant J. No, It’s Not Bilateral Hydronephrosis: It’s Pseudohydronephrosis! *J Am Soc Nephrol* 34: 2023, 1056 (PUB 030).
221. de Waal D, **Onuigbo MA**. Intradialytic Amino Acids Improved Malnutrition Markers in ESRD with Complex Congenital Heart Disease on Peritoneal Dialysis. *J Am Soc Nephrol* 34: 2023, 1133 (PUB 360).
222. **Onuigbo MA**, Krant N, Bair S. Scleroderma Renal Crisis: A Nephrologist’s Enigmatic Therapeutic Dilemma. *J Am Soc Nephrol* 34: 2023, 458 (FR-PO196).
223. de Waal D, **Onuigbo MA**. Successful Bariatric Laparoscopic Sleeve Gastrectomy in a Home Hemodialysis Patient Led to Reduced Hemodialysis Frequency. *J Am Soc Nephrol* 34: 2023, 633 (FR-PO824).

224. Henry A, Mann-Gow T, Agbasi N, Jeremiah C, **Onuigbo MA**. Unusual Polydipsia-Polyuria Syndrome, Hypernatremia, and Hypercoepitinemia: What Is the Diagnosis? J Am Soc Nephrol 34: 2023, 934 (SA-PO742).
225. **Onuigbo, Macaulay et al**. WCN24-839 THE NOVEL CONCEPT OF DECREMENTAL HOME HEMODIALYSIS FOLLOWING SUCCESSFUL BARIATRIC SURGERY IN END STAGE RENAL DISEASE. Kidney International Reports, Volume 9, Issue 4, S545.
226. **Macaulay Onuigbo**, Adam Locke, Niklas Cobb, Amber Doiron, Steven O'Driscoll. WCN24-1869 The Successful Design and Development of a Novel Second Generation NxStage Hemodialysis Filter Rotator for Anticoagulation-Free Hemodialysis: Developers, Sponsors and Investors Wanted. April 2024. Kidney International Reports 9(4):S406. DOI: 10.1016/j.ekir.2024.02.844
227. **Macaulay Onuigbo**, AARON HENRY, TRAVIS MANN-GOW, NNEOMA AGBASI, JEREMIAH UGWU. WCN24-897 ATYPICAL POLYDIPSIA-POLYURIA SYNDROME PRESENTING WITH HYPERCOPEPTINEMIA AND HYPERNATREMIA: IS THIS A NEW UNRECOGNIZED SYNDROME? Kidney International Reports. Volume 9, Issue 4, Supplement, April 2024, Page S4.
228. **Macaulay Onuigbo**, Jessica Okrant. WCN24-836 IT'S NOT HYDRONEPHROSIS - IT IS PSEUDOHYDRONEPHROSIS! Kidney International Reports. Volume 9, Issue 4, Supplement, April 2024, Page S527.
229. **Onuigbo M**. Weight loss after bariatric surgery may lead to drop in HHD frequency. Nephrology, News & Issues. May 17, 2024.
<https://www.healio.com/news/nephrology/20240517/weight-loss-after-bariatric-surgery-may-lead-to-drop-in-hhd-frequency>.
230. **Macaulay Onuigbo**, Leia Alston, Eileen Ashe, Robellito Jr Franje Salinas, Desiree De Waal. The novel concept of personalized decremental home hemodialysis following successful bariatric surgery in end stage renal disease. NKF 2024 abstract. Poster.
231. **Macaulay Onuigbo**, Adam Locke, Niklas Cobb, Amber Doiron, Steven O'Driscoll. The Successful Design and Development of a Novel Second Generation NxStage Hemodialysis Filter Rotator for Anticoagulation-Free Hemodialysis: Developers, Sponsors and Investors Wanted. April 2024. *Kidney International Reports* 9(4):S406 WCN24-1869. DOI:10.1016/j.ekir.2024.02.844. License CC BY-NC-ND 4.0
232. **Onuigbo, Macaulay A**. A Novel Anticoagulation-Free Hemodialysis Paradigm: A Second-Generation Hemodialysis Filter Rotator Prototype Using the NxStage Machine Is Ready for Clinical Trials: TH-PO252. *Journal of the American Society of Nephrology* 35(10S):10.1681/ASN.2024nm38nhdn, October 2024. DOI:10.1681/ASN.2024nm38nhdn
233. **Onuigbo, Macaulay et al**. WCN25-1918. Sustainable anticoagulation-free hemodialysis using a hemodialysis filter rotator – The second prototype rotator is ready for Prime Time! WCN25-1918. *Kidney International Reports*, Volume 10, Issue 2, S401 - S402.

234. **Onuigbo, Macaulay** et al. Severe acute kidney injury with suspected bilateral renal artery stenosis on renal Duplex while on concurrent ACE inhibition – A case for carbon dioxide renal angiography. WCN25-3425. Kidney International Reports, Volume 10, Issue 2, S606 - S607.

235. **Onuigbo, Macaulay** et al. IATROGENIC PERIOPERATIVE HYPERVOLEMIA: A NOVEL UNRECOGNIZED ETIOLOGY OF DELAYED RENAL ALLOGRAFT FUNCTION - TWO CASE SERIES. WCN25-2336. Kidney International Reports, Volume 10, Issue 2, S15 - S16.

236. **Onuigbo, Macaulay** et al. May-Thurner syndrome complicating left lower quadrant deceased donor kidney transplantation in Adult Polycystic kidney Disease. WCN25-1923. Kidney International Reports, Volume 10, Issue 2, S638 - S639.

237. **Onuigbo, Macaulay**. PROSPECTIVE ANALYSIS OF RENAL OUTCOMES FOLLOWING WITHDRAWAL OF CONCURRENT RAAS BLOCKADE IN PATIENTS PRESENTING WITH NEW DE NOVO AND PROGRESSIVE OTHERWISE INEXPLICABLE ACUTE KIDNEY INJURY – A 6-YEAR REPORT. WCN25-1932. Kidney International Reports, Volume 10, Issue 2, S31 - S32.

238. **Onuigbo, Macaulay A.** Can Arteriovenous Fistula Creation Cause a Dramatic Spontaneous Doubling of Estimated Glomerular Filtration Rate from 11 to 22 mL/min/1.73 m² Body Surface Area (BSA) in a Span of Five Months? A Case Report: PUB377. Journal of the American Society of Nephrology 36(10S):10.1681/ASN.202525gpamen, October 2025. | DOI: 10.1681/ASN.202525gpamen

239. **Onuigbo, Macaulay A.** Late-Onset Kidney Failure from Angiotensin Blockade: Combination Guideline-Directed Medical Therapy in CKD Must Be Individualized - How Concerning Is Late-Onset eGFR Decline with GDMT? A Patient's Wife Reacted Vigorously!: PUB012. Journal of the American Society of Nephrology 36(10S):10.1681/ASN.2025dx7vx4qk, October 2025. | DOI: 10.1681/ASN.2025dx7vx4qk

Patents Issued or Pending

U.S. patent application 63094958 filed October 22, 2020:

Hemodialysis Filter Rotator - Rotating Motor for Anticoagulation-free Hemodialysis with the NxStage Dialysis Machine. Submitted to US Patent Application via UVM Innovations in October 2020. In October 2020, we successfully submitted a US patent application on the Hemodialysis Filter Rotator in collaboration with the University of Vermont (UVM) Innovations Unit. This is a new mechanistic method of achieving anticoagulation-free hemodialysis using a novel Hemodialysis Filter Rotator. May 2023 update on the US Patent Application: The new US Patent filing application details are as follows: C834 / U.S. Pat. Appln. No. 18/250,092 / Onuigbo et al. - Hemodialysis Filter Rotator / 073777.00117. December 2, 2023, update on the US Patent Application: C834 / Notice of Publication / No Response Requested / U.S. Pat. Appln. No. 18/250,092 / Onuigbo et al. - Hemodialysis Filter Rotator / 073777.00117.

Other Creative Activities

1. BlackHealthOnline TeleMedicine Project:

Between 2015-2018, working collaboratively with three other Nigerian physicians, with the technical involvement of an international consortium of IT engineers (Nigeria, Sierra Leone and India), we completed work on a portable TeleMedicine portal called BalckHealthOnline, that was geared to offer affordable, convenient yet excellent TeleHealth options to the underserved patients in Sub-Saharan Africa and other parts of the developing world. Regrettably, due to some overriding circumstances, the program was never launched, and the effort was aborted in 2018.

2. Dissertations completed:

Dissertations for Master of Science (MSc) in Medical Biochemistry Degree and for a West African College of Medicine Nephrology Fellowship Award

1. Onuigbo MAC. Comparative Biochemical Indices of Renal Function in Health and Disease: A Thesis submitted in partial fulfillment of the requirements for the award of the degree of Master of Science. Department of Medical Biochemistry, Faculty of Medical Sciences and Dentistry, College of Medicine, University of Nigeria, Enugu Campus 1988 Aug.

2. Onuigbo MAC. Systemic Vasculitis – Microscopic Polyarteritis & Wegener's Granulomatosis: Clinical Spectrum and Prognosis of Renal Vasculitic Involvement: A Retrospective Report on One Hundred and Seven Patients and A Prospective Review of Three Nigerian Case Reports: A Dissertation in partial fulfillment of the requirements for the award of the Fellowship of the College West African College of Physicians 1989 Oct.

Quality Improvement and Patient Safety Activities

2018 Performance Improvement (PI) on the utilization of nicotinamide for phosphorus control among patients on maintenance dialysis: Nicotinamide as an adjunct therapy for phosphorus control.

PI – Macaulay Onuigbo MD.

I started work on this QI project in March 2018 and am in collaboration with Jeffords Institute of Quality. It was converted to a full Research Protocol in June 2018 and has been resubmitted for IRB approval in collaboration with Jeffords Quality Institute. Data collection and analysis led to its discontinuation in 2019.

International Conference – World Congress of Internal Medicine – 2018

Onuigbo M. World Congress of Internal Medicine 2018 in South Africa – My post-lecture interview on YouTube on the classification and diagnosis of glomerulonephritis in low-resource settings.

<https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fyoutu.be%2FnhtmBtWJoB4%3Fsi%3Db8EZJMPEDDdrweTg&data=05%7C02%7C%7Cb3c346db9f684aa65cab08dd3bfc82bc%7C84df9e7fe9f640afb435aaaaa%7C1%7C0%7C638732677896400234%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydW>

SUMMARY OF SCHOLARLY ACTIVITIES

I have contributed to the modern medical English literature and published and reported on several new syndromes including the syndrome of late onset renal failure from angiotensin blockade (LORFFAB, 2005), the concept of Renoprevention (2009), the syndrome of rapid onset end stage renal disease (SORO-ESRD, 2010), Cognitive Drift with the EMR (2012) and Quadruple Whammy (2013). I have 4 published Nephrology books, 20 book chapters, over 100 peer-reviewed PubMed-indexed journal publications, and over 200 published conference abstracts. My research interests include acute kidney injury and in particular, prevention of post-operative acute kidney injury. I am also working on a new CKD Care Model that involves IT-enabled remote monitoring of kidney function to improve population-wide CKD health. I am a frequent reviewer for journals in Nephrology, Hypertension and General Internal Medicine. For community service, I was part of a team that developed a Telemedicine portal to deliver robust, portable, reliable, convenient, affordable and patient-centered care to patients in the developing world. My long-term research interests include chronic kidney disease (CKD) progression, the impact of acute kidney injury (AKI) on CKD progression, Renoprotection strategies, Renoprevention paradigms, and perioperative risk stratification of CKD patients. More recently, we have investigated the critical, albeit neglected, role of intraoperative hypotension (IOH) in the pathogenesis of post-operative AKI. Since joining the Nephrology faculty here at UVM in February 2018, I have constituted a multidisciplinary team, the Postoperative Acute Kidney Injury Research Group (PARG) to investigate IOH and postoperative AKI together with the correlation of renal injury following both cardiac and non-cardiac surgeries with continuously monitored real time urinary oxygen tension.

Here at UVM/UVMMC, we investigated the critical, albeit neglected and unrecognized role of intraoperative hypotension (IOH) in the pathogenesis of post-operative AKI. We have applied for a research grant at UVM for this effort. Since joining the Nephrology faculty here at UVM in February 2018, I constituted a multidisciplinary team, the Postoperative Acute Kidney Injury Research Group (PARG) to investigate the impact of IOH and postoperative AKI. Subsequently, working in collaboration with Dr. Richard Solomon, we intended to study the correlation of acute kidney injury following both cardiac and non-cardiac surgeries with continuously monitored real-time urinary oxygen tension. The hope is that our findings and expertise in this field would increase the awareness of healthcare providers around the world to the role of IOH in postoperative AKI and to help develop strategies to limit the incidence of postoperative AKI, itself a significant contributor to hospital-acquired AKI. These would translate to reduced patient morbidity and mortality, reduced hospital length of stay and significantly huge savings in the increasingly scarce US healthcare dollars. We have so far been unable to get IRB approval to initiate this study.

Furthermore, we have an interest in the leveraging of Healthcare Informatics/Information Technology to optimize CKD care. In the last one year I have collaborated with the Department of Computer Science, University of Vermont, to develop The CKD Express © App, an iOS-based App that enables remote and total care of CKD populations anywhere in the world. The App consists of two user interphases - The Patient user interphase and The Provider user interphase. The App will track, monitor and analyze eGFR trajectories of registered patients and then trigger and stipulate new directions and instructions to the patients via a secure network, in

real-time. The App is unique, innovative, disruptive, state-of-the-art, and revolutionary. It provides convenient, effective, efficient, and patient-centered CKD care with significant cost savings through reduced waste. It enhances patient and provider satisfaction. It reduces patient wait times for nephrology referrals.

Finally, I had completed work on the process of developing a new Methodology of Medical Clerkship, an adaptation of the “Case Analysis” paradigm that had been utilized meritoriously over the past decades in the Social & Life Sciences. It was my Curriculum Development project at the LCOM Teaching Academy Fellowship, 2018-2019. I was elected to the rank of Expert Teacher of the LCOM Teaching Academy in January 2020.

I am a frequent reviewer for journals in Nephrology, Hypertension and General Internal Medicine including the Journal of the American Society of Nephrology NephSAP. I serve on the Editorial Board of General Medicine and Specialty journals including the International Journal of Clinical Practice. In June 2018, I served as an NIH-NIDDK Workshop Committee Participant at a Workshop on Chronic Kidney Diseases in Agricultural Communities in Bethesda, MD. I was an American Society of Nephrology (ASN) Kidney Week 2018 Abstract Reviewer, Geriatric Nephrology Section.

In July 2018, I published a Letter to the Editor, Mayo Clinic Proceedings, on new insights into mortality versus ESRD trajectories among adult patients with glomerulonephropathies.

In 2019, we described for the first time, the use of biochemical fingerprinting techniques to diagnose pleuro-peritoneal communication causing symptomatic right-sided pleural effusion in an ESRD patient on maintenance peritoneal dialysis using Icodextrin solution in the journal, Mayo Clinic Proceedings: Innovations, Quality & Outcomes.

My other scholarly achievements include a National (Academic) Merit award – Ministry of Education, Nigeria, 1978-1979, the Best Student Prize Award, Final MBBS (MD) medical school examination in 1981, Fellowship of the American Society of Nephrology (FASN) in 2007, Mayo Health System MacMillan Management Scholarship Award in 2009, Mayo Health System (MHS) Education System Oriented Application Research (SOAR) Grant Award in 2010, University of Wisconsin MBA Consortium Most Outstanding Graduate in 2012, “Best Abstract” Award, 16th International Conference on Dialysis/Renal Research Institute, NY in February 2014, Mayo Clinic 2014 Division of Hypertension and Nephrology Integration Research Award in June 2014 and election to membership of the MAYO CLINIC O’Brien Kidney Research Center, Rochester, MN, USA in September 2016.

INVITED PRESENTATIONS

REGIONAL PRESENTATIONS

Years	Host Organization	City, State
2/2003	“Angiotensin Blockade, Hypertension, Proteinuria and Renal Failure”. Luther Midelfort, Mayo Health System CME Grand Rounds Lecture.	Eau Claire, WI
2/2003	“Angiotensin Blockade, Hypertension, Proteinuria and Renal Failure”. Luther Midelfort, Mayo Health System CME Grand Rounds Lecture.	Eau Claire, WI
5/2003	“Evidence-based Treatment of Hypertension in Patients with Diabetes Mellitus”. Annual Conference for Primary Care Physicians.	Eau Claire, WI
1/2004	“Evidence-Based and Outcome-Based Management of Hypertension in Type II diabetes Mellitus after JNC VII: A Luther Midelfort Perspective. The Concept of Renoprotection with Angiotensin II Blockers”. Luther Midelfort, Mayo Health System CME Grand Rounds Lecture.	Eau Claire, WI
8/2004	“Evidence-Based Management of Dyslipidemia and Hypertension after JNC VII, and Beyond. The Concept of Combination Amlodipine-Atorvastatin Therapy. A Case for Caduet”. Red Cedar Clinic, Mayo Health System CME Grand Rounds Lecture	Menomonie, WI
2/2005	“Evidence-Based Treatment of Hypertension in Patients with Type II Diabetic Nephropathy post-JNC VII: A Case for the Use of Irbesartan. The Importance of Reaching Goal Blood Pressure and Using Fixed Dose Combination Therapy”. Red Cedar Clinic, Mayo Health System CME Grand Rounds Lecture.	Menomonie, WI
12/2006	“Renal failure from RAAS blockade in patients with chronic kidney disease: A prospective 50-month analysis - A call for pragmatic caution to further optimize cardiorenal protection with RAAS blockade”. Mayo Clinic, Rochester, Division of Nephrology/Hypertension CME Grand Rounds Lecture.	Rochester, MN
10/2007	“The Cardio Renal Anemia Syndrome: A Physician’s Dilemma” Cardiology for the Practicing Clinician, a multi-disciplinary conference for Physicians in Northwestern Wisconsin.	Eau Claire, WI
12/2007	“The Spectrum of Worsening Renal Failure in 100 CKD Patients Concurrently on ACE Inhibitors and Angiotensin Receptor Blockers (ARBs): Results of a 50-Month Mayo Health System Hypertension Clinic Experience”. Red Cedar Clinic, Mayo Health System CME Grand Rounds Lecture	Menomonie, WI
10/2010	“Syndrome of Rapid Onset End-Stage Renal Disease (SORO-ESRD): A New Unrecognized Pattern of Progression of Chronic Kidney Disease (CKD) to End-Stage Renal Disease (ESRD)”. Mayo Health System Practice-Based Research Network (MHS PBRN) 2010 Annual Fall Conference held at Mayo Clinic, Rochester, MN, “PBRNs at the Intersection of Quality and Research” (Poster).	Rochester, MN

10/2010	“Bilateral Lower Extremity Sequential Compression Devices (SCDs) for the Prevention of Intra-Dialytic Hypotension: A New Therapy for an Old Problem”. Mayo Health System Practice-Based Research Network (MHS PBRN) 2010 Annual Fall Conference held at Mayo Clinic, Rochester, MN. “PBRNs at the Intersection of Quality and Research” (Poster).	Rochester, MN
10/2010	“An Often Unrecognized Cause of Acute Kidney Injury in US Hospitalized Patients: Three Consecutive Cases Seen Over Six Months in a Mid-Western US Nephrology Practice”. Mayo Health System Practice-Based Research Network (MHS PBRN) 2010 Annual Fall Conference held at Mayo Clinic, Rochester, MN. “PBRNs at the Intersection of Quality and Research” (Poster).	Rochester, MN
10/2010	“A 120-Month Retrospective Analysis of De-Novo HBV Infection Versus Recombinant HBsAgemia in a Mayo Clinic Hemodialysis Population: Call for Change in US CDC Guidelines”. Mayo Health System Practice-Based Research Network (MHS PBRN) 2010 Annual Fall Conference held at Mayo Clinic, Rochester, MN. “PBRNs at the Intersection of Quality and Research” (Oral presentation).	Rochester, MN
11/2020	“Acute Kidney Injury (AKI) in COVID-19 – a mini-overview; COVID-19 recurrence in an ESRD patient? – A Burlington, VT Experience”	UVMHC Department of Medicine Grand Rounds
2/2025	"Implementation Research: From Patient Home Bedside to Industry - The Hemodialysis Filter Rotator Project for Anticoagulation-Free Hemodialysis" on February 22, 2025. University of Vermont health Network Department of Medicine Grand Rounds, Davis Auditorium, University of Vermont Medical Center, Burlington, VT.	UVMHC Department of Medicine Grand Rounds

NATIONAL PRESENTATIONS

Years	Host Organization	City, State
3/2002	“Sirolimus rescue therapy in renal transplant patients receiving tacrolimus, mycophenolate mofetil and corticosteroids”. Third Annual Transplant Fellows’ Conference “Advances in Organ Transplantation”.	Irving, TX
12/2006	“Renal Failure From RAAS Blockade in Patients with Chronic Kidney Disease (CKD): A Prospective 50-Month Analysis – A Call For Pragmatic Caution to Further Optimize Cardiorenal Protection with RAAS Blockade”. Department of Nephrology & Hypertension, Mayo Clinic, Rochester, Invited Lecture/Grand Rounds.	Rochester, MN
7/2007	“RAAS blockade accelerates loss of eGFR in contrast-induced nephropathy? – A 50-month Mayo Health System Hypertension Clinic experience”. 26th Annual Meeting of the North American Society for Dialysis and Transplantation.	Maui, HI
7/2007	“Renal failure associated with RAAS blockade in CKD patients with renal artery stenosis: Results of a prospective 50-month Mayo Health System Hypertension Clinic study”. 26th Annual Meeting of the North American Society for Dialysis and Transplantation.	Maui, HI
7/2007	“Late onset renal failure from angiotensin blockade (LORFFAB) in CKD patients with normal renal arteries and absent precipitating risk factors? Five patients followed over 50 months in a Mayo Health System Hypertension Clinic”. 26th Annual Meeting of the North American Society for Dialysis and Transplantation	Maui, HI
7/2007	“Renal failure from RAAS blockade? – Sustained improved eGFR following withdrawal of RAAS blockade in 100 CKD patients presenting with accelerated renal failure – A 50-month Mayo Health System Hypertension Clinic experience”. 26th Annual Meeting of the North American Society for Dialysis and Transplantation.	Maui, HI
5/2008	“Late-Onset Renal Failure From Angiotensin Blockade (LORFFAB): Need for a Paradigm Shift in Use of RAAS Blockade to Optimize Improved Cardio-Renal Outcomes”. Grand Rounds, Department of Medicine, Howard University Hospital, Washington, DC.	Washington, DC
9/2008	“Renal failure associated with concurrent RAAS blockade in CKD patients: A 72-month Mayo Health System Hypertension Clinic prospective report – The obligation to adjust BP treatment in CKD patients presenting with accelerated renal failure while on RAAS blockade”. Grand Rounds, Department of Medicine, Texas A & M Health Science Center, Temple, TX.	Temple, TX

11/2008	“Renal Failure and RAAS Blockade in CKD patients: A prospective 72-month MHS Clinic Report – A Call for More Circumspection. Renoprevention vs Renoprotection. A Critical Re-appraisal of the Large RAAS Blockade Trials”. Grand Rounds, Department of Medicine, Greater Baltimore Medical Center, Baltimore, MD.	Baltimore, MD
3/2009	“Drug-induced Encephalopathy Secondary to Non-renal Dosing of Common Medications in Two Dialysis Patients”. 29th Annual Dialysis Conference/15th International Symposium on Hemodialysis.	Houston, TX
3/2009	“Reno-Prevention vs. Reno-Protection: A Critical Reexamination of the Evidence-Base From the Large RAAS Blockade Trials: Is it Time for a Paradigm Shift?” 29th Annual Dialysis Conference/15th International Symposium on Hemodialysis.	Houston, TX
3/2009	“Does Concurrent RAAS Blockade in Older CKD Patients Play a Role in the Acute Renal Failure Epidemic in US Hospitalized Patients?: Three Cases of Severe ARF Encountered Over Three Days in a Northwestern Wisconsin Nephrology Practice”. 29th Annual Dialysis Conference/15th International Symposium on Hemodialysis.	Houston, TX
3/2009	“Bilateral Lower Extremity Sequential Compression Devices, A Novel Approach to the Management of Intradialytic Hypotension in the Outpatient Setting: A Luther Hospital Mayo Health System Dialysis Unit Experience with Three Consecutive Patients”. 29th Annual Dialysis Conference/15th International Symposium on Hemodialysis.	Houston, TX
3/2009	“The Natural History of chronic Kidney Disease (CKD) Revisited: A 72-month Mayo Health System Hypertension Clinic Practice-Based Research Network Prospective Report on ESRD and Death Rates in 100 High-Risk CKD Patients: A Call for Circumspection?”. 29th Annual Dialysis Conference/15th International Symposium on Hemodialysis.	Orlando, FL
3/2010	“New-onset central diabetes insipidus in a hemodialysis patient with adult polycystic kidney disease following intracranial hemorrhage: The first reported case”. Oral presentation. 30 th Annual Dialysis Conference, 2010.	Seattle, WA
3/2010	“Renal artery stenosis: To stent or not to stent – Results of a Mayo Health System Hypertension Clinic prospective 84-month patient-level data analysis of 26 high risk CKD patients”. Oral presentation. 30 th Annual Dialysis Conference, 2010.	Seattle, WA

3/2010	“ESRD, focal segmental glomerulosclerosis, nephrotic syndrome and p-ANCA associated necrotizing cresenteric glomerulonephritis associated with chronic lithium therapy: A case report”. Invited poster. 30 th Annual Dialysis Conference, 2010.	Seattle, WA
3/2010	“Transient Hepatitis B surface antigenemia following Recombinant Engerix B Hepatitis B vaccine in an 81-year old hemodialysis patient”. Invited poster. 30 th Annual Dialysis Conference, 2010.	Seattle, WA
3/2010	“ESRD and Death Outcomes in Chronic Kidney Disease: What do we know? – Results of an 82-month PBRN-based Community-level Patient-level prospective data analysis of 100 High Risk CKD Patients”. Invited poster. 30th Annual Dialysis Conference, 2010.	Seattle, WA
4/2010	“Chronic Kidney Disease Progression to ESRD: Smooth and Progressive Vs Uneven and Staccato Patterns? – A Mayo Clinic PBRN-Based 82-Month Analysis of 100 High-Risk CKD Patients – Implications for a Paradigm Change in Reno-Protection”. National Kidney Foundation (NKF) Spring Clinical Meetings. (Abstract published in the American Journal of Kidney Disease: <i>Am J Kidney Dis</i> 2010 Apr; 55(4):B87).	Orlando, FL
4/2010	“To Stent or Not To Stent: Renal Artery Stenosis – A Mayo Health System Hypertension Clinic 82-Month PBRN-Based Patient-Level Prospective Data Analysis of 26 High- Risk CKD Patients with Renal Artery Stenosis Presenting with Acute Kidney Injury”. National Kidney Foundation (NKF) Spring Clinical Meetings. (Abstract published in the American Journal of Kidney Disease: <i>Am J Kidney Dis</i> 2010 Apr; 55(4):B87).	Orlando, FL
4/2010	“Bilateral Lower Extremity Sequential Compression Devices (SCDS) for the Management of Intra-Dialytic Hypotension – A New Approach to an Old Problem”. National Kidney Foundation (NKF) Spring Clinical Meetings. (Abstract published in the American Journal of Kidney Disease: <i>Am J Kidney Dis</i> 2010 Apr; 55(4):B87).	Orlando, FL
4/2010	“Nondilated Obstructive Uropathy – An Unrecognized Cause of Acute Renal Failure in Hospitalized US Patients: Three Case Reports Seen Over Six Months in a North-Western Wisconsin Nephrology Practice”. National Kidney Foundation (NKF) Spring Clinical Meetings. (Abstract published in the American Journal of Kidney Disease: <i>Am J Kidney Dis</i> 2010 Apr; 55(4):B87).	Orlando, FL

11/2010	“A 120–Month Retrospective Analysis of De Novo HBV Infection in a Mayo Clinic Hemodialysis System - A Comparative Effectiveness Review and a Call for Change in Current US CDC Guidelines for HBV Immuno–Surveillance and Immuno–Prophylaxis”. American Society of Nephrology ASN's 43rd Annual Meeting and Scientific Exposition. (Published abstract).	Denver, CO
11/2010	“Non–Dilated Obstructive Uropathy _ An Unrecognized Cause of Acute Renal Failure in Hospitalized US Patients”. American Society of Nephrology ASN's 43rd Annual Meeting and Scientific Exposition. (Published abstract).	Denver, CO
11/2010	“Syndrome of Rapid Onset End-Stage Renal Disease (SORO-ESRD): A New Unrecognized Pattern of CKD Progression to ESRD”. American Society of Nephrology ASN's 43rd Annual Meeting and Scientific Exposition. (Published abstract – Poster presentation).	Denver, CO
2/2011	“Syndrome of Rapid Onset End-stage Renal Disease (SORO-ESRD): A New Unrecognized Pattern of Progression of CKD to ESRD”. 31ST Annual Dialysis Conference, 2011.	Phoenix, AZ
11/2011	“Economic Impact of Reduced HBV Testing among Hemodialysis Patients in the New Environment of Bundling: Results of a Study of De Novo HBV Infection Rates in a Mayo Clinic Hemodialysis Population – A Call for Changes in Current US CDC Guidelines on HBV Testing Protocols”. American Society of Nephrology (ASN). (Poster presentation).	Philadelphia, PA
11/2011	“The Validity of Current CKD Staging Paradigms Revisited and Disputed: A 2-Year Snap Shot of Stage IV CKD Patients in a Mayo Clinic Laboratory Database: A Call for Process Reengineering in Nephrology Practice”. American Society of Nephrology (ASN). (Poster presentation).	Philadelphia, PA
11/2011	“Lessons Learnt from Consecutive Health-Related Quality of Life (KDQOL-SF) Surveys in a Mayo Clinic Stable Hemodialysis Patient Population”. American Society of Nephrology (ASN). (Poster presentation).	Philadelphia, PA
2/2012	“The Syndrome of Rapid Onset End-stage Renal Disease (SORO-ESRD) Described in Two Consecutive Renal Transplant Recipients Seen Over Six Months”. 32nd Annual Dialysis Conference. (Poster presentation).	San Antonio, TX
2/2012	“Evidence of the Syndrome of Rapid Onset End-stage Renal Disease (SOROESRD) in the Acute Kidney Injury (AKI) Literature - Preventable Causes of AKI and SORO-ESRD - A Call for Re-engineering of Nephrology Practice Paradigms”. 32nd Annual Dialysis Conference. (Poster presentation).	San Antonio, TX

2/2012	“Reno-Prevention: A New Concept For Re-engineering Nephrology Care: An Economic Impact and Patient Outcome Analysis of Two Hypothetical Patient Management Paradigms in the CCU”. 32nd Annual Dialysis Conference. (Poster presentation).	San Antonio, TX
2/2012	“De Novo Hepatitis B Virus Infection in a Mayo Clinic Hemodialysis Population: Practical Lessons - Economic Impact of Reduced HBV Testing and A Call for Changes in Current US CDC Guidelines on HBV Testing Protocols”. 32nd Annual Dialysis Conference. (Oral presentation).	San Antonio, TX
8/2016	“The syndrome of rapid onset end stage renal disease (SORO-ESRD) - Results of a thirteen-year Mayo Clinic incident hemodialysis study, 2001-2013”. Grand Rounds Presentation in the Division of Nephrology and Hypertension, Mayo Clinic Rochester, MN.	Rochester, MN
8/2016	“The neglected role of intraoperative hypotension in postoperative AKI”. Grand Rounds Presentation in the Division of Nephrology and Hypertension, Mayo Clinic Rochester, MN.	Rochester, MN
10/2017	“Healthcare Costs Accelerate With Chronic Kidney Disease Progression”. J Manag Care Spec Pharm 2017 Oct 23 (10-a Suppl);S1-S92. Poster presentation at AMCP Nexus 2017.	Dallas, TX
6/2018	“The Utility of Intravenous Decongestive Diuresis in Type 1 Acute Cardiorenal Syndrome: Accelerated Rising Pro B Natriuretic Peptide At Presentation Is a Prognosticator for Good Renal Outcomes”. Poster presentation at the 2018 Annual Dialysis Conference.	Orlando, FL.
6/2018	“TeleMedicine – An Innovative Affordable Convenient Paradigm of Rendering Prompt and Personalized ‘Medical Missions’ in Sub-Saharan Africa”. Lecture presented at the 24th Annual Association of Nigerian Physicians in the Americas (ANPA) Convention & Scientific Assembly.	Dallas, TX

INTERNATIONAL PRESENTATIONS

Years	Host Organization	City, State
9/2005	“Late onset renal failure from angiotensin blockade (LORFFAB): A Prospective Thirty-month Mayo Health System Clinic Experience”. 4th Annual International Conference on “Prevention in Renal Disease”.	Toronto, Quebec, CAN
2/2006	“Late onset renal failure from angiotensin blockade (LORFFAB): Extended observations. Implications for	Merida, Yucatan, MEX

	late onset accelerated loss of GFR in susceptible patients on RAAS blockade – Time for a paradigm shift in use of RAAS blockade?”. XIII International Congress on Metabolism and Nutrition in Renal Disease.	
9/2007	“Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease?”. 6th Annual Conference on “Prevention in Renal Disease”.	Toronto, Quebec, CAN
9/2007	“RAAS blockade and worsening azotemia in CKD patients with hemodynamically significant renal artery stenosis: Results of a prospective 50-month Mayo Health System Clinic Study”. 6th Annual Conference on “Prevention in Renal Disease”.	Toronto, Quebec, CAN
9/2007	“Late onset renal failure from angiotensin blockade (LORFFAB) – Sustained improved eGFR following withdrawal of RAAS blockade in 100 CKD patients presenting with accelerated renal failure”. 6th Annual Conference on “Prevention in Renal Disease”.	Toronto, Quebec, CAN
1/2008	“Does Renin-Angiotensin Aldosterone Blockade Exacerbate Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease? A Prospective 50-Month Mayo Clinic Study”. 10th International Conference on Dialysis, Advances in CKD, 2008.	Cancun, MEX
1/2008	“RAAS Blockade and Worsening Azotemia in CKD Patients with Hemodynamically Significant Renal Artery Stenosis: Results of A Prospective 50-Month Mayo Health System Clinic Study". 10th International Conference on Dialysis, Advances in CKD, 2008.	Cancun, MEX
1/2008	“Late Onset Renal Failure From Angiotensin Blockade (LORFFAB) – Sustained Improved eGFR Following Withdrawal of RAAS blockade in 100 CKD Patients Presenting with Accelerated Renal Failure. A Subgroup Analysis of Five Patients with Normal Renal Arteries and No Precipitating Risk Factors: Results of A Prospective 50-Month Mayo Health System Hypertension Clinic Study”. 10th International Conference on Dialysis, Advances in CKD, 2008.	Cancun, MEX
4/2011	“Two consecutive health-related quality of life (KDQOL-SF) surveys in a stable hemodialysis population – Present and past scores compared”. The International Society of Nephrology (ISN). World Congress of Nephrology 2011. (Poster presentation).	Vancouver, CAN
4/2011	“The syndrome of rapid onset end stage renal disease (SORO-ESRD) revisited across two continents: A transcontinental experience from Eau Claire, WI, USA, and from Enugu, Nigeria: What lessons can be learnt?”. The International Society of Nephrology (ISN). World Congress of Nephrology 2011. (Poster presentation).	Vancouver, CAN

4/2011	“A 120-month retrospective analysis of de novo HBV infection versus recombinant HBsAgemia in a US mid-western Mayo Clinic hemodialysis population – A comparative effectiveness review and a call for changes in current US CDC guidelines for HBV immune-surveillance and immune-prophylaxis”. The International Society of Nephrology (ISN). World Congress of Nephrology 2011. (Poster presentation).	Vancouver, CAN
4/2011	“Syndrome of rapid onset end stage renal disease (SORO-ESRD): A new unrecognized pattern of progression of CKD to ESRD”. The International Society of Nephrology (ISN). World Congress of Nephrology 2011. (Poster presentation).	Vancouver, CAN
4/2011	“Non-dilated obstructive uropathy – An often unrecognized cause of acute kidney injury in US hospitalized patients: Three consecutive cases seen over six months in a mid-western US Nephrology practice”. The International Society of Nephrology (ISN). World Congress of Nephrology 2011. (Poster presentation).	Vancouver, CAN
4/2011	“Bilateral lower extremity sequential compression devices (SCDs) for the prevention of intra-dialytic hypotension – A new therapy for an old problem”. The International Society of Nephrology (ISN). World Congress of Nephrology 2011. (Poster presentation).	Vancouver, CAN
6/2013	“The Newly Described Syndrome of Rapid Onset ESRD (SORO-ESRD) Versus Traditional ESRD - A Tale of Two Cities - Implications for Dialysis Planning and Dialysis Care, Worldwide”. Moderated Poster Abstract. [SA544]. World Congress of Nephrology	Hong Kong, HK
6/2013	“Asymmetric information in the practice of medicine, over diagnosis, unnecessary tests, unnecessary procedures and futile care – \$750 billion blown annually in US healthcare _ Blame the doctors!: How to make The Affordable Care Act affordable; Yes we can!” Moderated Poster Abstract. [MO470]. World Congress of Nephrology.	Hong Kong, HK
6/2013	“Nondialytic Therapy (NDT) for US ESRD patients: An Ignored Paradigm in US Nephrology Practice: A Call for a Robust Reappraisal”. Moderated Poster Abstract. [MO466]. World Congress of Nephrology.	Hong Kong, HK
6/2013	“The CKD Express © Software Program - A novel effective, efficient and cost-containing IT-based program to extend improved CKD care to large populations: Results of a Mayo Clinic Health System pre-production analysis”. Moderated Poster Abstract. [MO103]. World Congress of Nephrology.	Hong Kong, HK
6/2013	“The CKD Enigma – Statistics and Myths about CKD: Conflicting ESRD and Death Rates in the Literature:	Hong Kong, HK

	Do they all really die before reaching ESRD?: A Revisionist Mayo Clinic Perspective and Implications for CKD care. The Concept of Asymptomatic vs Symptomatic CKD - Non-Progressors vs Progressors". Moderated Poster Abstract. [SU356]. World Congress of Nephrology.	
6/2013	"Process Reengineering in US Healthcare: Why Old Paradigms Have Failed – The Impacts of Critical Healthcare-specific Complex yet Unidentified Bottlenecks in a Complex Adaptive System". Moderated Poster Abstract. [MO461]. World Congress of Nephrology.	Hong Kong, HK
6/2013	"New PD Starts Per Period – A New PD CQI Tool: An 80-year Old Atherosclerotic Man Successfully Transitions from HD to PD in a Mayo Clinic Dialysis Unit". Moderated Poster Abstract. [MO457]. World Congress of Nephrology.	Hong Kong, HK
3/2015	"Rapid normalization of severe hyponatremia after a single 15 mg dose of oral tolvaptan: Need for caution in younger patients with preserved renal function". Moderated poster abstract. World Congress of Nephrology.	Cape Town, SA
3/2015	"Mortality outcomes and causes of mortality in patients with the syndrome of rapid onset ESRD compared with "classic" ESRD in a Mayo Clinic Hemodialysis Unit". Moderated poster abstract. World Congress of Nephrology.	Cape Town, SA
4/2016	"Intraoperative Hypotension (IOH), Acute Kidney Injury (AKI) and the Syndrome of Rapid Onset End Stage Renal Disease (SORO-ESRD): The Role of the Anesthesiologist in the Prevention of Hospital-Acquired AKI". Keynote Lecture. 2016 College of Anesthesiologists of Singapore Annual Refresher Course.	Singapore, SIN
4/2016	"Intraoperative Hypotension (IOH), Acute Kidney Injury (AKI), Pre-emptive Withdrawal of RAAS Blockade in the Peri-operative Period". Nephrology Grand Rounds Lecture. National University Health System (NUHS), Division of Nephrology.	Singapore, SIN
4/2016	"Introduction of the syndrome of rapid onset end stage renal disease (SORO-ESRD)". Grand Rounds Lecture. Garki Hospital, Abuja, Nigeria.	Abuja, NIG
4/2016	"The new study - A Mayo Clinic, Rochester, Thirteen-Year Retrospective Investigation of the Syndrome of Rapid Onset End Stage Renal Disease (SORO-ESRD) in an Incident Hemodialysis Cohort, 2001-2013". Grand Rounds Lecture. Garki Hospital, Abuja, Nigeria.	Abuja, NIG
4/2016	"Intraoperative Hypotension (IOH), Acute Kidney Injury (AKI), Pre-emptive Withdrawal of RAAS	Abuja, NIG

	Blockade in the Peri-operative Period”. Grand Rounds Lecture. Garki Hospital, Abuja, Nigeria.	
4/2017	“Three-year Kidney Transplant Experience at Garki Hospital, Abuja, Nigeria, 2013-2016”. Poster presented at the World Congress of Nephrology, International Society of Nephrology (ISN) Meeting.	Mexico City, MEX
4/2017	“A Mayo Clinic 13-year Retrospective Investigation of the Syndrome of Rapid Onset ESRD Among Renal Transplant Recipients, 2001-2013”. Poster presented at the World Congress of Nephrology, International Society of Nephrology (ISN) Meeting.	Mexico City, MEX
4/2017	“Healthcare Costs Accelerate With Chronic Kidney Disease Progression”. Poster presented at the World Congress of Nephrology, International Society of Nephrology (ISN) Meeting.	Mexico City, MEX
8/2017	“Syndrome of rapid onset end stage renal disease (SORO-ESRD) – The results of a Mayo Clinic 13-year retrospective investigation”. Lecture presented at the Annual Update Meeting, Instituto Mexicano de Investigaciones Nefrologicas. Instituto Nacional de Ciencias Medicas y Nutrition. “Salvador Zubiran”, Mexico City, Mexico.	Mexico City, MEX
8/2017	“Recent reports of the demise of contrast-induced nephropathy in the current nephrology literature: A contrarian perspective”. Lecture presented at the Annual Update Meeting, Instituto Mexicano de Investigaciones Nefrologicas. Instituto Nacional de Ciencias Medicas y Nutrition. “Salvador Zubiran”, Mexico City, Mexico.	Mexico City, MEX
8/2017	“Current management paradigms for hyperkalemia: the nephrologist’s dilemma”. Lecture presented at the Annual Update Meeting, Instituto Mexicano de Investigaciones Nefrologicas. Instituto Nacional de Ciencias Medicas y Nutrition. “Salvador Zubiran”, Mexico City, Mexico.	Mexico City, MEX
5/2021	“Hyponatremia – An Overview”. Division of Nephrology, Department of Medicine, The Robert Larnier, M.D. College of Medicine, University of Vermont, Burlington, VT, USA. Department of Medicine Grand Rounds.	Burlington, VT (Virtual Presentation)
7/2021	“Paracetamol and the Kidneys: Facts, Fallacies and Fiction – Implications of Cooking with Paracetamol in Nigeria”. Association of Nigerian Physicians in The Americas (ANPA) 27th Annual Convention & Scientific Assembly.	Burlington, VT (Virtual Presentation)